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SYNOPSIS
This research work has been a biochemical 
investigation of the effects of different preparations 
of human urinary and pituitary gonadotrophins on the 
excretion of steroids by women with different 
endocrinological conditions.
The effects of different dosages of hormones 
were studied in a group of women with secondary 
amenorrhoea in statistically designed experiments and 
the results were analysed by comparison to the excretion 
of steroids during the normal menstrual cycle.
Usinsr the information gained from these experiments 
these women have become pregnant, and one pregnancy 
occurred during an experiment. One woman gave birth 
to dissimilar twins, two to single children and another 
aborted. The excretion of hormones during pregnancy 
was followed and compared to the excretion patterns 
found in normal pregnancy. The excretion of oestriol 
and pregnanediol following treatment with gonadotrophins 
and other trophiO hormones was studied in a woman with 
Simmonds' disease.
The hormones controlling the excretion of steroids 
in the urine of women with the Stein-Leventha1 Syndrome 
and the occurrence of steroids in the follicular fluid 
from the patients was investigated. During this work 
a short rapid method for the estimation of oestriol 
in urine was developed. The accuracy, precision, 
sensitivity and specificity of the method was discussed.
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INTRODUCTION
INTRODUCTION.
Biological properties of gonadotrophins.
Historical introduction:
The presence (in the anterior lobe of the pituitary 
gland of hormones possessing specific gonad stimulating 
effects) was established by the work of Smith & Engle 
(1927) and Zondek & Aschheim (192?). These workers 
demonstrated that pituitary extracts induced precocious 
sexual development in immature male and female rodents. 
Gonadal stimulating factors were also demonstrated in 
chorionic tissue (Murata & Adaehi, 1928) and in the 
urine of post-menopausal women and castrated men 
(Aschheim, 1928; Hamburger, 1931)*
Pituitary gonadotrophins;
It was soon clear that pituitary extracts or implants 
could produce two gonadal reactions (a) the stimulation 
of follicular growth in the ovaries and of sperm&t$genic 
activity in the testis and (b) the final ripening of the 
ovarian follicles together with the exhibition of oestrus 
or heat, the rupture of the follicles and their 
subseauent transformation to corpora lutea, and in the 
testis the assumption of a functional role on the part 
of the Leydig cells which secrete testosterone which in 
turn causes development of the secondary sex glands.
The first separation of pituitary gonadotrophic 
extracts into two components with their different 
biological activities was showao by Fevold, Hisaw & 
Leonard, (1931). The first preparation was called 
"Follicle stimulating hormone" (F.S.H) and the second 
"luteinizing hormone" (L.H) or "interstitial cell 
stimulating hormone" (I.G.S.H). Subseauent work from 
other laboratories (for review see Evans, 1950), has 
confirmed the concept that the two hormones F.S.H. and 
L.H. are present in pituitary extracts. More recently 
several workers have succeeded in purifying pituitary 
gonadotrophins; Gemzell, Dicfalusy & Tillinger (1958) 
by precipitation using ammonium sulphate; Steelman & 
Segaloff (1959) used a chromatographic procedure that 
employed ion exchange cellulose; Roos & Gemzell (I960) 
by chromatography on carboxymethyl and diethylamino-ethyl 
cellulose followed by zone electrophoresis on a 
copolymerizate of polyvinyl chloride and polyvinyl 
acetate. In this laboratory the method of Steelman &
Segaloff (1959) has been modified and extended and 
F.S.H. has been prepared which is largely free of L.H. 
(Butt, Crooke & Cunningham, 1961; Butt, Crooke, 
Cunningham & Wolf / , 1963) and in Cambridge L.H. has 
been obtained which appears to be free of F.S.H.
(Hartree, Butt Eirkham, 1963).
It is now accepted that pituitary extracts contain 
a third gonadotrophin x^hich in the rat' is responsible 
for the maintenance of activity of corpora lutea and 
for the secretion of progesterone (.Astwood, 194-1, 1953-; 
Evans, Simpson, Lyons & Turpeinen, 194-1). This 
substance has been termed luteotrophin (LTH) and rpay be 
identical to the lactogenic hormone, prolactin.
Placental gonadotrophins:
Human chorionic gonadotrophin (H.C.G):
The gonadotrophic action of the urine of ’pregnant women 
was first shown in normal immature rate and mice in 
which it induced the formation of haemorrhagic follicles 
and corpora lutea (Ashhheim & Zondek, 192?). When 
tested in hypophysectomised female rats it induced only 
stimulation of intezdsitial cells and did not cause 
follicular development (Simpson, Li &. Evans, 1951). 
Ovarian hypertrophy is slight (except at high doses) 
but uterine stimulation due to oestrogen production 
may be marked. In the male, repair and stimulation 
of interstitial cells occurs with, resulting androgen 
production. As a result spermatogenic activity may 
be maintained (Smith & Leonard, 1934-; Evans, Penchurz 
& Simpson, 1934-*, Simpson et al. , 1951). The effects in 
the intact rat are in sharp contrast to those in the 
hypophysectomised rat. Thus, in the female injection 
of H.C.G. is followed by ovarian hypertrophy due to 
follicular development and corpora lutea. The 
associated hyperaemia and ovulation in immature animals 
serve as indices for pregnancy diagnostic tests. In 
the male the testicular elements are stimulated with 
resulting hypertrophy of the testis and secondary sex 
organs. . The more commonly accepted explanation of the 
gametokinetic action of H.C.G. in the male rat is that 
it is secondary to androgen production by the stimulated 
Leydig tissue. $The hormone most similar to H.C.G. 
would be pituitary L.H.).
Human urinary gonadotrophins;
The assumption has been made that because F.S.H. and 
L.H. activities are readily concentrated in independent
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protein moieties from pituitary tissue, the same must 
be true of urine from non-pregnant individuals.
Donini & Marchetti (1955) using chromatography on 
permutit ion exchange resin obtained a preparation 
from the urine of post-menopausal women that contained 
mainly E.S.H. activity. Johnsen (1955) using similar 
techniques obtained a preparation of greater specific 
activity. Segaloff & Steelman (1959) also used 
chromatography on ion exchange resins and presented 
evidence, that it is possible to prepare an L.H. fraction 
from the urine of non-pregnant individuals, which is 
remarkably free of E.S.H. At the same time these 
workers claimed to have isolated urinary E.S.H. in 
apparently homogenous form. Independently Butt,
Brooke & Cunningham (1959) using similar techniques 
prepared fractions of gonadotrophin from the urine of 
male subjects which were relatively rich in E.S.H. and 
L.H. respectively. More recently Bourillon, Got &
Marcy (i960) have obtained a preparation of high E.S.H. 
activity from the urine of post-menopausal women by 
precipitation with ethanol, absorption on kaolin, 
chromatography on ion exchange resins and electrophoresis 
on starch gel.
Pregnant Mare's Serum gonadotrophin (P.M.S).
In 1930 Cole and Hart demonstrated the presence of 
a potent gonadotrophin in the serum of the pregnant mare 
which unlike H.C.G. showed physiological activity similar 
to E.S.H. Biological studies on this gonadotrophic 
hormone have established additional distinct differences 
between it and H.C.G., P.M.S. has been found to possess 
predominantly E.S.H. activity with smaller quantities of 
L.H. activity (Davis & Koff, 1938: Siegler, 1939).
P.M.S. was considered to be a single gonadotrophin 
(Huber &. Davis, 194-0) possessing both E.S.H. and L.H. 
properties in the same molecule until the separation 
into "E.S.H" and ML.H" fractions by Evans, (1936) and 
Hellbaum, (1937). However, the preparation of Li,
Evans &. Wonder (194-0) appeared to be electrophoretically 
homogenous retaining the original physiological property 
of the serum. Evidence in favour of separate gonadotrophic 
factors in P.M.S, comes from the work of Kapperman, Meyer 
& McShan (194-1) who produced an anti-serum against sheep 
pituitary E.S.H. which inhibited the follicle stimulating? 
factor of the injected mare serum without affecting the 
action of the luteinizing factor.
-  4  -
From thw original report by Cole & Hart, (1930) 
of the potent gonadotrophic effects of P.M.S. on the 
ovaries of rats, further extension of the work showed 
that it had the effect not only of inducing folliciilar 
development ovulation and corpus luteum formation in 
hypophysectomised animals, (Palmer, 1957) hut also 
in intact mice, ewes, sows, cows and rabbits (Catchpole 
& Lyons, 1954-; "Van Wagenen & Cole, 1938; Sieglerr, 1939, 
and Kurland, 1951)*
Clinical Trials with Gonadotrophins:
Attempts to induce ovulation.
The effects of human chorionic gonadotrophin on ovulation.
Many investigators have used E.C.G. in an attempt to 
stimulate the ovaries of non-pregnant primates. The 
ready availability of this .source of gonadotrophin, the 
development of preparations without general or local 
reactions and the early misconception that the substance 
was of pituitary origin served to stimulate extensive 
investigation and therapeutic trials. Early in the 
investigations some workers reported stimulation of 
ovulation and corpus luteum formation in women (Novak 
& Hurd, 1931, and Kenny & Daley, 194-0). Reports have 
continued to appear during the past 25 years claiming 
that H.C.G. may cause ovulation, however, the results 
of Engle (1933), Hartmanri, (1934-), Marshal}., (1935) and 
Johnson, (1935) with the monkey as well as the results 
of Giest, (1933) , Westman, (1935), Hamblen, (1939) (194-0) , 
Brown, Bradbury & Metzger, (194-1), and Bushnell, (194-8) 
in women demonstrate clearly that H.C.G. does not 
stimulate the development of Graafian follicles or cause 
maturation and liberation of ova in primates. Pregnancy 
when it occurred was only coincidental (Palmer, 1957). 
Instead of causing secretion of oestrogen and ovulation 
there is evidence that the large follicles became atretic 
while smaller follicles -were hyalinised, concomitant 
with decreased ovarian secretion (David, 194-7). Brown 
& Venning (1938) demonstrated that prolonged treatment 
with H.C.G. in women having normal menstrual cycles 
leads to atrophy of the endometrium which suggested 
suppression of oestrogen production by the ovaries.
In Scandinavia, on the other hand, interest in the 
therapeutic uses of H.C.G. has continued and reports of 
its successful use have continued to appear. These 
workers, including Rydberg, (194-3); Pahlson, (1951),
-  S -
Wahlen, (1952), Bergman, (1958), have shown that, in 
patients with metropathia haemorrhagica cystica, a 
high success rate is possible but the authors stipulated 
that before H.C.G. could be effective, the ovaries must 
contain more or less mature follicles as they do in 
metropathia haemorrhagica cystica.
The effect ©^pregnant mare's serum (P.M.S) on ovulation.
Initially studies on the therapeutic uses of the 
substance were retarded because of the technical 
difficulties involved in the isolation of this 
gonadotrophic activity from blood. Captland & Nelson 
(1937, 1958) obtained a preparation largely free of 
serum proteins which they standardised by measuring the 
increase in weight of the ovaries of rate. Since then 
many experimental trials of the effects of P.M.S. in- 
women were undertaken and evidence of luteinization in 
the ovaries was obtained by Buttner, (1937); Watson,
Smith & Kurzrok (1938). However, when P.M.S. was given 
to women .in•(Wlkoififethe ovaries were later removed (Westman, 
194-3) evidence was obtained of follicular development but 
there were no signs of corpora lutea formation. 
Histological evidence showed that the preparation caused 
ovulation and follicular development in 16 of the 30 
women treated by Siegler & Pein, (1939), Siegler, (194-0). 
The clinical use of P.M.S. was found to be inconsistent 
and disappointing. Despite the evidence that it 
produced follicular stimulation, ovulation followed by 
corpus luteum formation rarely occurred (Hamblen, 1938; 
Giest, Gaines & Salmon, 194-1, and Bydberg, 1943).
The effect of the combinations of H.O.G. and anterior 
pituitary extract (A.P.E.) or P.M.S. on ovulation.
H.C.G. has been widely used clinically as an 
ovulatory factor. To be effective it was administered 
after maturation of the follicles was thought to have 
occurred under the stimulating effect of extracts of the 
anterior pituitary or of pregnant mare's serum. The 
effectiveness of such a combination of treatment has 
been proved in laboratory animals (Engle & Hamburger, 
1935) and it was found that the administration of H.C.G. 
with anterior pituitary extracts greatly enhanced the 
action of the latter in rodents (Leonard, 1932; Mazer 
& Katz, 1933; Bodemerij Rumery, & Blandau, 1959). Mazer 
& Ravetz (1941) studied the effect of H.C.G. together 
with animal anterior pituitary extract Synapoidin (Parke 
Davis) when given to 23 women over a period of 1 - 18
&
days before laparotomy. In 20 of the 23 women there 
was definite evidence of ovarian stimulation and 
microscopic examination of the ovaries of 16 of these 
women revealed in all but one of the women, multiple 
haemorrhagic follicles, with luteinized granulosa 
layers. Two of the patients who were considered to 
have anovulatory cycles conceived and periods followed 
in 19 of the, 23 women. In some of the women with 
normal ovaries treatment caused over stimulation as 
judged by an increase in size at laparotomy.
From these studies the idea originated that better 
results could be obtained by injecting H.C.G. after 
the follicles had been stimulated than by the 
simultaneous injection of H.C.G. and F.S.H. The use 
of P.M.S. to stimulate follicular development, followed 
by H.C.G. to induce ovulation and luteinization 
appeared a logical approach and has been used bv 
Rydberg & Pedersen-Bjergaard, (194-3); Hamblen & Davis, 
(194-5) ; Riisfeldt (194-9) with greater success than has 
treatment with# the hormone alone. The results of 
Wahlen (1952) indicated that in the presence of a 
mature follicle, ovulation could be induced by the 
administration of- H.C.G. alone. Igorashi 8; Nat sumo to 
(1957) used P.M.S. followed by H.C.G. but they used 
individual doses of hormones for different patients as 
suggested from a daily examination of cervical mucus 
which indicated in an empirical way the state of 
maturity of the follicle. ■ H.C.G. was injected when 
the follicle was thought to be mature. Recently a 
number of deaths following intravenous Synapoidin 
therapy have been encountered in America so that this 
approach can no longer be justified (Swyer, 1963).
The effect of human pituitary gonadotrophin on ovulation.
Gem age 11 et al (1958) were the first workers to 
successfully use human pituitary F.S.H. (HP-FSH) 
to induce ovulation in wora&n with amenorrhoea. These 
workers used a partially purified material in a daily 
dosgae of lOmg. equivalents of HMG—IHP, as judged by the 
ovarian augmentation assay in rats, for 10 days followed 
by H.C.G. 6,000 i.u./day for 4 days. The effects of 
the treatment were followed by measuring the excretion 
of oestrogen and preghanediol in urine and by recording 
the body temperature and by the examination of vaginal 
smears. The ovaries of some of the patients treated 
were also examined by culdoscopy. ■ There was evidence 
of ovulation in 29 out of a group of 40 women. Some of
these women had secondary amenorrhoea while others had 
primary amenorrhoea with gonadal dysgenesis. In some 
instances the responses in oestrogen and pregnanediol 
were enormous and polycystic enlargement of the ovaries 
was observed at laparotomy. These responses suggested 
that the doses of gonadotrophin used was too high and 
this has since been confirmed by the large number of 
multiple pregnancies which followed treatment (Gemzell, 
1962) .
It was found that repeated ovulations could be obtained 
in the same women using pituitary preparations in contrast 
to the finding that P.M.S. induced anti-hormone 
formation (Haddock, 19A-9)♦ Later work has shown that 
the effect of exogenous gonadotrophin is abolished by 
the simultaneous administration of progesterone (Gemgell, 
I960) arid testosterone propionate (Diezfalusy, 1962).
These authors have suggested that these two compounds 
exert their effects at the ovarian level and render 
the ovary insensitive to gonadotrophic stimulation.
Neither were (Gemgell et al, 1958) able to induce any 
ovarian changes to gonadotrophin in A- women that were 
pregnant, the lack of response has been attributed to 
the high circulating levels of blood progesterone. The 
same authors attempted to shorten the successive 
treatments to periods of less than one month but no 
responses were obtained since the level of blood 
progesterone was elevated as a result of corpus luteum 
formation duning the first month of treatment. These 
findings suggest that inhibition to gonadotrophin can 
exist at ovarian level.
The finding of Gemzell (1961) that higher levels of 
HP-PSH were effective in inducing ovulation was based on 
the results of treatment ofahypopituitary dwarf with 
KP-PSH lmg, 2mg. Jmg. 5mg. lOmg./day for lOdays. The 
only response obtained was with a dose of lOrng. and this 
has been used unchanged for the treatment of all patients 
with amenorrhoea. H.C.G. was found to induce ovulation 
in 2 out o'f a group of 50 amenorrhoeic women but the 
effects of the dose of HP-PSH used in conjunction with 
the dose of H.C.G. was not investigated.
Buxton & Hermann (1961) administered a daily dose 
of 20mg./day for four days of a human pituitary P.S.H. 
preparation to women with amenorrhoea and found- 
evidence for ovulation in 5 of the 7, as judged by 
changes in body temperature, endometrial biopsy and 
vaginal smears. Ovulation occurred when H.C.G.
(16,000 i.-u./dayj for 4 days) was given after F.S.H. 
but not when the two hormones were used simultaneously. 
Human pituitary F.S.E. followed by H.C.G. (6,000 i.u/day 
for 6 days) has been used by Rosemberg, Cfeleman, Gibree, 
Mac Gilliwcay, (1962) to induce ovulation in two women 
with secondary amenorrhoea. With the low doses of 
F.S.H. used by $osemberg et al (1962) the responses 
obtained were small as shown by excretion of oestrogen 
and pregnanediol but With"larger doses of F.S.H. 
(lOmg/day for 5 days) followed by 5mg./day for /5 days 
together with 6,000 i.u. H.C.G/dav, the same type of 
enormous response as frequently occurred in some of 
the patients described by Gemssell et al (1958),
Gemzell (1961) .was obtained.
The effect of Human Urinary gonadotrophin on ovulation.
The gonadotrophic material prepared from the urine 
of post-menopausal women (Pergonal) has been used 
successfully to induce ovulation. Lunenfeld, Rabau 
Rumney & Winkelsberg (1961) used Pergonal (13.6mg./day) 
for periods between 8 - 1 4  days in two women with 
secondary amenorrhoea. The last doses of Pergonal 
were given simultaneously with H.C.G. (6,000 i.u./day) 
for periods between 5 - 10 days and the changes in 
steroid excretion and body temperature charts suggested 
that ovulation had taken place. Pregnancy occurred 
in tm> women during ovulatory cycles induced by the 
combined Pergonal-H.C.G. treatment (Lunenfeld et al, 
1962). The patients became pregnant during the first 
and fifth months of treatment.
Six women with secondary amenorrhoea have also 
been treated with Pergonal by Rosemberg et al (1963).
The doses used ranged from 6.8 to 27,2mg./day over 
periMs of 5 - 15 days. H.C.G. (6,000 i.u./day) for 
5 days was used together with the last injections of 
Pergonal, Changes were observed in the oestrogen and 
pregnanediol levels, and these in conjunction with 
the changes in body temperature and endometrium 
suggested that ovulation followed treatment. Ho 
pregnancy occurred after any of the induced cycles, 
Shelesnyak (1962) has reported pregnancy occurring in 
2 of 4 patients treated with human pituitary F.S.H. 
in a series of experiments of factorial design but the 
scheme of treatment or the method of assessment of 
ovarian responses has not been published.
Introduction to Section on the treatment of women with, 
the Stein-Leventhal Syndrome.
The Stein-Leventhal Syndrome (1935) is characterised 
hy oiigomenorrhoea or amenorrhoea, sterility and 
enlarged polycystic ovaries and frequently by hirsutism 
of a masculine type. Originally Stein and Leventhal 
(1935) proposed that the syndrome was due to an increased 
production of pituitary gonadothrophins which resulted 
in the stimulation of a large number of ovarian follicles. 
However, this thery has not been established. Many 
other theories have been suggested to explain the 
syndrome and histological studies, estimations of 
steroids in urine and follicular fluid, and studies 
involving cina^ alt^ caBi of ovarian tissue slices and 
homogenates from patients with the syndrome have been 
made.
The metabolic pathways for the formation of 
oestrogen in the normal human ovary according to 
Eyan & Smith (1961, a,b) and Smith & Ryan (1961) are 
shown diagramatically.
Short & Lohdon (1961) and Short (1962) have suggested 
that the ovaries of patients with the Stein-Leventhal 
Syndrome do not synthesise oestrogen due to the failure 
of the enzyme responsible for 19-hydroxylatibn. This 
leads to an accumulation of androstenedione which has 
been found in high concentration in the ovarian cyst 
fluid of these patients. Axelrod & Goldzieher (1961). 
where unable to detect any oestrogen when ovarian 
slices from patients with the Stein-Leventhal Syndrome 
were circulated with various steroid substrates.
They concluded that their negative findings resulted 
from a blockage in the conversion of 19-hvdroxy 
androstenedione to oestrone. A similar approach was 
adopted by Mahesh & Greenblatt (1961; 1962) who found 
large quantities of A  5-compounds in the follicular 
fluid and urine of these patients. The A  5-compounds 
consisted of dehydroepiandrosterone (DHA), 17-e><Jiydroxy 
A, 5-pregnenolone a n d A  5-pregnenetriol.
- i -
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Cholesterol
1Pregnenolone.
Progesterone 17 hydroxypregnenolene
17^hydroxy progesterone \S.dehydroeriandrosterone
2. B jol_ jiehydrogenase^
Androstenedione
19 hydroxylase
' " " T19- Hydroxyandrostenedione
J/Oestrone
IOestradiol - 17f$
Diagram of 2 of the biosynthetic pathways leading to 
the formation of oestrogen by the human ovary. The 
two enzymes that are considered deficient in the ovaries 
of women with the Stein-Leventhal Syndrome are also 
shown.
They proposed, therefore, that the enzyme defects 
occurred in the 3p - ol dehydrogenase system that 
converts the A 5-compounds into androstenedione. This 
matabolic pathway is well established in the ovary and 
the proposed enzyme defect is shown in figure. Both
theories explain the failure of such ovaries to produce 
oestrogen but apparently conflict in the location of 
the enzyme defect.
Several workers have investigated the effects of 
exogenous gonadotrophin in patients with the Stein- 
Leventhal Syndrome. Keetal, Bradbury & Stoddard (1957) 
used log P.S.H. and showed that the ovaries of 11 of 
12 patients treated were greatly enlarged following 
treatment. Increased levels of urinary DHA and 
17-ketosteroids were frequently observed. Similar 
findings were reported by Borell (1954), Pensonen,
Timonen & Mikkonen (1959) using H.C.G. and Gemgell et al 
(1959; 1961) also noted a marked increase in 17-ketosteroids 
and 17 hydroxycorticosteroids in patients treated with
human F.S.H and H.C.G. Mahesh & Greenblatt (1961) 
used a preparation of human pituitary F.S.H. and hy 
giving dexamethasone at the same time suppressed the 
production of adrenal cortical steroids. They found 
increased levels of DHA, pregnenetriol, pregnanetriol, 
17^-hydroxy pregnelone, etiocholanolone and androsterone 
in the urine after treatment with F.S.H. and at 
laparotomy the ovaries of the woman were greatly 
enlarged and typical of the syndrome. The excretion 
of oestrogen was not measured in this patient.
Dexamethasone,was used hy Netter, Jayles;, Musset,
Lambert, Mauvais-Jarvis (I960) who found that increased, 
levels-of oestriol, 17-ketosteroids and androsterone 
occurred after treatment with H.C.G. (10,000 i.u./day 
for 2 days), little change was noted in the other 
oestrogen levels and to explain these findings the 
authors concluded that the enzyme defect in the ovaries 
of the patients treated lay in an exaggerated excretion 
of 16-hydroxylmetabolites such as oestriol and
16- hydroxyoestrone. More recently using dexamethasone 
Bailieu, Mauvais-Jarvis & Corpechot (1963) have shown 
that increased levels of androsterone and aetiocholanolone 
were excreted after treatment with H.C.G. (5»000 i.u./day 
for 3 days) and both androstenedione and D.H.A. were 
tentatively identified in homogenates of the ovarian 
tissue removed at wedge resection.
In this work the effects of treatment with F.S.H. 
and with F.S.H. and H.C.G. were studied in an attempt 
to show differences in the production of steroids. 
Dexamethasone was used in the first three patients in 
- order to suppress the production of adrenocortical steroids 
so that it could reasonably be assumed that any steroids 
formed after treatment with gonadotrophin were specifically 
of ovarian origin. Follicular fluid was collected from 
all patients treated and the steroids present were 
estimated. The cyst fluid "was collected at laparotomy 
which was performed at different times during and after 
treatment so that a comparison could be made between 
the excretion of urinary steroids and the steroids 
found in the follicular fluid. By this means it was 
hoped to establish that treatment with F.S.H. and with 
F.S.H. and H.C.G. could induce changes in the 
constituents of the cyst fluid. The effects of 
gonadotrophin on the excretion of D.H.A, androstenol,
17- oxosteroids and 17-oxogenic steroids were also 
investigated. In addition the effect of gonadotrophin
- /a. -
on oestriol and pregnanediol excretion in urine and 
progesterone and oestrogen formation in the follicular 
fluid was studied. *
*ft’ •
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Objectives of the present work.
The jnain objective of the present work was to 
obtain information about the effect of human urinary 
and pituitary gonadotrophin on the ovary as judged 
by the excretion of steroids in urine.
The method of Brown (1955) appeared to be a 
convenient method for the estimation* of oestrogen.
The normal pattern for the daily excretion of oestrone, 
oestradiol and oestriol has been reported (Brown, 1959). 
Oestriol is excreted in the greatest quantity and 
fluctuates by the greatest amount during the normal 
menstrual cycle and was therefore considered a 
suitable estimation of ovarian activity. The method 
of Brown (1955) for the estimation of oestriol is 
lengthy for routine use and one of the objectives was 
to simplify the method without sacrificing specificity 
and sensitivity. The method of Klopper, Michie & 
Brown, 0-955) has been widely adopted for the estimations 
of pregnanediol and the normal pattern of excretion has 
been published (Klopper, 1957)*
It was decided to investigate three different kinds 
of clinical treatment; (i) the treatment of women with 
secondary amenorx-hoea. The purpose of this study was 
to compare the effectiveness of pituitary and urinary 
F.S.H. preparations of various degrees of purity, 
given in combination with H.C.G. A series of 
experiments of factional design were used to establish 
the optimum conditions for 3t±ce±r administration of the 
hormones with the ultimate object of inducing ovulation 
and enabling the women to become pregnant. (ii) A 
study was' performed in a woman with Simmonds' disease 
so that the effects of the treatment were uncomplicated 
by endogenous hormones.
Finally the study of women with the Stein-Leventhal 
Syndrome: The recognised treatment for this syndrome
is wedge resection of the ovaries and this afforded 
the opportunity of studying both the steroids obtained 
from ovarian cyst fluid and urine.
INTHDmCTJDN gfl CLINICAL TRIAL.
The Patients.
The patients selected had complained of infertility 
associated with secondary amenorrhoea of unknown 
aetiology of at least three years duration. They were 
chosen because they were considered to be sufficiently 
intelligetnt, co-operative and willing to undertake a 
series of trials with human gonadotrophins. They had 
no other complaints and their excretion of urinary 
gonadotrophins was in the lower half of the normal range 
on at least three occasions.
They were coded alphabetically in the order in 
which they volunteered for treatment, with the intention 
that if one gave up for any reason whatever, she would 
be replaced by the patient having the next letter.
They were admitted to the ward for clinical 
investigation which included a pelvic examination under 
anaesthesia, uterine curettage, tubal insufflation and 
euldoscopy. All other investigations including the 
chromosonal pattern of buccal or vaginal smears gave 
normal results. The husbands' semen specimens were 
also normal. Table Iflshows that all patients had 
small uteri and the endometrium, when obtainable, was 
scanty and inactive. Guldoscopy revealed small 
ovaries with glistening white capsules and no cysts or 
only occasional tiny subcapsular translucent cysts 
visible.
The Objective of the Experiement.
The normal pattern of daily oestriol excretion was 
reported by £Brown,^1959)• It was based on 
observations on sixteen women aged 18 to 41 years who 
had regular menstrual cycles. The mean, maximum and 
minimum figures are shown in Fig. 2A. From this 
figure it was seen that the oestriol level increased to 
a maximum at about day 10 and remained at an elevated 
level for about 4 days after which it fell on about 
day 14. In some cases it rose again to form a secondary 
oestriol peak and in some of the women the secondary 
rise (luteal phase) was higher than the primary one 
(ovulatory phase). Some of the women showed no 
secondary rise so that apparently it is not a requisite 
for ovulation. The oestriol always had fallen after 
the secondary rise before menstruation occurred.
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FIG. 2B
DAYS
Mean, maximum and minimum figures (shaded) for the excretion of oestrlol by healthy women In
(A) dally and (B) selected specimens of urine. 
The first day of menstruation Is adjusted to occur on day 24.
In view of the amount of work involved in following 
each month of treatment in such a detailed way that 
Brown did to establish normal excretion values, it was 
decided to collect eight 24hr. samples of urine, these 
specimens were pooled in pairs and single specimens 
were collected at the beginning and end of each cycle. 
When the results for similar samples were taken from 
the figures of (Brown, 1959) and treated in the same 
way the mid cycle peak of oestriol was reduced. The 
resulting pattern is shown in 3Tig. 2B.
The normal pattern of excretion for pregnanediol is 
based on figures for daily excretion by 16 women aged 
16 to 47 years with normal menstrual cycles reported by 
(Klopper, 1957)* The figures for different age groups 
are shown in Figure 3A. The pattern of excretion by
the women in the youngest age group, all of whom were • 
single, was lower then the others. There was only one 
other single woman. She was in the next age group 
and her exeretion was also low and the figures for these 
five women have been excluded. The mean, maximum and 
minimum figures for the remaining 11 are shown in 
Figure 3B. Figure 3C shows the effect of using the 
same pooled samples of urine for pregnanediol as was 
used in Figure 2B for oestriol.
The principal characteristics of this excretion 
pattern is the high plateau level in the luteal phase 
of the cycle. The increased values were maintained for 
about 10 days when they fall prior to menstruation. 
Comparison with Figure 2B shows that the primary peak 
in oestriol occurred when little change occurred in the 
pregnanediol level but as the oestriol level fell after 
the primary peak the pregnanediol level increased. The 
secondary oestriol peak, when it occurred, coincided 
approximately in time with the pregnanediol plateau.
Both fell togesbher prior to menstruation.
From the excretion patterns of both pregnanediol 
and oestriol during the normal cycles it can reasonably 
be assumed that this type of pattern could be a suitable 
model to try to induce using gonadotrophin stimulation 
in women that do not normally ovulate. The 
experiments described were designed with a view to 
induce this model pattern of steroid excretion.
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The Design and Analysis of the Experiments:
The experimental trials were designed to study 
the effects of a number of different factors 
simultaneously in a single set of trials. Each set 
has been called an# experiment.
In Experiment 1, the trials were arranged in the 
form of a Latin J3quare (Davies, I960). Its objective 
was to compare the effects of different preparations 
of F.S.H. after eliminating possible bias due to 
differences between patient and between succeeding 
months of treatment. Exoeriment 11 was of simpler design, 
all the patients being given the same treatment for one 
month.' It provided further information on the 
differences between patients.
The trials in Experiment 2 were also arranged in 
the form of a Latin Square. Here, the effects of 
changing both the total dosage and the daily dosage of 
E.S.H. were examined. As in Experiment 1, possible bias 
due to differences between patients was eliminated.
The factors examined in Experiment 2 did not appear 
to be acting independently of one another and it was 
considered likely that the factors to be studied in the 
next set of trials would also interact. These factors 
were the total dosage and the number of injections of 
H.C.G., the dosage of P.S.H., and the timing of the 
injections of H.C.G. relative to infections of E.S.H. 
Experiment 3 was therefore arranged to follow a half- 
replicate factorial design which enabled the effects 
of the above factors and some of their interactions to 
be assessed independently. Once more, possible bias 
due to different responses from patient to patient was 
eliminated.
The details of each experiment are described in 
association with their results since the design of 
succeeding experiments partly depended on these results. 
After the completion of the set of trials each patient 
was treated with the particular treatment that apneared 
to offer the best chances of producing an ovulatory 
type of steroid pattern.
The effects of the treatment on the amounts of 
oestriol and pregnanediol excreted have been assessed by 
analysis of variance. The object of the analysis was 
to isolate those differences in the experimental results 
which could not reasonably have occurred by chance from 
random fluctuations. Such differences are said to be 
statistically significant.
METHODS
AMD
MATERIALS
METHODS AND MATERIALS.
Reagents and Materials.
Acetic acid A.R. (B.D.H.) was distilled from chromium 
trioxide and acetic anhydride.
Acetyl chloride and dimethyl sulphate A.R. (B.D.H.) 
were both distilled.
Eurfuraldehyde A.R. (B.D.H.) was distilled twice.
A solution was prepared 0.56% (V/V) in 50% (V/V) acetic 
acid which was stored at 4°.
Sodium bisisirthate (Ha Bi O5) laboratory reagent (B.D.H.) 
about 90%.
Sodium borohydride (Na B H4). L.Light & Co. Solnbrook.
M-dinitro benzene (B.D.H.) "specially purified for 
17-ketosteroids".
Pyruvic aldehyde (L. Light & Co., Ltd.) 25% solution 
in water.
Petroleum ether A.R. (B.D.H.) Boiling range (66-80°) 
and benzene (A.R.) were shaken with H2 SO4. and allowed to 
stand overnight. They wsere washed free of acid and 
distilled through a fractionating column, the first and 
last fractions of each solvent were discarded.' •
Chloroform A.R. (B.D.H.) was distilled from potassium 
carbonate and stored in a dark bottle.
Diethyl ether A.R. (B.D.H.) was washed once with a 
saturated solution of ferrous sulphate followed by 
successive washings with water. It was distilled 
through a fractionation column and used soon after 
distillation. Ether recovered during the experiments 
was redistilled before use.
Other reagents were of analytical grade unless otherwise 
stated.
Silica Gel: (L. Light & Co., Ltd.) 100 - 200 mesh size, 
Davison, U.S.A. - Grade 923-
Alumina for androstenol. Type H (Peter Spence & Co. , Ltd. 
Widnes) was partly deactivated by adding 3-4% water. 
Alumina used in the estimations of oestriol, oregnanediol 
and dehydroepiandrosterone (Savory & Moore Ltd) 100/150 
mesh size, was adjusted by adding water unuil the desired 
activity was attained.
^glucuronidase:
B-glucuronidase was prepared, to powder Stage B , "by 
the method of Dodgson & Spencer (1953)• Subseauently, 
however, ethanol was used instead of acetone to 
precipitate the enzyme as this had the advantage of 
giving a cleaner powder. The dry powder was stored 
in a refrigerator at 4° and the enzyme activity was 
determined at regular intervals using the method of 
Fishman, Springer & Brunetti (1948).
Sulphatase activity of the preparation was not 
estimated.
Chromatographic columns:
These columns were 1cm. x 10cm. and had a B14 cone 
joint at the res|jroir end into which a B14/B24 adaptor 
was placed to act as resevoir. The absorbent material 
was supported by a disc of sintered glass of porosity 0. 
The column was filled with the solvent required by the 
particular method and the absorbent run in to the 
column. The column was then tapped gently and a small 
quantity of silver sand (acid washed) was added to 
prevent any disturbance of the absorbent when extracts 
were added. The solvent was run to the level of the 
sand before any extracts were added. Flow rates of 
solvents were regulated by the taps fitted to the columns 
and the rate was adjusted to that recommended for each 
individual method.
All glass aonaratus was used throughout to avoid 
contamination from cork or rubber. Glassware was 
generally cleaned by immersing in chromic acid overnight 
and rinsing with dilute acid sulphite solution and 
finally water. Separating funnels were cleaned 
generally by rinsing in a solution of 50% HCL 
containing about 2% of FeSOq-i followed by several rinses 
of water.
Perspex agglutination trays were supplied by 
R. B. Turner & Co., Ltd.
Methods used for Steroid Estimations:
17-0xogenic steroids.
A procedure based on the general method of Appleby, 
Gibson, Norymberski & Stubbs (1955) was followed.
4ml. of urine was added to a glass stoppered test 
tube containing 20mg. NaBHq. and the solution was allowed 
to stand overnight. 4ml. of acetic acid was added and 
after 5 min. lg. Na Bi03. The tube was shaken for
30 min in the dark. Then 12ml. of a 12% sodium 
bisulphite solution (W/V) was added and the tube 
shaken on the mechanical shaker for a further 5Trn' 11 •
4-ml. of H Cl. was added and the tube stood in a boiling 
water bath for lOmin. On cooling the tube 15ml. of 
ethylene dichloride was added and the contents shaken 
for 5 min. The solvent layer was allowed to separate 
out and the acid layer was removed by suction. The 
solvent was washed successively with 50% H Cl. 15ml., 
water 15ml., 2N-NaOH and water until all traces of alkali 
were removed. The solvent was evaporated after the 
addition of a little ethanol and a few pieces of anti­
bump granules.
Colorimetry:
To the dry extract 0.4ml. of 1% metadinitrobenzene in 
ethanol was added followed by 0.2ml. of 2.5 N-KOH in 
methanol. The reagents were mixed by rotation of the 
tube and allowed to stand for 1 hr. in the dark. A 
pair of standard tubes, each containing lOC^jjig. 
(dehydroepiandrosterone) and a blank containing reagents 
only were set up. After standing for 1 hr. 5ml. of 
ethanol was added to each tube and the extinction (E) 
read for each analytical solution against the blank at 
520 and 430 mju,. A Unicam SP. 600 was used for all 
colorimetry. The E values of the analytical solutions 
were corrected by substitution in the formula as 
recommended by the Clinical Endocrinology Committee of 
the Medical Research Council (1951).
E cor. = E 520 - (0.6 x E 430)
0.73
All results were expressed in terms of D.H.A, as 
mg. equivalents/24 hr.
17-0xosteroids,
1.5ml. of HCL was added to 10ml. of urine in a glass 
stoppered test tube and heated in a boiling water bath 
for lOmin. After cooling 15ml. of ethylene dichloride 
was added and the contents shaken for 5min. The acid 
layer was removed by suction and the ethylene dichloride 
was washed with 15ml. water, 15ml. 2N-Ua0H and water 
until the last wash was neutral to litmus. The remainder 
of the procedure is similar to that described for the 
17-oxogenicsteroids. Results were exuressed, in terms 
of a DHA standard, as mg. equivalents DHA/24hr.
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Pregnanetriol:
The method of Morris (1959) was employed. 50mg.
ITaBH4 was added to 10ml. of urine in a glass stoppered 
test tube and the contents allowed to stand overnight 
at room temperature. 10ml. of acetic acid, and 2;g 
NaBi03 were added and the tube shaken for 2 hr. in 
the dark. 8ml. of 12% Wa2Sp05 was added and the 
contents cooled. 4ml. of H Cl. was then added and 
the contents of the tube heated for lOmin. in a boiling 
water bath. The solution xvas cooled and extracted in 
30ml. of ethylene-dichloride by shaking for 3-5 min. on 
a mechanical shaker. The urine layer was removed by 
suction. The ethylene-dichloride was washed with 30ml. 
quantities of 50% H Cl, water, 2N-NaoH and water until 
neutral. A little ethanol and some anti-bump granules 
were added and the solvent was evaporated.
Chromatography:
The dry extract was dissolved in 10ml. of 25% ethyl 
acetate / petroleum ether (V/V) and applied to a 
chromatographic column containing 2g. silica gel set 
up in the same solvent. The test tube was rinsed with 
a further 2 x 5ml. ox uhe same solvent, each addition 
was made to the column when the level of the previous 
extract had reached the level of silica gel. The 
first 20ml. of the effluent was discharged. Then 20ml. 
of 35% ethyl acetate / petroleum ether was added and 
the eluate was collected. This was called Fraction II 
and contained the oxidation product of pregnanetriol. 
Further elution of the column with 20ml. of 65% ethyl 
acetate / petroleum ether gave the corresponding 
11-oxygenated 17-oxosteroids. This fraction was 
called Fraction III. The solvent was evaporated and 
both fractions were treated in a similar manner for 
colorimetry.
Colorimetry:
To each tube o.4ml. of metadinitrobenzene in ethanol 
and o.3ml. aoueous 8N-K0H were added. Two tubes 
containing 20pLg. aetiocholanolone were included as 
standards. The reagents were mixed by rotation and 
allowed to stand for 25min. in the dark. 2ml. of 75% 
ethanol was added and the extinctions of the solutions 
were read against a blank containing reagents only at 
440, 520 and 600 mp. The Allen correction was 
applied to analytical tubes and to.the standards.
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Both fractions II and III are expressed in terms of 
ms. of aetiocholanolone/24hr. R^ ration of the two 
fractions was derived by dividing the value of 
fraction II by value of fraction III (Hill, I960).
Pregnanediol♦
The method of Klopper, Michie & Brown (1955) was 
used except that a smaller volume of urine was 
hydrolysed and the volumes of reagents used were 
reduced accordingly.
Hydrolyses and Extraction;
1/A-Oth. of a 24- hr. specimen of urine was made up to 
75ml. with water and added to a round bottomed flask 
containing 25ml. of toluene and anti-bump granules.
The mixture was boiled under reflux and 7.5ml. H 61. 
was added. The urine was boiled for a further 10 min. 
cooled and the toluene layer separated in a separating 
funnel. The urine layer was extracted in a further 
25ml. of toluene and was then discarded. The combined 
toluene extracts were washed with 1 2 .5ml. 25% Na01 in 
N-NaOH. The alkali layer was discarded with the 
curdy precipitate at the liquid interface. The toluene 
layer was transferred back to the original flask used 
for hydrolysis and shaken for 10 min. with a mixture of 
5ml. of 5N-Na0H and 20ml. of 5% KMn04 (W/V). The 
mixture was transferred back to the separating funnel 
and the permanganate layer was discarded. The toluene 
layer was washed with water until it was free of the . 
purple colour.
Chromatography:
The toluene extract was then applied to a chromatographic 
column containing 3g. of alumina in benzene. The column 
was first washed with 25ml. of 0.8% ethanol in benzene 
(V/V) and pregnanediol was then eluted in 12ml. 3% 
d;hanol in benzene. The solvent was evaporated in a 
water bath. 2ml. of dry benzene was now added and 
warmed gently until all of the steroid residue had 
dissolved. 2ml. of acetyl chloride was then added to 
each tube and the contents left at room temperature for 
1 hr. 25ml. of petroleum ether was added and the 
solution v/as transferred to a separating funnel, washed 
once with 50ml. water and once with 25ml. of 8% NaHCo3 , 
followed by 25ml. of water. When all traces of water 
had been removed the petroleum ether extract was added 
to a second chromatographic column containing the same
quantity of alumina but using petroleum ether instead 
of benzene. When the extract had reached the level
of the alumina 15ml. of benzene was added and the 
pregnanediol diacetate was eluted. The solvent was 
evaporated and the tube was stood in a desiccator for 
1 hr. at room temperature.
Colorimetry;
lOmg. of sodium sulphite was added to each tube followed 
by 5nil* of H2SO4. Blank and standard tubes were 
treated in a similar manner. All tubes were stood 
overnight and the extintion of each read at 4-30 mji. 
Results were calculated in terms of an authentic 
standard which had been brought through the method and 
was-i corrected for the difference in molecular weight 
between pregnanediol and its diacetate. Recoveries 
and differences between duplicates were similar to those 
at Klopper et al. (1955).
Oestriol.
Oestriol was measured by the method of Brown (1955). 
Hydrolysis and Extraction;
200ml. of urine was boiled under reflux in a round 
Dottomed flask 30ml. of H Cl. was added and boiling 
continued for 60 min. When cold the urine was 
extracted once with 200ml. of diethyl ether in a large 
separating funnel, both layers were allowed ample time 
to separate and the urine layer was run off and further 
extracted twice with 100ml. of diethyl ether.
Alkali washings;
The combined ether extracts were transferred to a 
separating funnel and washed with 80ml. of NaOH/NaHCo3 
buffer. (150ml. of 5R-N&0H added to 1 litre of 8%
NaHCOj pH approx. 10.4-). The bicarbonate layer was 
discarded. 20ml. of 2N-HaOH was added to the ether 
layer and the funnel was shaken vigorously. After 
standing for 5 min. 80ml. of 8% NaHC03 was added and the 
funnel again shaken thoroughly. After separation 
of the two layers the alkali was discarded and the ether 
was washed with a further 5ml. of 8% NaHC03 followed by 
5ml. of water. When all the water had been drained off, 
the ether was transferred to a clean dry round bottomed 
flask and was evaporated on a water bath. The ether 
was recovered and was used again without purification 
for further extractions. The last traces of ether
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were removed by tilting the flask on its side while 
still warm.
The dry extract in the flask was dissolved in 
lml. of ethanol and 25ml. benzene was added. The 
flask was rotated and the contents were transferred 
to a small separating funnel that contained 25ml. of 
petroleum ether. The flask was rinsed with 25ml. of 
water which was added to the separating funnel.
Methylation:
The contents of the separating funnel were shaken and 
the oestriol was extracted from the solvent layer into 
the water layer. This water layer was run into a 
large glass stoppered test tube (methylation tube) and 
the solvent layer was extracted further with 25ml. of 
water which was also added to the tube. 4ml. of 
5N-NaOH and 0.9g. boric acid were added to the 
methylation tube and the contents were shaken until 
all the boric acid had dissolved. 1ml. of dimethyl 
sulphate was added (to the methylation tube) and the 
contents were shaken until all the dimethyl sulphate 
had dispersed. The tube was heated at 37° for 30 min.
A second methylation was brought about by adding 2ml. of 
5N-NaOH to the methylation mixture followed by lml. of 
dimethyl sulphate. After shaking, the tube was allowed 
to stand at 37° overnight in an incubator. The 
methylation mixture., after cooling, was added to a small 
separating funnel and the tube was rinsed out with 25ml. 
of benzene which was also added to the separating 
funnel, 2.5ml. of HpOp and 10ml. of 5N-NaOH were also 
added and the separating funnel shaken thoroughly. The 
alkali was discarded and the benzene was washed twice 
with 5ml. water.
Chromatography:
When the last traces of water had been drained off the 
oenzene extract was applied to a chromatographic column 
containing 2g. of alumina in benzene. After the benzene 
extract had percolated through the column 12ml. of 1.4% 
ethano 1/benzene was aac.ec. to the column and a band of 
pigment eluted. Oestriol methyl ether was eluted in 
16ml, of 2.5% ethanol/benzene. 0.2ml. of 1% quinol in
ethanol was added to the tubes containing the oestriol 
methyl ether and the solvent was evaporated off. An 
identical amount of quinol was also added to a blank 
and two tubes containing standards.
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Color!metry:
3ml. of Kober reagent (2% ft//V) ouinol in 76% HpSOq. V/V) 
v;as added to each tube, and after the contents were 
mixed by rotation the tubes were placed in a boiling 
water bath for 20 min. During the first 6 min. the 
tubes were shaken three times to ensure dissolution 
and mixing of the contents. After 20 min. the tubes 
were removed, cooled, lml. of water was added to each 
and heated in the boiling water bath for a further
The tubes were cooled in ice water for 10 min. 
and/extinctiors read against a reagent blank at 480,
516 and 552 mji.
The Allen (1950) correction was applied to the 
extinctions of both the analytical and standard tubes.
E cor. (analytical) = 2 E (516) - (E 480 + E 516) 
Results were calculated from the standards of oestriol 
methyl et^ eT* and were converted to oestriol by 
correcting/the differences in the molecular weights.
The method was checked by adding oestriol standard to 
acid hydrolysed urine when-ever new batches of solvent 
or alumina were used.
The recovery of oestriol added to acid hydrolysed 
urine was similar to the recovery described by Brown 
(1955).
Estimation, of Androstenol.
The method of Brooksbank & Haslewood (1961) was used. 
Hydrolysis and Extraction:
l/10th, or in cases of low androstenol level l/5th of 
a 24 hr. specimen of urine was adjusted to approx. pH 
^.5 with a few drops of H Cl. 4iI-sodium acetate buffer 
was added, 6.25ml. to every 100ml. of urine. Also 
limpet powder was added to give a concentration of 
B-glucuronidase of 1,600 Fishman units/ml. of incubation 
mixture and the urine stood at 37° for 70 hr. in an 
incubator. After incubation the urine was extracted 
with an equal volume of diethyl ether, followed by 2 
extractions in the same solvent using 0.5 vols. The 
combined ether extracts were washed with 0.1 vol. of 
N-NaOH followed by water (3 x 0.1 vols). Any 
precipitated material from the incubation flask was 
washed thoroughly with diethyl ether prior to the alkali 
wash. After the diethyl ether extract had been drained 
of excess water it was dried by adding about 10g:.. of 
Na2S0u and left for 1 hr. The ether was filtered into 
a long necked round bottomed flask and the filter paper
and Na2S04 washed twice with 25ml. of ether. .The 
ether was evaporated on a warm water oath and the 
last traces were removed by standing the flask in a 
vacuum desiccator.
Chromatography;
One solvent system was used throughout both to apply 
and elute the androstenol fraction. The dry extract 
was dissolved in 4-ml. of a mixture of benzene/petroleum 
etner (V/V) and applied to a chromatographic column 
containing 5g* of alumina in the same solvent system.
The extract was applied to the column slowly so that 
little spreading at the origin took place. This was 
necessary so that the androstenol eluted in a sharp 
band. The flask was rinsed with 2 x 2ml. of solvent 
and the rinsings also applied to the column. The 
column was allowed to run slowly (30ml./hr.) and the 
eluate containing androstenol was determined by 
plotting the elution pattern either of an extract of 
urine that contained large quantities of androstenol 
or by adding authentic standard to the column. It was 
found that androstenol was eluted after 55ml. of solvent 
had passed through the column, and rhe fraction eluted 
between 65 - 100ml. was collected in a 150ml. long 
necked flask. Constant checks were carried out on 
rhe elution of androstenol and the solvents were made 
up in large batches to avoid any source of variation.
Dry solvents were used for chromatography.
The solvent was evaporated under reduced pressure 
on a water bath and the final traces were removed by 
standing in a vacuum desiccator.
Colorimetry:
The dry extract was dissolved in the flask by adding 
3ml. of 0.5% resorcylaldebyde in acetic acid (¥/V).
The flask was stoppered and rotated so that all traces 
of rhe extract were dissolved and rhe solution obtained 
would be homogeneous. Then, two 1ml. samples v?ere 
pipetted into colour reaction tubes (10 x 1cm.) and 1ml. 
of 5% HoSOq/acetic acid (V/V) was added with careful 
mixing to each tube. Androstenol standards and a blank 
were prepared using the same volumes of both reagents.
The tubes were placed without delay in a boiling 
water bath for 8 min. and then cooled in ice water in 
the dark. After 20 min. the solutions were diluted by 
adding 2ml. of acetic acid to each and E° measured at
5?5 and 530 mji against a reagent blank. The colour 
correction of Gibson & Evans (1937) as adapted by 
Brooksbank & Haslewood (1961) was used. The 
corrected reading E(cor) for the androstenol 
fractions was calculated by substitution in the 
formula as derived by Brooksbank & Haslewood (1961).
E 575 (cor) = K]_ E575 (obs) - E 530 obs.
Kl - Ka
In this method of colour correction, the limiting 
value of m530/E575 was taken as 2 , (Kg) that was where 
an extract contained representative amounts of 
interfering chromogen and little androstenol. The 
value for pure androstenol E530/E575 (Ko) derived in 
this work was 1.04, so that Kp - Ka = 2 - 1.04 = 0.96.
Substitution in the above formula gave
E 575 cor = 2 E575 obs - E 530 obs.
0.96.
Colormetric duplicates were estimated.
Results were expressed as the mean of duplicate 
estimations. Androstenyl B-glucosiduronic acid was 
not available for recovery experiments but experiments 
based on adding pure androstenol to urine before and 
after hydrolysis gave similar results to those attained 
by Brooksbank & Haslewood (1961).
Dehydroeni^androsterone.
Dehydroepi^androsterone was estimated by the method of 
Potherby (1959)•
Hydrolysis and Extraction:
4-Oml. of urine was heated for 6 hr. under reflux on a 
boiling water bath. The urine was used when fresh and 
the pH was not adjusted. After ceding, the urine was 
extracted with 40ml. of benzene and the benzene layer 
was washed three times each with 20ml. of water. 35ml. 
of the benzene extract was evaporated to dryness under 
reduced pressure on a warm water bath. 8ml. of benzene 
was added to the flask, the contents were mixed well 
and the benzene transferred to a chromatographic column 
containing 3g. of alumina in benzene. The flask was 
rinsed with a further 2 x 4ml. of benzene and these 
rinsings were also added to the column. The column 
was washed with a further 10ml. of benzene, this step 
ensures the removal of some pigment band and 
dehydroepiandosterone was eluted in 30ml. of 0.1%
ethanol in benzene (V/V). The eluate was evaporated 
to dryness and the residue together with standard 
dehydroepiandrosterone were subjected to the modified 
Pettenkoffer reaction (Munson., Jones, McCall &
Gallagher, 194-8).
Colorimetry:
The extract was dissolved in 0.2ml. acetic acid and 
0.8ml. of 0.56% furfuraldehyde in 50% acetic acid was 
added followed by Jml. of 8M-H2SO4 . The contents were 
mixed and the tubes were incubated at 68° for 12 min. 
After colour development and cooling E° of each tube 
was read against a blank containing reagents only at 
620, 660 and 700 mp. The correction formula of 
Allen (1950) was applied to both standard and analytical 
tubes.
Recovery:
Recovery experiments were performed by adding DHA - 
sulphate to urine, the results of these experiments 
were calculated after subtraction of the endogenous 
DHA already present. The results obtained were similar 
to those obtained by (Fotherby, 1959).
Preparation of Gonadotrophins from human pituitary glands.
Extracts of human pituitary glands were supplied 
as acetone dried powder by Dr. A. Korner (University 
of Cambridge, Dept, of Biochemistry).
The acetone dried powder was extracted in 10% 
ammonium acetate-ethanol (60 : 4-0: V/V) and then 
precipitated by the addition of ethanol until the 
concentration was 80% (V/V). The fractionation scheme 
is shown on the flow sheet (Fig. 4)- Amounts of 
100-200mg. were applied to columns (20cm. x 1 cm.) of 
carboxymethyl cellulose in 0.01 M-ammonium acetate pH 
6.1. Fraction CM1 was not absorbed under these 
conditions and fraction CM2 which was absorbed was eluted 
in lM-ammonium acetate pH 6.1 GM1 was further 
fractionated on a column of diethylaminoethyl cellulose 
(10cm. x 1cm) by the method described for urine (Butt, 
Crooke & Cunningham, 1959). The fraction eluted in 
0.2M-ammorium acetate was then put directly through a 
column of calcium phosphate (10cm. x 1cm.) and the 
fractions eluted in ImM-and 0.02M-disodium phosphate 
were collected, dialysed and reprecipitated by the 
addition of 5 vol. of ethanol.
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CM2 was refractionated on cartoonymeliFl cellulose 
(20cin. x 1cm.) by stepwise elution in ammonium acetate 
(O.Ol - O.OM). Gonadotrophin was detected only in 
the fraction eluted in 0.1 M-ammonium acetate. In 
all chromatographic work the elution of protein was 
detected by observing the U.V. absorption of the eluate 
at 280mp in a Unicam spectraohotometer S.P. 500.
Pituitary-gland powder
4'"Chromatography on Cm-cellulose
0.01 k-ammonium acetate,pH 6,1 M-amm^nium acetate pH 6.1
c h 1 ck: 24  i
Chromatography on DBAS- Chromatography on CM-
cellulose
0.2 M ammonium 
acetate
/ f 1Chromatography on calcium Phosphate
mM-sodium
phosphate
0.02 M-sodium 
phosphate
CP 1 CP 2
cellulose
__0,1 H ammonium 
acetate
CM 2/2
pH gradient
CP 3
-gig.1.__________________________________________________
Scheme for the chromatographic separation of pituitary- 
gland powders with carboxymethyl (CM)-cellulose and 
diethylaminoethyl (DEAE)-cellulose and calcium phosphate
(CP)._______  , _______________
Other preparations used.
Gonadotrophins from urine were obtained from commercial 
sources, they were Organon &15 prepared from post 
menopausal urine and human chorionic gonadotrophin (HCG) 
obtained from Paines & Byrne Ltd.
human growth hormone:
(HGH) batch No. 83> prepared from acetone dried human 
pituitary powder by the Paben method.
Tlmtftrophic hormone (TSH) and adrenocorticotrophic 
hormone (ACTH) were commercial preparations
Biological Methods.
Ovarian augmentation assay.
In this assay an excess of luteinizing hormone in 
the form of human chorionic gonadotrophin is added to
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the test material (Brown, 1955) and the combined, weight 
oi the ovaries is the criterion of the response. The 
procedure is sometimes termed the 'augmentation assay' 
and is thought to be fairly specific for P8H (Brown, 
1959).
Immature female mice of an albino strain supplied 
Dy a dealer accredited by the Medical Research Council 
(Mr. W. Clarke of Oldham) were used. The gonadotrophi 
material to be assayed and the added HCG were injected 
subcutaneously in five equal doses, each in 0.5ml. 
physiological saline, over a three day period.
Injections were made twice a day on the first two days 
and once on the third. The animals were killed approx.
hr. after the first injection and the ovaries were 
dissected and weighed.
Ovarian ascorbic acid depletion assay.
Parlow (1958) described a method for the estimation 
of LH activity in pituitary extracts in which intact 
rather than hypophysectomised animals were used. The 
end point of the assay depended on the depletion of 
ascorbic acid in the ovaries of pseudopregnant rats.
This assay was claimed by Parlow to be highly specific 
and sensitive for LH. The technique used was 
essentially that of Parlow (1958, 1961) with a few 
minor modifications. The procedure was carried out 
in two stages -
Pretreatment of animals:
Immature female rats weighing'40 - 50g. were used.
Each animal received a subcutaneous injection of 50 i.u. 
of pregnant mare serum gonadotrophin (PMS Gestyl,
Organon) and 56 - 65 hr. later a subcutaneous injection 
of 25 i.u. HCG. (Pregnyl-Organon) . Both preparations 
were dissolved in physiological saline and eaafe injection; 
wasa given in a total vol. of 0.5ml.
As a result .of this treatment the animals became 
pseudopregnant and showed heavily luteinized ovaries 
ranging in weight from approx. 80 - lOOmg.
Bioassay of preparation:
This was performed on the 5th or 6th day after the 
injections of HCG. The rate were injected intra- 
peritoneally with the gonadotrophic material to be 
assayed dissolved in 0.2ml. of physiological saline.
The animals were killed 4 hr. later by cervical 
dislocation. The right ovary from each animal was 
removed, rapidly cleaned on filter paper moistened with
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2.5% metaphosphoric acid, and weighed. Ascorbic acid
was estimated according to the specification of Dekanski
& Harvie (I960). Each ovary was homogenized using a
mortar and pestle with 2.5% meta phosphoric acid (W/V,
freshly prepared) and a trace of sand. After a
thorough grinding the homogenate was suspended in a
total volume of 10ml. of 2.5% metaphosphoric acid and
allowed to stand for-at least 30min. At this stage
the siispension could "be left overnight in a refrigerator
at 4 provided freshly prepared ascorbic acid standards
were kept similarly. The suspension was centrifuged
at 2,500 r.p.m. for 5 min. and 8ml. of the supernatant
was taken for the estimation of ascorbic acid. 7.0ml.
of 4.53% sodium acetate adjusted to pH 7.0 with acetic
acid was added followed by lml. of 0.03% 2 : 6
dichlorophenolindophenol. This produced a pink colour
the extintion of which was read at 520 mja* A
calibration curve for ascorbic acid in concentrationsphonicup to 200 ug./lOml. in metaphosy0 acid was prepared.
The unknown values for the test solutions were interpolated 
and the results were expressed as pg. ascorbic acid/lOOmg. 
tissue.
Immunological Methods.
Immunological estimation of ECG in urine.
Production of antisera:
lg. of bentonite (B.D.H. Ltd.) was suspended in 100ml. 
of 0.9% sodium chloride solution. Coarse particles 
were allowed to settle out and were separated by 
decantation and discarded. 2.7mg. of a preparation of 
chorionic gonadotrophin (Leo Pharmaceutical Products, 
Copenhagen) equivalent to 4-,4-00 units of International 
Standard was mixed with an equal weight of suspended 
bentonite. The volume was adjusted with the saline to 
12ml. and 2ml. was administered intravenously to rabbits 
(Sandylops) twice a week for .three weeks or more until 
a satisfactory antibody titre was obtained. The rabbits 
were bled seven days after the last injection and a few 
drops of 10% solution of sodium azide was added to the 
serum as a preservative and. stored at 4°.
Red cell haemagglutination technique.
The reaction between anti HCG and red blood cells 
coated with HCG was used for the quantitative estimation 
of HCG in the urine of pregnant women.
Sheep cells preserved in Alsever solution were
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obtained from Wellcome Research Laboratories Ltd. The 
cells were washed three times with normal sodium 
chloride solution and then treated with pyruvic aldehyde 
(25% solution, L. Light & Co., Ltd.). 1.6 vol. of this 
reagent was added to 3.0 vol. of sodium chloride solution 
and the pH was brought to approx.* 7.0 with 10% sodium 
carbonate solution. 0.7 vol. of 0.15M-phosphate buffer 
pH8.0 and 1 vol. of 50% suspension of red cells were 
than added to the mixture and stored at A-0 for two 
days with occasional mixing. The cells were thoroughly 
washed with sodium chloride solution and stored as a 
10% suspension containing 0.1% of sodium azide as 
preservative.
Antisren was then attached to the cells. A portion 
(2ml.) of the 10% suspension of cells was centrifuged 
and the suoernatant discarded. The cells were washed 
once with dilute buffer (sodium chloride-water-phosphate, 
0.15M, pH 6; 10 : 10 : 1 x vol.) and then suspended in 
1.5ml. of the same buffer containing 100 - 500 ug. of 
antigen. After heating at 50° for 1 hr. the cells 
were centrifuged and washed three times with sodium 
chloride solution containing rabbit serum (0.5%) and 
finally were suspended in 10ml. of sodium chloride 
solution containing 1% (V/V) of rabbit serum and 0.1% 
azide. Antiserum was heated at 56° for 30 min. to 
destroy complement and was then absorbed with sheep red 
cells as described by Read & Bryan (I960),
0.2ml. of sodium, chloride was added to each well 
in a perspex agglutination tray and a series of doubling 
dilutions of urine and of a laboratory standard of HCG, 
starting at a concentratianof 10 i.u./ml., were set up.
A portion 0.2ml. of serum-sodium chloride solution was 
added to each well followed by 2 drops (0.05ml. approx.) 
of red cell suspension. After mixing, the cells were 
allowed to stand overnight. If no haemagglutination 
occurred the cells sank to the bottom of the well 
forming discrete buttons: if haemag-Tlutination occurred 
the cells spread out evenly over the bottom of the well. 
Results were calculated by companion between the 
haemagglutination in the standard and test rows and 
expressed as i.u. HCG/24- hr.
Statistical Methods and Presentation of Results.
Standard statistical procedures were employed both 
for analysis and design of experiments. Analysis of
-  2% -
variance was carried out as described by Davies (I960). 
Where ever possible results of experiments were shown 
~raohically as well as graphic illustrations of the 
statistical analyses. The results of bioassays were 
calculated by the method of Gaddum (1953) and Borth 
(I960).
RESULTS
SECTION I
A shortened procedure for the estimation of Oestriol 
in Urine.
This section describes a method for the estimation 
of oestriol in urine based on the method of Brown (1955) 
and the modification of that method by Brown, Bulbrook 
and Greenwood (1957) and Salokangas and Bulbrook (1961).
Experiments and Results.
Hydrolysis :
In the method of Brown (1955) HC2D.G. was used to
hydrolyse the three oestrogens, oestriol, oestr&sge and
oestradiol- 17^ from their urinary conjugates. The
hydrolysis involved adding 15ml. HCI.G. to 100ml. of
urine and refluxing for 1 hr. Using the same method
Brown and Blaie (1958) showed that oestriol was liberated
from its conjugate in urine in a much shorter time if
the amount of acid used was increased. They found that
adding 20ml, UGT>/100ml. of urine liberated maximum
quantities of oestriol in 50 mins, but the hydrolysis
of the other two oestrogens required a longer time.
Preedy and Aitken (1961) also found that 17.5% of gg^.G.
with 4-5 mins, boiling resulted in maximum recovery of
oestriol. In the method described here 20ml. of HGI-G.
was added to 100ml. of urineiwhich was boiled under!
reflux for 50mins.
Extraction:
It was found that a single extraction with an 
equal volume of diethyl ether was adequate to extract 
oestriol from acid hydrolysed urine but occasionally 
emulsions were formed between the 2 layers. T^ese 
emulsions are not troublesome in the Brown method as 
they are dispersed by the large volumes of ether used.
To overcome this difficulty, in the shortened procedure, 
sodium chloride was added to each separating funnel 
before the urine was extracted. This had the extra 
advantage that the increase in salt content of the 
urine altered the partition coefficient of oestriol in 
favour of the ether layer. The addition of sodium 
chloride was therefore incorporated in all estimations.
The extraction and washings with buffer and alkali are 
identical to those used by Brown (1955) hut the volumes 
were reduced by approximately one third. In the 
method of Brown the ether extract after washing with 
alkali and water was e'vaporated to dryness and the 
residue was taken up in benzene/petroleum ether (25/15 V/V)
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Oestriol was extracted from the mixture with water, and 
oestronee and oestradiol with dilute alkali. Since 
the oestrcasee and oestradiol fraction was not needed 
in this short method it was decided tV-extract the 
oestriol directly from the diethyl ether layer by dilute 
alkali, so omitting'the benzene/petroleum ether 
partition stage. In a later modification of the method 
of Brown (Brown, Bulbrook and Greenwood, 1957 b) used 
this step to extract oestriol from diethyl ether.
The extract of oestriol prepared by this procedure 
contained more pigment than is normally found in the 
corresponding oestriol fraction. This was partly due 
to the slight solubility of diethyl ether in alkali so 
that some ether that contained pigment was brought 
through by the alkali. This ether evaporated off 
during the methylation procedure and did not cause any 
trouble at the chromatography stage.
Colorimetry:
The conditions for the development of the Kober 
colour were identical to those described by Brown (1955). 
A greater sensitivity could be attained for the method 
if the volumes of reagents used were reduced. The work 
of Salokangas and Bulbrook (1951) showed however that 
the development of the Kober colour was reduced as the 
amount of urine residue increased and no improvement 
in the results were obtained even after extraction of 
the Kober colour into organic solvent.
Comparison of the established method with the 
shortened procedure using the original Kober colour 
without solvent extraction, showed clearly that at low 
concentrations of oestriol the shortened procedure 
over-estimated the quantities of oestriol present.
This was due to the fact that the colours produced in 
the shortened procedure were observed to contain more 
pigment than the corresponding extracts obtained by the 
longer method. A further purification stage was 
therefore required in the method to remove this non­
specific interference by pigment and to achieve this 
the final Kober colour was extracted into an organic 
solvent.
Bradshaw (1961) found that the addition of 
trichloroacetic acid (T.C.A.) to the final Kober 
solution of oestrone and oestradiol enabled the colour 
to be extracted into chloroform. The extracted colours
were found to absorb at longer wavelengths and had 
increased in intensity and were more stable than those 
extracted by the method of Ittrich (1958). Chloroform 
had the advantage of extracting less non-specific colour 
than tetrachloroethane (Alderceeutz, 1965). The 
extraction procedure of Bradshaw was therefore used to 
estimate oestriol.
This procedure was more suited for extraction than 
some of the other solvents used (tetrachloroethane, 
tetrabromoethane) which had unpleasant toxic fumes.
This procedure of extraction into chloroform was found 
suitable for a method to be used in a routine laboratory 
where special fume cubboards are generally not installed. 
When this extraction was applied to oestriol methyl ether 
after development (of the Kober colour) it was found that 
the extracted colour exhibited an absorption maximum at 
552mji and had increased in intensity. Taking the 
absorption maximiM at 532mp. and applying the Allen 
correction using extinction readings equidistant from 
the maximum on each side of the absorption spectrum, a 
straight line graph was obtained by plotting corrected 
reading distance (mja) from the maximum. This satisfied 
the condition (O'Sullivan, 1958) for the validity of 
the Allen correction; so in the method, readings were 
taken at 502, 532 and 562 mp. and the Allen correction 
applied.
This change in wavelengths of the extracted colour 
of oestriol methyl ether led to a greater degree of 
specificity to the colour reaction and a greater degree 
of purity of the final colour. Considerable quantities 
of pigment were found coagulated at the interface of the 
acid and chloroform layers, this pigment was removed 
with the acid layer before colorimetric estimations.
The absorption spectra and calibration curves for the 
shortened procedure (B) and the method of - Brown (A) 
are shown.
Stability of the colour:
Salokangas and Bulbrook (196i) claimed that 
considerable fading took place when the Kober colour 
was extracted into chloroform following dilution of the 
original Kober colour with water. Similar results were 
found by Aldercreutz (1963) who reduced the degree of 
fading considerably by working with ice cold reagents.
In this work it was found that after dilution of the 
Kober colour with trichloracetic acid the amount of fade
C
O
R
R
EC
TE
D
 
R
E
A
D
IN
G
Calibration curves for oestriol methyl ether
(A) prepared according to the method of Brown (1955)
(B) prepared hy the conditions described in the short 
method.
Absorption spectra of(1 ) authentic oestriol methyl ether (closed circles)
(2) extract from pregnancy urine (open circles)
(3 ) extract from urine that contained only a small 
quantity of oestriol (broken line)
at 532mji was negligible during the first 30min. when 
ice cold reagents were used f'or dilution and extraction. 
This small amount of fading in colour did not 
constitute any disadvantage to the method as never more 
than ten estimations were made at any one time and 
standards were incorporated with each hatch. When the 
colour was extracted the tubes were protected from 
sunlight as much as possible and each batch estimated 
by a standardised procedure for centrifugation and 
colorimetric estimation.
Method in Detail
As in the method of Brown (1955) no preservative 
was added to the urine.
Hydrolysis and extraction:
100ml. of urine was boiled under reflux arc, when 
coiling 20ml. HOI was added and some alundum chips and 
boiling continued for 30min. The urine was cooled 
under running water and transferred to a separating 
funnel that contained 120ml. of diethyl ether and I6g. 
of sodium chloride. The funnel was shaken thoroughly 
and the two layers were allowed to separate. The acid 
layer was discarded and the ether was washed with 25ml. 
of NaOH/HaHCO^ buffer (pH 10.A) which was discarded. 
6.5ml. of 2N-NaOH was then added to the separating 
funnel and the contents were shaken. After allowing 
this alkaline layer to stand for 5 min. 25ml. of 8% 
NaHCO^ was added and the flask again shaken thoroughly. 
The alkaline layer was discarded and the ether was 
washed with 5ml. of 8% FaHCOj to remove the last traces 
of the previous alkaline wash from the stem and tap of 
the separating funnel.
Methylation;
When the last traces of bicarbonate had been 
drained off, the ether was extracted twice with 25ml. 
of 1.6% NaOH which was added to a methylation tube 
(large ground glass stoppered test tube approx, vol. 
100ml.). 0.9g« of boric acid was also added and the
tube was stood at 57° in a water bath. When the boric 
acid was dissolved 1ml. of dimethyl sulphate was added 
to the tube which was then shaken so as to disperse the 
dimethyl sulphate. A few alundum chips were added to 
the methylation tube, they assisted in the evaporation
of the ether, that had "been brought through by the 
alkali. After standing the tube for 30min. at 37°,
2ml. of 5N--HaOH was added followed by 1ml. of dimethyl 
sulphate. The mixture was again shaken and stood at 
37° for a further 30min.
Extraction and chromatography:
The methylation mixture was cooled and added to 
a separating funnel that contained 10ml. of 5N-HaOH.
2.5ml. H2O2 was then added and the. methylation tube 
was rinsed with 25ml. of benzene which was also 
transferred to the separating funnel. The funnel was 
shaken thoroughly and the alkaline layer separated.
The benzene layer was washed with a further 2 x 5 ml. of 
water. When the benzene was finally drained free of 
water it was transferred to a chromatographic column 
that contained 2g. of alumina set up in benzene.
When the level of the benzene had reached the level of 
the alumina the extract was added to the column. The 
first fraction was eluted in 12ml. of 1.4% ethanol/ 
benzene which was discarded and the second fraction,
16ml. of 2.5% ethanol/benzene was collected. 0.2ml. 
of 1% quinol in ethanol and some anti-bump granules was 
added to this fraction and the solvent evaporated.
Colorimetry:
The Kober reaction was performed on the dry extract 
by adding 3ml. of Kober reagent and heating for 20min. 
in a boiling water bath. The tubes were shaken twice 
during the first 6 min. of heating to dissolve the 
extracts. On cooling' 1ml. of water was added and the 
tube heated for a further lOmin. The tube was again 
cooled.
3ml. of this Kober solution was added to a small 
glass stoppered tube (Quickfit and Quartz) which contained 
1.8ml. of ice cold trichloracetic acid. The two acid 
layers were mixed by gentle rotation and the tube was 
cooled again in ice. After 5min. 2ml. of ice cold 
chloroform was added and the tube was shaken for 30sec. 
Immediately it was centrifuged at approx. 1700g. for 
2 min. to separate the two layers. The acid layer 
was removed by suction together with any coagulated 
pigment at the interface of the two liquids. The 
extinction was read at 502, 552 and 562 nyx. on a Unicam 
S?P.600/ against a reagent blank brought through the 
method. Standards were incorporated in each batch of
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estimations and from the Allen correction the quantity 
of oestriol methyl ether and hence the amount of 
oestriol present was calculated.
Comparison of the modified method with the 
method of Brown (1935)
Urine from women with secondary amenorrhoea who 
were excreting small quantities of oestriol was pooled. 
Estimations were performed "by the method of Brown and 
"by the short procedure on the pooled sample of urine 
to which had Been added different quantities of oestriol 
after hydrolysis. Each estimation was carried out in 
duplicate and the results by the short method are shown 
before and after extraction into chloroform (Table A).
Oestriol 
added/iaq / 24hr.
Brown
1955 A
Short Procedure 
Extracted. B.
Short Procedure 
Unextratted. C.
0 3.2 4,1 8.8
6.8 1.7 4.8
4.5 10.0 6.7 10.7
9.4 • 7.? 12.9
9.0 1 1 .? 10 .1 13.9
1 1 .2 10.0 14.5
15.5 13.1 13-3 17.7
13-5 16.6 24.5
18.0 19.1 19.7 22.4
19.4 19.2 22.6
22.5 22.2 23.9 30.0
i'O • 19.8 22.4
“t i & o W 81 87 98
TABLE A. The results of duplicate estimations and
mean percentage recovery at different levels of 
oestriol using
A) The method of Brown 1955*
B) The short procedure.
C) The short procedure without colour extraction.
These results show that the estimates obtained by 
the short method agree reasonably well with those 
obtained by the method of Brown when the colour was 
extracted*. Since the extraction procedure auaitidtati^ely 
extracts the Kober colour (Bradshaw, 1961) the reason
for the differences must he due to pigment present 
that is not accounted for by the Allen correction.
After this initial experiment the extraction stage 
was therefore incorporated in all estimations.
Recovery experiments were performed by adding 
known Quantities of oestriol to samples of pooled urine 
from women who excreted small quantities of oestriol.
At low levels of oestrogen excretion the percentage 
error of a single estimation increased (Brown, Bulbrook 
and Greenwood, 1957) and therefore the range of recovery 
experiments was split into three groups. The results 
are shown in Table B.
Range. 
^ig./24hr.
No. of
duplicate
estimations.
Mean % 
Recovery. + S.D.
4.5 - 9.9 10 76 ± 16.7
10.0 - 15.1 10 87 ± 8.6
15.2 - 40.0 14 85 ± 6.5
TABLE B. Results are shown as the mean percentage 
recovery ± standard deviation and are corrected 
for the endogenous blank value. The range of 
oestriol expressed as jig./24 hr. and the number 
of duplicate estimations oerformed are also shown.
Since oestriol conjugates were not available for 
recovery experiments and the object of the investigation 
was to derive a method to replace the method of Brown 
(1955) it was considered suitable to compare the results 
of duplicate analyses on aliquots of the same urine 
samples by both methods over a wide range of concentrations 
and to estimate the S.D. of each method in the range 
chosen.
An analysis of variance was performed on 20 
duplicate estimations of the oestriol levels in urine 
from a group of different patients who excreted oestriol 
in the range 4.0 - 45.0jig/24hr. Results are shown in 
Table C. It was found that in this series there was 
no significant difference between the values obtained 
by the method of Brown and the shortened procedure.
The standard deviation was derived for the range 4.5- 
130)ig/24hr. for the shortened procedure and 4.5- 45jig/
24hr. for the method of Brown.
-4.0-
U )  (B)Range 
jXE • /24hr.
S.D. of
Shortened
Procedure
Number of 
duplicate 
estimations
S.D. of
Brown
Method.
Number of 
duplicate 
estimations.
4.5 - 9.9 e. 65 19 1.07 8
9.9 - 15 1.45 13 - -
15 - 45 1.19 22 1.00 11
40 - 130 1.63 16 —m
TABLE C , ^ This table shows the standard deviation
derived for the short method (A) and the method of 
Brown (1955) (B) over different ranges of oestriol 
values. The number of duplicate estimations performed are also shown.
The method of Brown was not investigated at levels 
above 45. O^g ./24hr. as above this level the urine was 
diluted with water which gave better results by reducing 
the amount of pigment present at the colour development 
stage and the decrease is oestrogen destruction during 
hydrolysis (Brown & Blair, 1958). The results show 
that the shortened procedure appears to be suitable for 
estimating oestriol levels up to 13CyUg./24hr. without 
introducing any greater error.
Comparison of the two methods on urine from 
pregnant women.
The method of Brown (1955) was compared -with the 
short method by carrying out duplicate estimations on 
20 samples of urine from women at different stages of 
pregnancy. There was no significant difference between 
the results of the two methods.
The standard deviation of the methods was derived 
over the range of oestriol excretion encountered in 
early pregnancy.
Ban?re ^S.D.(b ) Number of ^,S.D. of(A) Number of
mg./24hr. '°Brown duplicate ^shortened duplicate
Method. estimations, procedure. estimations.
0.98-12.0 a»4iC> 20 0,36 50
TABLE D. This table shows the%standard deviation of
the short method (A) and that of method of Brown (B) 
when used for estimating oestriol in urine from 
pregnant women. The number of duplicate estimations performed are also shown.
The results show that the short procedure is 
applicable to the range of oestriol levels encountered 
during pregnancy and the standard deviation of both 
methods is approximately the same.
RESULTS
SECTION II
RESULTS.
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Presentation of results.
The results have been presented as follows: 
first, the individual responses of the patients have 
been recorded graphically in full in Eigures 4, 8-10 
and 14; second, the analyses of variance of the 
responses have been given in .Tables in the text' 
and the results described in the text and shown graphically 
with the 95% confidence limits in Eigures 5-7? 11-15 and 
15-19* Finally they have been summarised briefly in 
the Conclusions following each Experiment.
Experiment 1.
Comparison of the Effects of Different Gonadotrophin 
Preparations on Steroid Excretion.
In this experiment four patients, A,B,C and D, 
were given four treatments:- control (gelatin), CM 1,
CP 2 and 615 over four courses of 28 days each. Each 
course of treatment was given in equally divided doses 
of ES.H daily for ten days, followed by H.C.G. for four 
days. The daily doses of CM 1, CP 2 and 615 were all 
equivalent to 500mg. I.R.P.-H.M.G., measured by the 
augmentation method for E.S.H. Since they contained 
different amounts of luteinizing hormone, however, the 
amounts of total gonadotrophin varied between 
preparations. From the 11th to 14th day inclusive 
of each month each patient received 6,000 i.u. H.C.G. 
daily. Twenty-four hour samples of urine were 
collected on alternate days and oestriol and 
pregnanediol determined. The results are shown 
graphically in Figure 4. None of the patients 
responded in the control month despite the fact that 
they received 24,000 i.u. H.C.G.
Patient A responded to CM 1 with a slight mid­
cycle rise in oestriol followed by a higher secondary 
rise and a slight rise in pregnanediol (Figure 4, A2).
She responded to CP 2 with a normal mid-cycle rise in 
excretion of oestriol with a normal luteal rise of 
pregnanediol followed by menstruation (Figure 4, A5).
With 615 she showed a secondary rise in oestriol which 
was even more pronounced than with CM 1 but there was 
no rise in pregnanediol (Figure 4, A4).
Patient B failed to respond to CM 1 (Figure 4, Bl).
She responded to CP 2 with a slightly delayed but good
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rise in excretion of oestriol and a poor rise in 
pregnanediol in the luteal phase (Figure 4, B2) and 
she showed a slight mid-cycle rise in oestriol with 
613 "but no change in pregnanediol (Figure 4-, B3).
She showed no change in the control month. She 
menstruated only after 613.
Patient C was found to have a high excretion of 
pregnanediol in the control period (Figure 4, C3) •
She showed no response to CM 1 (Figure 4-, C4-) but with 
CP 2 the pregnanediol fell to the normal level and she 
showed a slight rise in the excretion of oestriol 
(Figure 4-, Cl). With 613 the pregnanediol again fell 
to the normal range and rose in the luteal phase despite 
the absence of any rise in excretion of oestriol 
(figure 4-, C2). She failed to menstruate with any 
treatment.
Patient I) showed a slight rise in excretion of 
oestriol following CM 1 (Figure 4-, D3) and 613 (Figure 4-, 
Dl), but there was no response to CP 2 (Figure 4-, D4-). 
There was no change in pregnanediol and she failed to 
menstruate with any treatment.
Analysis of Results.
Each cycle of 28 days was divided into four-day 
periods during the majority of which there was two 
measurements of oestriol and two of pregnanediol. The 
effects of the treatment were analysed separately for 
each of;the first five four-day periods (i.e. the first 
20 days -;®f the cycle). . The oestriol and pregnanediol 
results were analysed independently (Tables I and II). 
Oestriol:
Only the first four four-day periods were analysed.
The fifth^as omitted from the analysis because there 
were not sufficient observations, but the average for 
that period is shown with the others in Figures 5 and 6A.
Periods 1 to 3: The differences between the average 
figures for different patients and between the effects 
of different preparations were small and could be 
attributed to chance.
Period 4-: The excretion of patient A was probably
higher than that of patients B and D whose excretion was 
probably higher than that of patient C (figure 5) • 'The 
average excretion following treatment with CM 1, CP 2 
and 613 was higher than that following the control. The 
highest average excretion was after CP 2, although it was 
not significantly higher than that after CM 1 or 613 
(Figure 6A).
FIG. 5.
PERIODS
Average excretion of oestriol in periods 1 to 5 in the four patients
The bars represent the 95 per cent confidence limits in this and 
succeeding figures.
FIG. 6A
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The experiment provided no evidence that the 
average excretion differed significantly from month 
to month.
The results of oestriol excretion for the four 
periods were combined into one analysys (Table III), 
which showed the following significant factors:
1. Period to period differences - the average for the
fourth period was higher than that for the other 
three periods (Figure 7 A). . .
2. Patient to patient differences - Patient A had a 
higher overall response than the other 3 patients 
(Figure 7B) .
3. Treatment to treatment differences - CM 1, CP 2 
and 613 produced a higher oestriol excretion than 
the control treatment. It is probable that CP 2 
and 613 produced a higher response than CM 1, 
(Figure 7C).
Pregnanediol:
An analysys was made for each of the first five 
four-day periods. Patient C was found to have a 
significantly higher basal excretion than the others 
and therefore her figures were omitted from the analysis 
The effects of different treatments for the other three 
patients are shown graphically in Figure 6B.
Periods 1 and 2: There were no significant
differences between the average figures for different 
patients and for different preparations. Patient A 
showed a rise in excretion above the control level with 
CM 1, CP 2 and 613. Patient B showed no change with 
CM 1 or CP 2 but it is probable that there was a small 
increase with 613 while patient 33 showed a rise with 
CM 1 and CP 2 but not with 613-
Period 3i Patient A again showed a rise with 613 
but with CM 1 and CP 2 her excretion did not differ from 
the control level. Patient B also probably showed a
slight rise with 613 and no change with CM 1, or CP 2 
but with patient D excretion rose with CM 1 and CP 2 
and there was no evidence of a significant rise with 613 
Period A: Patient A showed an appreciable rise
above the control level with CP 2 and there was also a 
rise with CM 1 but with 613 it fell to the control level 
again. Patient B showed no change with CM 1 or CP 2 
but it is probable that there was a small increase above 
the control level with 613. In patient D excretion 
remained above the control level with CM 1 and CP 2 but 
there was no evidence of a significant rise with 613.
Tafcle III Analysis of Variance
Experiment 1: Oestriol
Source Sum of squares
df Mean
square
Between periods 162,669 3 5U,223
Between patients 50,293 3
***16,761+
Between treatments 59,609 3
«{! 5g? $19,870
Interactions:
Periods x patients 53,1+21 9 5,936
Periods x treatments 5U,615 9 6,068
Patients x treatments 36,181+ 9 l+,020
Periods x patients x 
treatments
116,898 27 U,330
Residual 2i+l+>997 60 l+,083
Total 778,686 123
* * # Significant at 0.1^ level
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Effect of different treatments on the excretion of 
pregnanediol by patients A, B and D.
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Period 5* As in period 1 the apparent 
differences could he readily explained by chance variation.
Combining the results of pregnanediol excretion for 
the 5 periods into one analysis confirmed the above 
observations without providing any further information.
Conclusions:
The patients showed different degrees of sensitivity 
to treatment suggesting that they require different doses. 
The graphical summary of the results, shown in Figures 
5 and 6, suggests that CP 2 had produced the most normal 
pattern of excretion of oestriol and pregnanediol and 
that the response with CM 1 and 613 was less than with 
CP 2. There was no evidence of any difference in 
response in different months of treatment.
-4s"
Experiment 1A.
Treatment with (CP 2)^  the gonadotrophin preparation 
that appeared to give the best responses in Experiment 1.
Since Experiment 1 had shown that’ CP 2 gave the 
most promising results this material was given in the 
same dosage and for the same number of days to all 
four patients again. In order to try to increase the 
responses, however, particularly in patients C and D, 
they were all given H.C.G. in a dosage of 6,000 i.u. 
daily for eight days instead of four, from the 7th to 
the 14-th day inclusive. Thus they received HCG 
simultaneously with F.S.H. for four days, from the 7th 
to the 10th day inclusive.
This short experiment was not analysed statistically 
since the differences between the responses of the 
patients were obvious from the plotted results.
The effect of increasing the total dosage and the 
length of treatment with H.C.G. was surprising. Patient 
A showed a similar rise in excretion of oestriol at mid­
cycle and of pregnanediol in the luteal phase (Figure 8, 
A5) to that seen previously with CP 2 (Figure 4, A3).
The rise in oestriol however was followed by a sustained 
secondary rise during the luteal phase. This was 
followed by menstruation. Patient B showed only a 
sustained late rise in excretion of oestriol without 
any appreciable change in the excretion of pregnanediol 
(Figure 8, B5). This was also followed by menstruation. 
Patient C showed an early rise in excretion of oestriol 
but no change in pregnanediol (Figure 8, C5) nnd patient 
D failed to respond (Figure 8, D5)• Neither patient 
C nor D menstruated.
All four patients were readmitted for a second 
examination under anaesthesia and culdoscopy on the 
15th day of the cycle. The results are shown in 
Table III/}. The uterus and ovaries of patient A had 
increased in size and she showed developing follicles 
but no corpora lutea. The uterus of patient B was 
larger than when first examined while those of patient 
C were unchanged. The uterus of patient D was slightly 
larger but her ovaries were unchanged.
The stroma and glands of the endometrium of 
patients A and B now looked functional and in the 
proliferative phase whereas those of patient C showed 
very little change and of D no change.
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The excretion of oestriol and 
pregnanediol "by patients A, B, 
C and D, given FSH (CP 2) and 
HCG.
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Conclusions:
None of the patients had a response which was 
similar to the normal pattern. The response of 
patient A was nearest to normal and the varying 
responses confirmed the suggestion in the first 
experiment that the patients would require different 
dosage levels. The observations made by culdoscopy 
further confirmed the differences in response between 
patients.
After Experiment 1A the patients had two months 
with no treatment to establish whether they would now 
menstruate spontaneously, but none did.
Experiment 2.
The effect of varying; the total and daily dosage of 
P.S.H. on steroid production.
This experiment was designed to test the effect of 
varying (a) the total dosage and (b) the daily dosage 
of P.S.H. The preparation used throughout the 
experiment was CP 1 as no more CP 2 was available.
Since it had been shown previously that there was 
a difference in sensitivity of the different patients 
to F.S.H., and since pregnancy was the primary objective 
of the experiment, it was decided to vary the dosage 
arbitrarily to suit each patient. The dosages for 
each patient were therefore called low (L), medium low 
(ML), medium high (MH) , and high (H). Since it had 
also been shown previously that the order of treatment 
did not appear to alter its effects it was decided to 
give each patient the ML dose in the first month. If 
at the end of the first month it was found that this 
dosage was too great or too small for any of the 
patients it was still possible to adjust it for the 
individual patient concerned by calling this dose H,
MH, or L instead of ML, and this was found in practice 
to be necessary for patients A and D.
It-was decided to reduce the treatment with F.S.H. 
arbitrarily from ten days to eight days and to divide 
the total dosage of CP 1 so that it was reduced by a 
factor of 0.9 each day in one month, 0,8. in another and 
0.? in a third, while in the fourth month the daily 
dosage would remain constant so that the factor was 1.0 
These factors have been called the rates of fall-off.
The final total dosages and the factors varying the 
daily dosages are shown in Table TV £
TABLE IVft
EATS OP PALL OPP OP F.B.H.
PATIENT e.7 0.8 0.9 1 . 0
2400 2640 2904 3200
A L ML MH H
B 3200 2640 3520 2904MH L H . ML
f t 4184 3800 3456 3128H MH ML L
I) 4120 4981 3744 4528ML H L MH
Table shows the Total dose of P.S.H. (CP 1) in
- U 8  -
terms of mg. equivalents IEP-HMG used with different 
rates of fall off. The letters designate the level 
of dose used in each patient.
H.C.G. (6,000 i.u.) was given daily for four days 
as in Experiment 1.
Perusal of the data obtained so far showed that 
the peak in excretion of oestriol at mid-cycle was of 
short duration and it was possible that small peaks 
would be missed if the urine was examined only on 
alternate days. Two day collections of urine v/ere 
therefore pooled over a period of eight days. These 
pooled samples were for days 8 and 9, 10 and 11, 12 
and 15, and 14 and 15- It was decided to examine 
also isolated samples on days 4, 17, 19, 21, 25 and 28, 
the last serving as control for the following month.
The normal patterns of excretion of oestriol and 
pregnanediol based on these samples was given in 
Figures 2B and 50.
The results and dosages are shown graphically in 
Figure 9- Patient A showed a doubtful rise in 
excretion of oestriol on L dose at a rate of fall-off 
of 0.7 (Figure 9, A6) , a good rise on MH at 0.9 
(Figure 9, A7) and no rise on ML at 0.8 (Figure 9, A9) 
but there was no rise in pregnanediol in any of these 
months. On H at 1.0 (Figure 9, A8) , however, she 
showed a slight rise in excretion of oestriol on days 
8 and 9 followed by a fall and then a pronounced rise 
in the luteal phase. There was also a pronounced 
rise in excretion of pregnanediol which reached a maximum 
level of 9.9mg/24hr. during days 14 and 15. She failed 
to menstruate after any of these treatments.
Patient B showed a normal pattern of excretion of 
oestriol and of pregnanediol on ML at 1.0 and menstruated 
scantily afterwards (Figure 9, B6). She showed no 
response on H at 0.9 (Figure 9, B7) and a slight rise 
of oestriol at mid-cycle on L at 0.8 (Figure 9, B8).
Both were followed by slight bleeding. There was no 
change in excretion of oestriol on MH at 0.7 (Figure 9, 
B9) but surprisingly there was an increase in 
pregnanediol during the luteal phase and she menstruated.
Patient C showed a slight rise in excretion of 
oestriol at mid-cycle and another during the luteal 
phase on ML at 0.9 (Figure 9, 06) but no response on 
MH at 0.8 (Figure 9, C7). She had a scanty 
menstruation after the latter. There was a striking
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rise in oestriol but only a slight rise in ' 
pregnanediol in the luteal phase on H at 0.7 
(Figure 9 5 08) followed by menstruation. There was 
no rise on L at 1.0 (Figure 9* 09) but she had another 
scanty menstruation. Changes in excretion of 
pregnanediol were obscured by her high control figures.
Patient D showed a striking rise of oestriol on 
days 10 and 11 on H at 0.8 (Figures 8 and 10, D6).
This was followed by a fall on days 12 and 13 and then 
it soared to 376 jag./24hr. by the 17th day. Both 
steroids fell to normal again on the 28th day and she 
menstruated for the first time. On ML at 0.7 she 
failed.to respond (Figure 9, D7). On MH at 1.0 the 
excretion of both oestriol and pregnanediol showed 
changes which were remarkably similar in quantity and 
timing to those observed previously on H at 0.8 
(Figures 9 and 10, D8). On this occasion, however, 
they continued to rise progressively, oestriol 
reaching a figure of 856 £g./24hr. on the 28th day 
and pregnanediol 78.5mg/24hr. on the 23rd day of the 
cycle suggesting pregnancy. This was subsequently 
confirmed.
Analysis of Results:
The 28 day cycle was divided into five periods 
each containing two observations. These periods were:- 
(1) days 1-4, (2) days 9-10, (3) days 13-16,
(4) days 17-20, (5) days 21-24. No observations were
made during days 5-8 or days 25-28. The effects of 
treatment were analysed separately for oestriol and 
pregnanediol as in Experiment 1.
Because of the design of the experiment it was 
possible to isolate and examine separately the effects 
of three factors; the differences between patients, 
between different dosages of F.S.H. and between the 
different rates of fall-off in dosage. It was originally 
designed as a Latin Square in which each patient was 
given each of the four dosage levels of F.S.H. using 
each of the four rates of fall-off in dosage. However, 
the results for patient I) who became pregnant during 
the third month of the experiment had to be omitted 
leaving the rest in the pattern of a Youden square.
Each period was analysed separately for oestriol and 
for pregnanediol as shown in Tables IV and V.
Oestriol:
The apparent differences between the average 
excretion of oestriol in different patients and following
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different dosages of F.S.H. and different rates of 
fall-off in dosage during each, of the periods could 
easily have occurred by chance. (Figures 11, 12 and 
13A and Table IV).
Pregnanediol:
The differences between patients was only 
significant during periods 2 and 5 and this was due 
to the high basal level of patient C (Figure 11B and 
Table V). There was not sufficient evidence that the 
apparently large differences in the effect of different 
dosages of F.S.H. were not due to chance (Figure 12B). 
The differences between the different rates of fall-off 
could also readily be attributed to chance except in 
period 5 (Figure 13B) in which treatment without fall- 
off produced a higher level of pregnanediol excretion 
than treatment with fall-off.
Conclusions:
This experiment indicated that the dosage levels 
chosen for the three patients were in the correct 
proportion. Although the differences were not 
significant the results in Figures 12A and B suggest 
that the response to the high dosage was better than 
to the other dosages and the results in Figures 13A and 
B that the response to treatment at a constant daily 
dosage was slightly better than with any of the rates 
of fall-off. In subsequent experiments therefore a 
higher dosage at a constant level was adopted, and the 
relative levels for the different patients were 
maintained.
No treatment was given in the month after this 
experiment was completed and none of the three remaining 
patients menstruated spontaneously.
Experiment 3:
The effect of varying; the total and daily dose of
H. C.G. used with two levels of F.S.H.
In this experiment patient E was substituted for 
patient D who had become pregnant. The experiment 
was designed primarily to test varying methods of 
treatment with chorionic gonadotrophin. Four doses 
of H.C.ff. were used, 3,000, 6,000, 12,000 and
24,000 i.u. They were arranged so that the whole 
dose was given in a single injection in one instance 
and divided into four equal daily doses in another.
The single injection was- given with the last dose of 
P.S.H. or on the following day; the four injections 
were given simultaneously with the last four doses, or 
two with and two after the last doses of P.S.H. In 
addition two dosages of P.S.H. were used for each 
patient, high (H) and low (L), with a dose interval of
I. 33, the individual dosages varying with patients A,
B and C on the basis of their previous responses. An 
intermediate pair of dosages were chosen for patient E.
The individual dosages are shown in theliable.
The treatment for each patient was derived from
the combination of factors being investigated as shown
in table below.
Order of Patients: 
Treatment s. A B C T?uli
4th month a b c e
3rd month d ede bde ade
1st month bee ace abe abc
2nd month abede abd acd bed
The factors corresponding to each of the code 
letters were:-
H.C.G. to overlap (a) or not overlap (-) P.S.H.
H.C.G. to be given in 1 or 4 injections (b).
Total dose of H.C.G. to be
3,000  ; 6,000 (d), 12,000 (c), 24,000 (cd) i.u.
The levels of P.S.H. adjusted for each patient 
(0), (e).
The excretion of oestriol and pregnanediol were 
measured in urine which was collected and pooled as in 
Experiment "2. The results and dosages are shown 
graphically in Figure
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Two levels of F.S.H. were used as indicated by 
the large and small dense black area on each months 
treatment, the parallel lines represent (a) the total 
dose of H.C.G. used (b) the way in which it was given 
- either in 1 or 4 injections (c) whether given with 
or after F.S.H.
Patient A given H dosage of F.S.H. and 12,000 i.u. 
H.C.G. in four doses with partial overlap showed a rise 
in excretion of oestriol! on days 10 and 11 followed by 
a fall and later a secondary rise together with a rise 
of pregnanediol in the luteal phase (Figure 14, A10).
She subsequently menstruated. On H dosage with
24,000 i.u. H.C.G. in four doses and complete overlap, 
however, she showed no response (Figure 14, All). On 
L dosage with 6,000 i.u. H.C.G. in a single dose and 
no overlap she showed only a late rise in excretion of 
oestriol in the luteal phase (Figure 14, A12) and on L 
dosage with 3,000 i.u. H.C.G. in a single dose with 
overlap she showed no response (Figure 14, A13) •
Patient B given H dosage and 12,000 i,u. H.C.G. 
in a single dose with overlap showed only a doubtful 
rise of pregnanediol in the luteal phase with no rise 
of oestriol and she menstruated (Figure 14, BIO). On 
L dosage and 6,000 i.u. H.G.G. in four doses and complete 
overlap she showed a slight rise in excretion of oestriol 
on days 8 and 9 (Pigure 14, Bll). On H dosage and 
24,600 i.u. H.C.G. in a single dose without overlap 
she showed a pronounced rise of oestriol on days 10 and 
11. This was followed by a considerable fall and a 
second rise of similar magnitude later in the cycle.
The pregnanediol rose to a high level between these two 
peaks of oestriol excretion but both returned to normal 
at the end of the cycle and she menstruated (Figure 14, 
B12). On L dosage and 3,000 i.u. H.C.G. in four doses 
with partial overlap she showed a considerable rise in 
excretion of oestriol on the 4th day of treatment with 
F.S.H. but it returned to control levels subsequently 
and there was no -rise when changes are normally 
expected to occur. She failed to menstruate (Figure 14,
B13).
Patient C given H dosage and 3*000 i.u. H.C.G. in 
four doses with overlap showed a good rise in excretion 
of oestriol on days 12 and 13 followed by a return to 
the control level and a second good rise in the luteal
There was no change m  excretion of pregnanediol
- 5 3 -
but she subsequently menstruated (Figure 14, CIO).
In the next three months she failed to respond to any 
treatment (Figure 14, Cll, 12 and 13) except for a 
scanty period after the first of these.
Patient E was give L dosage for the first two 
months and failed to respond (Figure 14, E10 and 11).
On H dosage with 6,000 i.u. H.C.G. in a single dose 
with overlap, however, she showed a pronounced rise in 
excretion of oestriol followed by some further 
fluctuations. There was a moderate early but ill- 
sustained rise of pregnanediol and she failed to 
menstruate (Figure 14, E12). On H dosage with 3,000 i.u. 
H.C.G. in a single dose without overlap she showed a 
slight rise in excretion of oestriol on the fourth day 
of treatment followed by a slight and early rise of 
pregnanediol occurring on days 8 to 11. She menstruated 
correspondingly early (Figure 14, E13).
Analysis of Results.
The experimental design permitted the isolation 
and separate estimation of the following:- the 
avergae effect of differences between patients, between 
different dosages of H.C.G. and between different dosages 
of F.S.H. of differences in the timing of treatment with 
H.C.G; of differences in the number of injections of 
H.C.G. and finally the extent to which some of these 
factors were interdependent. For example, it was found 
that the effect of different dosages of H.C.G. depended 
on the timing of the injections, the number of injections 
and also the dosage of F.S.H. The statistical analysis 
allowed the interdependence of the dosage of H.C.G. 
and its timing to be isolated free from the bias of 
other significant effects. In a similar manner, using 
all the experimental data once again, the interdependence 
of the dosage and the number of injections of H.C.G. was 
estimated free from the bias of the other significant 
effects. Finally, it was possible to estimate the 
interdependence of the dosage of H.C.G. and the dosage 
of F.S.H. in the same manner.
There were four dosage levels of H.C.G* in this 
experiment, and the analysis allowed the effects of 
two alternative pairs of higher and lower dosages to be 
assessed. In the first groupings the higher levels 
were 12,000 and 24,000 i.u. with an avergae dosage of
18,000 i.u., and the lower levels were 3,000 and 6,000 i,u. 
with an average dosage of 4,500 i.u. In the second
- S t -
groupings, the higher levels were 6,000 and 24,000 i.u. 
with an average dosage of 15,000 i.u., and the lower 
levels were 3*000 and 12,000 i.u. with an average 
dosage of 7,500 i.u. Since only a half of the 
complete factorial design was used, the interaction of 
the dosage of H.C.G. with the other factors had to be 
assessed by using one or other of these alternative 
methods of grouping.
The cycle of 28 days was divided into five periods 
each containing two observations exactly as in Experiment 
2. Each period was analysed separately for oestriol 
and pregnanediol as before. (Table VI and Vll).
Oestriol:
Period 1. There was no significant difference 
in excretion between the four patients and no evidence 
that any treatment affected it. (Figure 15A to 18A).
Period 2. Patients B and E had a higher average 
response to treatment than patieht A who in turn had a 
higher average response than patient C (Figure 15A).
The effect of an increased dosage of H.C.G. was 
dependent on both the timing and the number of injections 
The two highest dosages (average 18,000 i.u.) given 
partly or wholly after F.S.H. produced a higher response 
than when given simultaneously with it. On the 
contrary the lower dosages (average 4-, 500 i.u.)given 
simultaneously with F.S.H. produced a higher response 
than when given partly or wholly after it (Figure 16A). 
The higher dosages (average 15,000 i.u.) given in a 
single injection produced a higher response than all the 
other alternatives (Figure 17A ii) and finally the 
higher dosages of H.C.G (average 15,000 i.u.) given with 
the high dosage of F.S.H. also produced a higher 
response than all the other alternatives (Figure 18A iv).
Period 5. The effect of an increased dosage of 
H.C.G. was dependent on the timing and the number of 
injections. This interdependence followed the same 
pattern as in period 2 (Figures 16A and 17A) .
The higher dosages of E.S.H. produced a higher . 
average excretion than the lower dosages (Figure 18A).
Period 4-. The average response was almost 
identical to that in Period 3. The only difference 
was in the interdependence of dosage and timing of H.G.G, 
The higher dosages (average 18,000 i.u.) given wholly 
or partly after F.S.H. gave a higher response than the 
other alternatives (Figures 16A ii).
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Period 5. The effect of an increased dosage 
of H.C.G. on the average excretion on oestriol 
depended only on the timing. As in Periods 2 and 3 the 
higher dosages given partly or wholly after F.S.H. gave 
a higher average excretion then when given simultaneously 
with it, while the lower dosages given simultaneously 
with F.S.H. gave higher averages than when given nartly 
or wholly after it (Figure 16A).
There was no evidence that any of the other factors 
affected the excretion of oestriol during this period.
Pregnanediol;
Period 1: Patient C had a higher average
excretion than the other three patients (Figure 15B).
Period 2: Patient C again had a higher average
excretion than the other three.
It is possible that the higher dosages of F.S.H. 
produced a higher average excretion of pregnanediol 
(Figure 18B).
Period 3: The effect of increased dosages of
H.C.G. was dependent on the same factors which 
operated for oestriol in the same period. The higher 
dosages (average 18,000 i.u.) given partly or wholly 
after F.S.H. (Figure 16B, ii) and in a single injection 
(Figure 1?B, ii) produced higher average responses than 
the other alternatives. The higher dosages of H.C.G. 
(average 15,000 i.u.) combined with the high dosages 
of F.S.H. produced the highest average excretion 
(Figure 18B, iv).
Period A-: The pattern of results was dominated
by the exceptionally high response of patient B-^ Apart 
from this patient C still maintained a nigher average 
excretion than the others. liven if the response of 
patient B was discounted it is clear that the excretion 
was highest with the high dosages of J.S.H. and the 
highest dosages of H.C.G. (15i000 i.u..), (figure 18B,iv).
Futhermore, the higher dosage of H.C.G. (average 
15,000 i.u.) given in a single injection produced 
higher average figures than rhe other alternatives 
(Figure l?B,ii).
Period 5: patient C still had a higher excretion
than the other three (Figure 15B) but the average 
excretion increased with the dosage of H.C.G. and was 
annroximately uroportional to the logarithm of the 
dose (Table Yll).
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FIG. 19
PERIODS
Effect of total dosage of chorionic 
gonadotrophin on the average 
excretion of pregnanedlol In the 
four patients
Conclusion.
The results have been presented graphically in 
figures 15 - 18 to facilitate comparison with the 
normal pattern of excretion of oestriol and pregnanediol. 
In addition Figure 19 shows the effect of the dosage 
level of H.C.G. on pregnanediol.
From these diagrams, the following appear to 
be the most promising treatments
1. H.C.G. in a dosage of 18,000 units, given partly 
or wholly after F.S.H. (Figure 15, ii>.
2. H.C.G. in a dosage of 15,000 units, given as a 
single injection (Figure 17, ii).
3. H.C.G. in a dosage of 15«000 units, given with 
the higher level of F.S.H. (Figure 18, iv).
4. H.C.G. in a dosage of 24,000 units (Figure 19)•
Combining these deductions the best treatment 
within the scope of the experiment would be to give
H.C.G. in a dosage of 18,000 units (or higher) 
in a single injection, after F.S.H. and using 
the higher level of F.S.H.
PREGNANCIES RESULTING PROW TREATMENT
WITH GONADOTROPHIN
Treatment with, gonadotrophin was continued in 
the three patients of Experiments 1 - 3  using the 
information gained from these experiments. Patients 
A, B and C subsequently became pregnant and the 
excretion of steroids and H.C.G. was followed throughout 
pregnancy.
The dates for the occurrence of each pregnancy have ■ 
been calculated from a hypothetical last menstruation 
cycle (IMP) based on the finding in Experiments 1,2,3 
that menstrual bleeding frequently occurred on the 
24th day of the induced cycle. In the graphs week 0 
corresponds to 3 days before the start of hormone 
treatment. The upper and lower 95% fiduci&L limits 
and the mean excretion of oestriol and pregnanediol in 
normal pregnancies are indicated (Coyle and Brown, 1963; 
Coyle, Mitchell, Russell, 1956). The dashed line for 
oestriol shows the lower limit of normal excretion 
where small babies were delivered. Bach pregnancy 
will be described in the order in which it occurred,
Pregnancy in Patient D:
During Experiment 2, month 3, patient D showed 
abnormally elevated levels of oestriol and pregnanediol 
(Figure D8, Expt. 2) and pregnancy was later confirmed. 
Oestriol and Pregnanediol were estimated twice every 
week in the first trimester of pregnancy and subsequently 
once a week.
The results during the first four months of 
pregnancy are shown in Figure 20. Pregnanediol rose to 
an abnormally high level reaching a maximum of 84.0mg/
24 hr. between week 5 — 5^, and fell to a level of 30mg/
24 hr. in week 13. It remained at about this level 
throughout the latter period of pregnancy. A sample 
of blood taken from the patient during the ninth week 
was estimated to contain 10.2 pg. progesterone/lOOml.
This was between 2 - 3  times the value that is normally 
found in women at a corresponding stage of pregnancy.
The excretion of oestriol, pregnanediol and H.C.G. are 
shown in Figure 21, a,b and c.
The excretion of H.C.G. reached a maximum of
W E E K S  A F T E R  LM P.
The excretion of oestriol, pregnanediol and HCG 
during early pregnancy in patient D.
P A T I E N T  c> FIG. 21
WEEKS OF PREGNANCY
a
b
c
The excretion of (a) oestriol, (b) pregnanediol and 
(c) HCG daring pregnancy. Also shown are the upper, 
mean, and lower limits for the excretion of oestriol 
and pregnanediol in a series of normal pregnancies, 
(see text). The broken line in (a) represents the 
lower limit for small babies, The limits are also 
shown in figs. 21+ and 26.
500,000 i .u./24- hr. at about the eighth week and 
remained at a high level for about a further three 
weeks. From week 14- to the time of delivery the level 
of H.C.G. fluctuated between 20,000 and 50,000 i.u./
24 hr. (Figure 210). At the 9th week oestriol was 
&ove the upper limit of normal but by the 14th week it 
had approached the normal mean (Figure 21 a). For 
the remainder of the pregnancy the level increased 
steadily between the normal mean and the upper limit 
of normal. The excretion of pregnanediol at the 
17th week had fallen to within the upper limits of 
normal and stayed fairly constant at about 34mg/24 hr. 
for the remainder of the pregnancy (Figure 21 b).
This patient gave birth to dissimilar twins at 
37 weeks.
Pregnancy of Patient C.
Treatment:
This patient was treated with F.S.E. (800mg. 
equivalents 1 KP-HMG/day) for 8 days and with H.C.G.
(12,000 i.u./day) on day 9 . A daily dose of 2.0mg. 
dexamethasone was also given to this patient until the 
44th day and it was then gradually reduced, first to
1.5mg/day on day 44, then to l.Omg/day on day 50,
0.5mg/day on day 59, and 0.25mg/day on day 68.
Treatment was finally stopped on day 74.
The excretion of oestriol, pregnanediol and H.C.G. 
is shown in Figure 22. Dexamethasone reduced the control 
level of px^egnanediol to 0.9mg/24 hr. After treatment 
with gonadotrophin oestriol rose to 70.0jig/24 hr. in the 
ovulatory phase of the induced cycle and pregnanediol 
reached 15.2mg/24 hr. during the luteal phase. The 
levels of both steroids were elevated on day 28 and 
estimations were continued until day 84.
After day 28 the steroid levels increased steadily, 
oestriol reached a maximum of 242pg/24 hr. on day 37 and 
pregnanediol a maximum of 20mg/24 hr. Both levels fell 
together and had returned to pretreatment levels at the 
time of operation, H.C.G. was barely detectable on 
most days but estimates were ootained by concentrating 
the gonadotrophin using alcohol precipitation. The 
level of H.C.G. fluctuated between 10,000 - 20,000 i.u./ 
day between days 44 - 66. Uterine bleeding commenced 
on the 70th day and the patient aborted. Surgical 
examination on the 84th day revealed portions of 
decidua, hyalanised chorionic villi gestation sac and 
fragments of trophoblast.
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FIG. 22
Patient C.
d a y s  a f t e r  .s t a r t  o f  f s h .
The excretion of oestriol, pregnanediol and 
HGG in patient C.The treatment with dexamethasone is also shown.
- & o  -
Pregnancy of Patient A.
The results of the previous trials on this patient 
suggested that high dosages of P.S.H. were required to 
cause ovulation. These were increased accordingly to 
1,OOOmg. equivalents 1BP-BMG given on day 1,3,5 and 7 
followed by H.C.G. 12,000 i.u. on day 8.
The excretion of oestriol, pregnanediol and H.C.G. 
are shown during early pregnancy (Figure 23) and 
throughout the entire, pregnancy in (Figure 24- a,b and c).
The excretion of H.C.G. increased from week 6 and 
reached a peak volume of 370,000 i.u./24 hr. between 
weeks 8-9♦ By the 11th week it had fallen to about
20,000 i.u./24 hr. at which level it remained, apart 
from a slight increase noted during week 34-.
Pregnanediol excretion was between the mean and 
the lower limits of normal until the 31st week when it 
fell rapidly to 15.2lmg/24 hr. Over the same period 
oestriol, which had been between, the mean and the upper 
limits of normal, fell from 14-.9mg/24- hr. to 6.5mg/24 hr. 
These changes were more than could be accounted for by 
daily fluctuation in steroid output during pregnancy so 
the patient was admitted to hospital and steroid therapy 
v;as commenced. The treatment is shown in Table
Table Vlft
Steroid Therapy 
Expressed as mg./week.
Patient A.
Treatment. Week Week Week Week Week32-33 33-34- 34— 35 35-56 36-Delivery
Ethinyl
Oestradiol 12 34 26 1
OestradiolMonobenzoate 10 20 20 15
Horethisterone 200 280 520 20
17 Hydroxy 
Progesterone 
Caproate 500 375
Progesterone 20 50
This table shows the quantities (expressed in 
mg./week) of different steroids administered 
to Patient A.
The excretion of both steroids returned to normal 
levels during treatment and a female baby was delivered 
by Caesarean section at 36 weeks.
FIG. 2 3
f j tlgnt A.
WE E K S  A F T E R  LM P,
The excretion of oestriol, pregnanediol 
and HCG daring early pregnancy in 
patient A.
fATI6NT A FIG. 24.
WEEKS O F  P R E G N A N C Y
Excretion of (a) oestriol, (T?) pregnanediol 
and (c) HCG during pregnancy .in patient A.
This patient was treated with F.S.H. 800mg. 
equivalents lBP-HMG/day for 8 days followed hy
24,000 i.u. H.C.G. on day 9. The excretion of 
oestriol, pregnanediol and H.C.G. is shown in Figures 
25 and 26 a,h and c.
The excretion of oestriol and pregnanediol increased 
until the 6th week "but then both began to fall. Uterine 
bleeding occurred at this time and the patient was 
confined to bed. H.C.G. was first detected at about 
the 7th week and reached a peak of 200,000 i.u./24 hr. 
at the 10th week. It fell to between 10-20,000 i.u./
24 hr. about the 14th week and apart from some high 
values in the 16th week remained at this lower level 
until the 50th week when it increased again during 
steroid therapy. The steroids remained at the lower 
limits of normal until the 28th week when they fell.
At this stage the patient was ad.mitted to hospital and 
steroid therapy was begun at 51 weeks. The treatment 
is shown in Table:
Table VI1ft
Steroid Therapy 
Expressed as mg./week.
Patient B.
Treatment. Week Week Week Week
51-52 52-55 55-54 54-Delivery.
OestradiolUndecylenate 100
Et hi ny 1- o e s t radi o 1 12 8 84
Oestradiol
Monobenzoate 20 20 40 20
17 Hydroxy Progesterone 
Carpoate 1000 1000 1550 1000
This table shows the quantities 
mg./week) of different steroids 
Patient B. ____________ _
(expressed as 
administered to
During treatment with steroids the pregnanediol 
level increased slightly but little change occurred 
in the level of oestriol. At 3*14 weeks a male child 
was delivered by Caesarean section.
Patient B.
FIG. 25
WEEKS A FTE ft LMP.
The excretion of oestriol, pregnanediol and HCG 
during early pregnancy in patient B.
The duration of uterine "bleeding is also shown.
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patient e FIG. 26.
The excretion of (a) oestriol (h) pregnanediol 
and (c) HCG- daring pregnancy in patient B.
RESULTS
SECTION III
The effect of treatment with gonadotrophin d.n the 
production of ovarian steroids by a woman with 
Simmonc^ Disease.
The Pstient.
This patient was aged 2? and had had a chromophobe 
adenoma of her pituitary gland removed six years 
previously. She. had no detectable gonadotrophins 
and the excretion of l?-oxosteroids and 17-oxogenic 
steroids was below normal. The radio-iodine uptake of 
the thyroid gland was at the lower limit of the normal 
range. She was given cortisone and thyroxin at various 
times but discontinued treatment voluntarily.
The patient (F) was treated with F.S.H. 600m.g. 
equivalents/)SP-HMG-/day for 12 days followed by H.C.G.
6,000 i.u./day for 3 days. Urine was collected every 
day and oestriol and pregnanediol was estimated on 
each specimen. The treatment and results are shown 
in Figure 27.
The excretion of oestriol was initially 2.3p€*/
24hr. and after treatment for 7 days with F.S.H. (day 14) 
it rose to 25^ig./24hr. After treatment with H.C.G. 
it rose to a maximum of 38j^g./24hr. on day 26. 
Pregnanediol on the other hand showed no change until 
after treatment with H.C.Gi and reached a maximum value 
of 1.4mg./24hr. on days 23 and 26. It is doubtful if 
this slight rise on pregnanediol represented an 
ovulatory change and further experiments were therefore 
undertaken.
The period of treatment with F.S.H. was 12 days in 
the first month because certain metabolic studies were 
in progress concurrently. Since however treatment 
over 8 days had been successful in the clinical trials 
reported in the previous section it was deciaed uo 
reduce tbe length of treatment to 8 days m  subsequent 
experiments. Single specimens of urine were collected
on days 5, 18, 20, 22, 24 and 28 and the specimens of 
urine collected on days 9 and 10, 11 and 12, and 
15 and 16 were pooled. Results were always expressed 
as the amount, of steroid excreted for 24hr. D*y 28 
was taken as the control day for uhe following, month
of treatment.
SECTIQNIII
FIG. 2 7
m o n t h  I
F IG .2 8
Fig. 27. The effect of PSH and HCG on the excretion of* oestriol 
and pregnanediol in patient P.
Pig. 28. The excretion of* oestriol and pregnanediol after 
treatment with PSH and HCG.
Month 2: HCG was given after PSH Month 3: HCG was given simultaneously with PSH 
Month k: HCG was given partly with and partly 
after PSH.
- £3 -
Months 2 - 4 .
These trials were to investigate the effect of 
altering the time of treatment with H.C.G. relative 
to F.S.H.
F.S.H. was given at a dosage of 600mg. equivalent 
1BP-HMG for 8 days and H.C.G. 6,000 i.u./day for 4 days. 
The H.C.G. was given in different ways as follows
Month 2: No overlap: H.C.G. was given
immediately after treatment with 
F.S.H.
Month 5: Complete overlap: H.C.G. was given
with the last 4 injections of F.S.H
Month 4: ' Partial overiant H.C.G. was given with 
the last two injections of F.S.H. and 
and for 2 days after F.S.H.
The results, treatment and doses of hormones used 
are shown in Figure 28.
Month 2: No overlap:
The response was poor since oestriol increased to 
only 16jog./24hr during treatment with H.C.G. while 
little change occurred in the level of pregnanediol. 
Menstruation (M) occurred on the day after treatment 
with H.C.G.
Month 3: Complete overlap:
In contrast to month 2 an enormous increase in 
the excretion of-oestriol during this trial. On day 
14 a maximum excretion of 780jhg./24hr. was reached and 
the level remained above the control level for fourteen 
days. There was no change in the excretion of 
pregnanediol during treatment with F.S.H. alone hut 
it increased steadily after treatment with H.C.G. and 
reached a peak value of 2.2mg./24hr. on day 14. 
Menstruation occurred on day 23.
Month 4:___Partial overlap:
Treatment this month was commenced while the 
excretion of oestriol was still elevated following the 
previous treatment. After treatment with H.C.G. it 
rose rapidly and reached- a maximum of 84^lg./24hr. on 
day 16. Only a slight increase in pregnanediol occurred 
during treatment with H.C.G. and it decreased again
Menstruation occurredimmediately after treatment, 
on day 24.
It is evident that treatment with gonadotrophin 
was followed by an enormous response in the excretion 
of oestriol hut there was little change in pregnanediol. 
The pattern of response therefore is not typical of 
that following normal ovulation.
Further trials were planned to investigate whether 
the failure of ovulation was due to the deficiency of 
some other pituitary hormone. Treatment with F.S.H. 
and H.C.G. was according to the schedule that was most 
effective in producing a rise in the excretion of 
oestriol and pregnanediol i.e. complete overlap of the 
two hormones.
The results are shown in Figure 29.
Month 51 A.C.T.H. (4-Oi .u./day) was given for 8 days
commencing on the first day of treatment with H.C.G.
The excretion of oestriol increased steadily after 
treatment with gonadotrophin and reached a maximum of 
46j|*g./24hr. on day 16. Again pregnanediol failed to 
rise after the increase in oestriol.
Month 6: A preparation of human pituitary LH (CM2
fraction) was used instead of H.C.G.^the daily dosage 
was equivalent to 6,000 mg. equivalents 1KP-HMG.
There was little change in the excretion of oestriol 
and pregnanediol either during treatment with F.S.H. 
alone or after the combined treatment with F.S.H. and 
pituitary L.H.
Month 7: In this month human growth hormone (H.G.H.
5mg./day) was given for four days on the same days as 
H.C.G. were given. The level of oestriol increased 
after the combined treatment with F.S.H., H.C.G., and 
H.G.H. and it reached a maximum value of 96.0^ /g./24hr, 
on day 12. There was a slight increase in
pregnanediol on day 12 but on day 16 it had returned 
to the control level.
Month 8: Thyroid stimulating hormone (T.S.H. lOi.u/
day for 4 days) was given with H.C.G. A slight 
increase in the excretion of oestriol occurred on day 
14 and in pregnanediol on day 10. These changes were 
not very pronounced.
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Conclusion:
With the doses of trophic hormones used the best 
oestriol response occurred in month 7 after treatment 
with H.G.H. and gonadotrophin and little change 
occurred after either T.S.H. or CM2. The addition 
of A.C.T.H. was followed by a normal oestriol response. 
The level of pregranediol showed little change in any 
of the months of treatment.
In a patient with secondary amenorrhoea (Patient 
C Section II) it was found that ovulation and 
pregnancy occurred after the simultaneous administration 
of dexamethasone and gonadotrophin. This was, therefor 
tried in this patient. Dexamethasone was used 
together with the gonadotrophin in months 9, IQ and 11. 
Treatment and results are shown in Pigure 30.
Month 9: Treatment was similar to month 3 hut
0.5mg. dexamethasone and 0.05yug. thyroxin was given 
daily during treatment.
The response in oestriol is nearly identical to 
the tyre of response attained in month 3 "but in this 
month the excretion of preenanediol reached a peak 
value of 3.0mg./24hr. but only remained elevated above 
control for 4 days. Menstruation occurred, as the 
oestriol level dropped. The very sharp increase in 
both oestriol and pregnanediol were not of the type 
seen in normal ovulatory cycles.
In the next two months variations were tried in 
the method of administering P.S.H. and H.C.G. The 
clinical trials reported in the previous section had 
shown that P.S.H. could be effective when given on 
alternate days instead of every d.ay and that H.C.G. 
could be given in one dose rather than four. While 
still on dexamethasone and. thyroxin P.S.H. was now 
given in 4 injections of l,200mg. equivalents 1KR-HMG 
?nd H.C.G. as 24,000 i.u. on the eighth day. This 
was followed by one month with P.S.H. in 8 injections 
of 600mg. eouivalents 1KP—HMG -and. H.C.G. in one dose 
of 24-,000 i.u. on the day following P.S.H.
The results are shown in Pigure 30.
Month 10: There was no increase in either oestriol
or o r e scnanediol following treatment but no estimations 
were performed between days 1 — 8 since the level of 
oestriol was probably still affected by the treatment 
of the previous month.
Month 11: There was a small increase in oestriol
after treatment with H.C.G. and probably a small 
increase in pregnaned.iol following Inis.
Conclusion:
The best pattern of steroid response occurred, when 
there was complete overlap of H.C.G. and F.S.H. and 
the patient was given dexamethasone and thyroxin. The
FIG.30
The excretion of oestriol and pregnanediol.
The different dosages of FSH, HCG, dexamethasone 
and thyroxin used are also shown.
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methods of giving E.S.H. on alternate days or p.S.H. 
every day and all of the H.C.G. in a single large dose 
did not appear to he effective in this patient. This 
was in marked contrast to the responses of the patients 
with secondary amenorrhoea.
Summary to Section III.
1. Treatment of a patient with Simmonds' disease with 
F.S.H. and H.C.G. was followed "by changes in the 
excretion of oestriol and pregnanediol.
2. The best response was obtained when H.C.G. was 
given at the same time as F.S.H.
3. In the dosages used the additional trophic hormones 
caused no additional change in the production of 
steroids.
4. None of the treatments induced a pattern of 
excretion of steroids similar to that seen in a 
normal ovulatory cycle.
RESULTS
SECTION IV
-  1 8  -
The Patients:
Each of the patients in this section possessed 
the clinical symptoms of the Stein-Leventhal Syndrome.
The first three experiments in this section were 
designed to study the effects of treatment with F.S.H. 
alone and with combined6. F.S.H. and H.C.G. on the 
production of ovarian steroids * Little wras known 
about the relative doses of F.S.H. to use or the way 
to combines E.S.H. and H.C.G. to achieve the best 
ovarian steroid production. Dexamethasone was 
incorporated into these experiments to suppress the 
production of adrenal steroids so that it may be assumed 
that the increased steroid levels found after treatment 
with gonadotrophin would be specifically of ovarian 
origin.
Doses of gonadotrophin used in Patients G, H and I.
E.S.H. was given in two injections, each equivalent 
to 2,000mg. 1EP-HMG, the second twelve days after the 
first. H.C.G. 12,000 i.u. was given in a single 
injection two days later. Treatment with dexamethasone 
(3mg./24hr.) was commenced at least 4-days before the 
first injection of E.S.H.
Collections of urine:
Urine was collected daily, beginning 2 days before 
treatment with dexamethasone. This served as a control 
and subsequent 24 hr. specimens of urine were pooled in 
48 hr. lots but the results were expressed as excretion 
/24 hr. The days referred to in the graphs refer to the 
day of completion of the 48 hr. pool.
Case G :
The results and treatment are shown graphically 
(Figure 31)• The excretion of oestriol and pregnanediol.
Before treatment commenced the excretion of 
pregnanediol was only 1.2mg./24hr. and oestriol was 
8.0^g./24hr. After treatment with dexamethasone for 
four days the excretion of pregnanediol was not 
significantly changed but oestriol had increased 
threefold.
Following a single injection of E.S.H. no chancre 
occurred in the excretion of pregnanediol but that of 
oestriol level increased to 68.Ojjug./24 hr. on day 6.
By day'8 it had fallen and on day 10 it was 50.Ojig./24hr.
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The injection of F.S.H. on. day 12 drought about an 
increase in the level of oestriol to 73.0^g./24hr. 
and a slight increase in pregnanediol. After the 
injection of H.C.G. there was an immediate increase 
in pregnanediol to 8.2mg./24hr. on day 16 and an 
increase in oestriol to 85^1g*/24hr. The excretion 
of both steroids fell rapidly and by day 22 had almost 
returned to the control levels.
Laparotomy was performed on day 22 and the ovaries 
were found to be slightly enlarged and contained 
numerous small cysts and a single corpus luteum. There 
was haemorrhage into the lumen and some of the cysts 
and an area of haemorrhage in the ovarian stroma.
Ovarian cyst fluid was removed from this patient
and was found to contain small quantities of progesterone,and170H progesterone/androstenedione. Part of the luteal 
tissue removed was also found to contain progesterone.
These results are summarized in Table VIII.
Figure 32 - The Excretion of Dehydroepiandrosterone,
Androstenol, and Fractions II and Fractions III.
Dexamethasone suppressed the excretion of DHA 
completely and reduced that of androstenol from 6J0.|*g./ 
24hr. on day 12. Fraction III decreased steadily from
3.1 to 0.5®g. equivalents aetiocholonolone/24hr. on day 
12 and remained at this level until the end of the period 
of treatment. The effect of the single injection of 
F.S.H. was not very clear as the steroid levels with the 
exception of Fraction II had been decreasing after 
treatment with dexamethasone. Wo change was observed 
in the excretion of DHA even after the combined treatment 
with F.S.H.-H.C.G.
The level of androstenol increased to 320}Jg./24hr. 
on day 20. The greatest change observed however was 
in the excretion of Fraction II which increased after 
the treatment with F.S.H. and H.C.G. in a manner 
resembling that of pregnanediol. The ratio of II/III 
at day 16 was 6.5- By day 22 it had returned to
almost the control level, which was 0.52. The increase 
in Fraction II suggested that there was an increase in 
the production of pregnanetriol by the ovary after 
stimulation with gonadotrophin.
Figure 33 - Excretion of 17-Oxoste.roids.
The resultant effect of the treatment with 
dexamethasone and F.S.H. was to.. Increase the level of 
excretion of 17-oxosteroids. On the other hand little
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increase occurred after treatment with P.S.H. and H.C.G-. 
Conclusion:
The results of this preliminary experiment suggest 
that the doses of F.S.H, and F.S.H. and H.C.G. were 
adequate to cause stimulation of the biosynthetic 
pathways leadin'? to oestrogen formation in the ovaries 
of this patient. Adequate suppression of adrenal 
steroids appeared to be maintained by the dose of 
dexamethasone used. Progesterone was detected in the 
luteal tissue and in the ovarian cyst fluid removed at 
laparotomy, and a freshly formed corpus luteum was also 
found.
Patient H .
The few estimations of urinary androstenol 
carried out in Patient G. suggested that dexamethasone 
failed to sunpress completely, in contrast to DHA, 
the level of androstenol excreted. Both Patients H and 
I were treated with A.C.T.H. in order to obtain information 
about the hormone controlling the excretion of androstenol. 
Laparotomy was performed at different times during 
treatment with gonadotrophin.
Preliminary A.C.T.H._test:
A.C.T.H. was given to patients H and I (12Qi .u./day) 
for 2 days, before treatment \*rith dexamethasone. The 
collections of urine were the same as for patient G.
The excretion of oestriol and pregnanediol.
The treatment with A.C.T.H. had no effect on the 
excretion of oestriol but it increased that of 
pregnanediol from 1.8 mg./24-hr, to 5«3 mg/24hr. The 
results in Figure' 54- show that treatment with dexamethasone 
caused a small decrease in the level of pregnanediol but 
a threefold increase in the level of oestriol. Treatment 
with P.S.H. alone caused little change in either of the 
two steroid levels but after the combined treatment with 
F.S.H. and H.C.G. there was an immediate increase in the 
excretion of both steroids, the pregnanediol level 
reached 5*0mg./24hr. on day 18 and oestriol 92 jig./24-hr. 
on day 22. The levels of both oestriol and pregnanediol 
increased and decreased at the same time. Laparotomy 
was performed on day 4-.
Figure 35« The excretion of Fraction II and III.
The effect of A.C.T.H. on both Fractions II and III 
is shown graphically. The ratio of II/III for the 
control urine specimen was 0.34-. After treatment with 
A.C.T.H. Fraction II increased to 8.3 mg. equivalents 
aetiocholanolone/24hr. and Fraction III to 29.4-mg. 
equivalents aetiocholanolone/24-hr. The ratio remained 
normal at 0.29.
Treatment with dexamethasone decreased the 
excretion of both Fractions and a single injection of 
F.S.H. appeared to have no effect, and the excretion 
of Fraction III remained at this low level throughout 
the experiment. The combined F.S.H. and H.C.G. 
treatment caused an increase in Fraction II to 3«9 mg*
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FIG.34
The effect of FSH and HCG on the excretion of oestriol 
and pregnanediol in patient H.The treatment with dexamethasone is also shown.
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The effect of ACTH, FSH and HCG on the excretion of 
Fractions II and III in patient H. .The treatment with dexamethasone xs also sho\m.
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equivalents aetiocholanolone/24hr. (Ratio 8.7), however 
the pattern of excretion of Fraction II was similar to 
that of pregnanediol (Figure 34-) • After day 20 the 
excretion of Fraction II decreased and by day 24- it 
was almost completely suppressed.
Figure 36. The excretion of dehydroepiandrosterone, 
androstenol and 17-oxosteroids.
The levels of all three steroids increased after 
treatment with A.C.T.H. DHA increased from 360}jg./
24-hr. to 780jag./24-hr. , androstenol from 64-0jig./24hr. to 
1200]u.g/24-hr. and 17-oxosteroids from 13.5&g./24-hr. to 
19mg./2#hr.
Treatment with aexamethasone was followed by a 
decrease in each of the steroid levels, by day -2 the 
level of DHA in urine was not detectable and it 
remained undetected throughout the period of treatment. 
The effect of a single injection of F.S.H. was not 
clear as the excretion of 17-oxosteroids and androstenol 
had not reached their minimum levels after treatment 
with dexamethasone. By day 10 it was considered that 
complete suppression of the steroids had been achieved.
At this point, however, the level of androstenol was 
200jig./24-hr. The effect of F.S.H. and H.C.G. was to
increase the excretion of androstenol to a maximum of 
525jJg./24-hr. on day 19. The excretion of 17-oxosteroids 
increased over the same period.
At laparotomy the ovaries were normal in size but 
contained numerous small cysts typical of the Stein- 
Leventhal Syndrome. Cyst fliiid was taken from this 
patient and the results of steroid estimations are 
shown in Table VIII.
It was found that a freshly formed corpus luteum 
was present in one ovary, and that the cyst fluid 
contained progesterone, 17cL hydroxyprogesterone, and an 
elevated level of androstenedione.
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Patient I.
The preliminary treatment with A.C.T.H. increased 
the excretion of oestriol from 3.OjUte./24-hr. to 7.0jj.g./24-hr 
and that of pregnanediol from 1. lmg./24-hr. to 12.0mg./24-hr
Figure 37. The exretion of oestriol and pregnanediol:..
Treatment with dexamethasone was followed by a 
threefold increase in the excretion of oestriol and. a 
decrease in pregnanediol from lmg./24-hr. to 0.5mg./24hr. 
The single dose of F.S.H. had no effect on the 
pregnanediol but the oestriol increased to 25.0jQg./24hr. 
on day 2. On day 8 it had fallen to 9 • Ojxg./24-hr. The 
effects of treatment with F.S.H. and H.C.G. was to 
increase the level of oestriol to 97* . /24-hr. on day
14- and the excretion of pregnanediol from 0.7mg./24hr. 
to 1.7mg./24-hr. On day 22 the levels of both steroids 
had returned to those observed before treatment with 
gonadotrophin.
Figure 38. The excretion of androstenol and 
dehydroepiandrosterone.
The effect of A.C.T.H. on the levels of androstenol 
and DHA d/s& shown. After treatment with A.C.T.H. the 
level of androstenol increased from 890jDig./24-hr. to 
3900.0}Ag/24-hr. DHA was increased, but to a lesser 
degree, after the same treatment. Treatment with 
dexamethasone caused a complete suppression of both 
DHA and androstenol on day 6. The effect of F.S.H. 
alone was obscurred by the fact that the steroid levels 
were falling after treatment with dexamethasone. The 
combined F.S.H. and H.C.G. treatment.brought about an 
increase in androstenol from 0;Ug./2§hr. to 300)Ag./24hr. 
on day 20. No change was observed in the excretion of 
DHA.
Figure 39. Excretion of 17-oxosteroids and 
17-oxogenic steroids.
This graph shows the response of 17-oxo and 17- 
oxogenic steroids to treatment with A.C.T.H. Treatment 
with dexamethasone suppressed the levels of both steroids 
but a slight increase in excretion of 17-oxosteroids 
was observed after treatment with F.S.H. The combined 
F.S.H. and H.C.G. treatment had no effect on the 
17-oxosteroid.level but a slight increase in 17-oxogenic 
steroids was observed.
On day 16 laparotomy was performed and the ovaries 
of this woman were small in size and contained many
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The effect of FSH and HGG on the excretion of oestriol 
and pregnanediol in patient I .
The treatment with dexamethasone is also shown.
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small cysts, no corpus luteum was found. Ovarian 
cyst fluid was removed and the results are shown in 
Table VIII. This woman had elevated levels of 
17-hydroxyprogesterone and androstenedione.
A
Conclusion:
In these two patients (H and I) the excretion of 
androstenol was controlled by A.C.T.H. The doses of 
gonadotrophin used had no effect on the excretion of 
DHA but caused an increase in the level of urinary 
androstenol in both women. A freshly formed corpus 
luteum was found in the ovary of one patient (patient H)
The follicular fluid taken at different times 
during treatment showed no change in steroid content 
from that found in the untreated woman with Stein- 
Leventhal Syndrome. In both women dexamethasone 
increased the level of urinary oestriol.
The results of patients H and I had shown that 
the excretion of oestriol started to decrease after a 
single injection of F.S.H. and that the greatest change 
in the excretion of "both oestriol and pregnanediol 
occurred after the combined F.S.H. and H.C.G. treatment.
In the next five patients the interval between the 2 
doses of F.3.H. was reduced to 4 days and dexamethasone 
was omitted. The A.C.T.H. test was also omitted as 
it had been established that the excretion of 
androstenol was under the influence of this hormone.
Urine collections and presentation of results were 
the same as described for Patients G, H. and I.
Gonadotrophins Used:
Each of the next five patients was treated with 
2 injections of P.S.H. (2,000 mg./eouivalents/lRP-HT1G/ 
day). There was a four day interval between the 2 
injections, and. the second injection of F.S.H. was 
followed 2 days later by H.C.G. (12,000 i.u.) in a 
single injection.
The results and treatment schedules are shown 
graphically.
Patient J:
Figure 40a: The excretion of oestriol and rregnanediol.
The single injection of F.S.H. was followed by an 
increase in oestriol from 8.O^lg,/24hr. to 40jUg./24hr. 
on day 4- but only a slight increase in that of 
pregnanediol. The combined treatment with F.S.H. and
H.C.G. increased the excretion of oestriol steadily to 
486.Oju.g./24-hr. and that of pregnanediol to 14.4mg./24hr. 
on day 12. On day 12 laparotomy was performed.
Figure 40b: The excretion of androstenol and
dehydroeuiandrosterone.
The single injection of F.S.H. caused increases in 
the excretion of both androstenol and DHA, but after the 
combined treatment with F.S.H. and H.C.G. androstenol 
increased from 786^ txg./24hr. on day 6 to 1720^./24hr. on 
day 12. Over the same period the excretion of DHA 
increased from 800jug./24hr. to 1800jt?g./24hr. on day 10, 
but in contrast to the level of androstenol it had 
begun to fall on day 12.
Figure 40c: The excretion of Fraction II and Fraction III.
The changes in both fractions are shown graphically, 
the ratio of both fractions on control day was 0.67.
FIG. 40
The effect of FSH and HCG on the excretion of
(A) oestriol and pregnanediol
(B) androstenol and DHA.
(c) Fractions II and III(D) 17-oxosteroids and 17-oxogenic steroids 
in patient J.
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Tiie single injection of F.S.H. had no effect on either 
Fraction II or III but the combined treatment with 
F.S.H. and H.C.G. brought about a large increase in 
Fraction II from 1.6mg. to 7.7mg. equivalents of 
aetiocholanolone/24hr. and Fraction III increased from 
2.4mg. to 3.7mg. equivalents of aetiocholanolone/24-hr. 
Over this period the ratio increased steadily reaching 
2.08 on day 12. In these patients (J and K) the 
increases in the ratio are not as large as in the first 
3 patients where the difference between fractions was 
magnified by the suppression of Fraction III. On day 
12 the levels were still elevated.
Figure 40d: Excretion of 17-oxosteroids and
17-oxogenic steroids.
The pattern of excretion of 17-oxosteroids and 
17-oxogenic steroids is shown: The single dose of
F.S.H. had little effect on either the 17-oxo or the 
17-oxogenic steroid levels but the combined F.S.H. and 
H.C.G. increased the 17-oxosteroids from 10mg./24hr. 
to 18mg./24hr. on day 10. Over the same period the 
17-oxovenic steroids increased from 14mg./24hr. to 
41mg./24hr.
At laparotomy the ovarian tissue taken from the 
patient showed extensive haemorrhage both into the 
cysts and into the ovarian tissue. Small and large 
cysts were present in the ovaries and some of the cysts 
showed luteinised granulosa cells.
Ovarian cyst fluid removed at laparotomy contained 
a large quantity of progesterone, 17a hydroxyprogesterone 
oestradiol- 17JJ, oestrone and a smaller amount of 
androstenedione. The results are shown in Table VIII.
- 7 7  -
Patient K:
This patient was treated in an identical manner 
to Patient J.
Results are shown graphically in Figure 41a,b,c,d. 
Figure 4-la: Excretion of oestriol and pregnanediol.
The control level of excretion of oestriol 
(26.0jjg./24hr.) was higher than that normally encountered 
in women with the Stein-Leventhal Syndrome. The excretion 
of pregnanediol however was within the normal limits.
The single injection of F.S.H. increased the excretion 
of both steroids. The greatest change was observed in 
the excretion of oestriol after the combined F.S.H. and 
H.C.G. treatment while that of pregnanediol increased 
steadily from the beginning of treatment. The excretion 
of pregnanediol had risen to 9*4mg./24hr. on day 12 but 
that of oestriol reached a maximum of 200jjg./24hr. on 
day 10 and had fallen to 120jjg./24hr. on day 12. 
laparotomy was performed on day 12.
Figure 4-lb: Excretion of androstenol and
dehydroepiandrosterone.
After a single injection of F.S.H. the excretion 
of DHA decreased slightly but that of androstenol had 
increased from 306jt(g./24hr. to 550^Ug./24hr. After the 
combined F.S.H. and H.C.G. treatment the DHA level 
increased from 770j4g./24hr. on day 4 to 5,OOOjUg./24hr. 
on day 12 while that of androstenol increased steadily 
from a control value of 306julg:./24hr. to 1 ,190^ig./24hr. 
on day 10.
Figure 41c; Excretion of Fractions II and III.
The control ratio of Fraction II/III was 0.61.
A single dose of F.S.H. had little effect on either of 
the two fractions, on the other hand after the combined 
F.S.H. and H.C.G. treatment there was a slight increase 
in both fractions and the ratio increased steadily to
1.05 on day 12.
Figure 41d : Excretion of 17-oxosteroids and
17-oxogenic Steroids.
The single injection of F.S.H. caused a small increase 
in the excretion of 17-oxosteroid.s but there was no 
change in 17-oxogenic steroids. After the combined F.S.H. 
and H.C.G. treatment the 17-oxogenic steroid level 
increased from 18mg. to 24mg./24hr. on day 8 and the 
17-oxosteroid level increased from 19mg./24hr to 23mg./
FIG. 41
The effect of FSH and HCG- on the excretion of : — 
(A) oestriol and pregnanediol 
(EO androstenol and DHA
(C) Fractions II and III
(D) 17-oxosteroids and 17-oxogenic steroids in patient K.
. 7 2
24hr. on day 12. Laparotomy was performed on
day 12.
The ovaries of the ratient were found to he 
enlarged and similar to those of patient I, hut a 
recent cornus luteurn was found on the right ovary.
The cyst fluid from hoth the left and right ovaries 
contained large quantities of progesterone, 17a hydroxy 
progesterone, and increased quantities of oestradiol - 
- 1 7 and oestrone. Androstenedione and pregnenolone 
were also found.
Results are summarised in Table VIII.
Conclusion:
Both of the patients showed similar responses to 
gonadotrorhin. The effect of shortening the time 
interval between the injections of F.8.H. appeared to 
be more effective as judged by the marked increases 
found in the excretion of oestriol and pregnanediol. 
This also had the effect of increasing the level of 
DHA in urine, this was not found in the previous three 
patients G, ff. and I. The level of androstenol also 
increased. The follicular fluid contained large 
quantities of progesterone, 17a hydroxyprogesterone, 
and oestradiol~17p but low levels of androstenedione. 
This suggested that treatment with gonadotrorhin had 
altered in some way the metabolism and biosynthesis of 
the steroid present in ovarian follicular fluid.
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The results of the steroid estimations in 
follicular fluid from all five patients show that an 
elevated level of androstenedione occurred when the 
levels of progesterone, 17©^. hydroxy progesterone and 
oestradiol-1 were low. In patients J and K in 
contrast, androstenedione was low when the other 
steroids were elevated. Some luteal tissue removed 
from Patient G contained rrosesterone.
In the next two Patients (l and K) treatment with
gonadotrophin was given in a similar manner as in
Patients J and K hut urine specimen^ were collected at
longer intervals after treatment. Steroid estimations
were carried on sins-le 24hr. specimens of urine collected don the days indicated. Similarly laparotomy was 
rerformed after a longer interval from the beginning 
of treatment.
Patient h.
RESULTS
Days after 
1st F.S.H. 
treatment.
17-oxo- 
steroids 
mg./24hr.
17-oxogenic
steroids
mg./24hr.
Oestriol
i^g./24hr.
Androstenol^g./24hr.
Pregnenediol
mg./24hr.
Control 12 20 9.0 210 0.8
9 27 62 490 973 13.4
16 - 40 1120 - 17.9
17 15 26 1210 351 8.9
24 12 22 16 230 0.8
40 Laparotony
Ovarian cyst fluid taken at laparotomy was
collected in labelled tubes from individual C 7 g s ts . The
fluid from 4- small cysts was pooled 1 & 2, 3 & 4, but
the others were estimated on fluid from individual cysts.
Results are shown in Table IX.
In this patient a similar type of response was
obtained as in Patients J and K, where large increases
%
in oestriol, pregnanedio£, and androstenol were obtained.
DHA was not estimated in this patient hut the 17-oxosteroids£Vv\ A 7*/and ^ e  androstenol^level of 17-oxogenic steroids had 
increased. On day 24 the steroid levels had returned 
almost to control values. Over the period of
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increased oestrogen output gross enlargement of the 
ovaries occurred.
The steroids present in follicular fluid showed 
the same constituents in each of the individual cysts 
but a distinctly different pattern to that previously 
found in the patients and K. In this patient
the progesterone level was low but the androstenedione 
and DHA levels were elevated. This had been the 
first time that DHA was detectable in the cyst fluid 
of any of the patients studied. Laparotomy was 
performed on day 40.
The- portion of ovary removed at laparotomy 
contained large follicular cysts and massive oedema. 
The appearances were consistent with acute enlargement 
of the ovary due to hormone stimulation.
Patient M.
This patient was treated in an identical manner 
to Patient L and steroid estimations we re done on the 
days shown below.
RESULTS
Days after 17-oxo 17-oxogenic Androstenol Oestriol Pregnanediol
start of steroids, steroids. ltg./24hr. Ajg./24hr. mg./2ifhr.
P.3 .H, mg./24hr. mg./24hr. ' *treatment
Control 13 13 192.0 9.9 1.1
9 24 31 1080.0 430.0 9.5
23
96
16 18 
Laparotomy.
226.0 1.1
At laoarotomy cyst fluid was taken from both 
the left and right ovaries. Results are shown in 
Table X.
Value Pregne&siu-. 17-OH Progesterone. 17-OH Androstene-
of olone Progesterone. Progesterone. dione.
fluid.________________________________________ _________ _ _________
4.7 3 3 8.8 23.5 208
.65 8 8 30.8 30.8 262
Results are expressed as fig/100 ml. of cyst fluid
The steroids present in the follicular fluid 
removed at laparotomy from patient M are shown.
The response to gonadotrophin treatment was 
similar in this patient to the# type of response foundXin oatient J, K and L where increased levels of 
oestriol, pregnanediol and androstenol occurred. The 
cyst fluid removed at laparotomy contained elevated 
levels of androstenedione and low levels of nrogesterone 
and 17t^Jiydroxyprogesterone.
The portion of the ris\ht ovary removed at laparotomy 
showed, histologically, a thin layer of condensed 
cortical stroma beneath which there were many small 
cysts. Most of the cysts were linecf by granulosa cells 
and for the most part there was a well defined and 
sometimes very prominent layer of theca interna. A 
corpus luteum was observed in the left ovary.
-  ex-
Patient N.
This ratient was treated as Patients L and M 
and urine analysis was performed on the days shown.
Since little res-nonse was obtained in the first month 
of treatment on the day selected (day 9) ■> the treatment 
was reoeated to find out if the effects of the treatment 
were cumulative. In the third month the level of 
H.C.G. was increased to 24,000 i.u./day.
Results are_ shown :
Pirst month.
Days after start Oestriol
of P . 3.H. treatment. JkkP'/2AYiT.
Control 8.2
9 23.8
Second month.
9 34.0
11 23.3
18 17.0
Third month.
9 17.0
12 9.4
13
67 Laparotomy.
Pregnanediol 
me. /74h.r.
1.0
1.1
1.3
1.2
1.1
1.2
1.5
1.0
At lararotomy cyst fluid was collected from cysts 
on the left and ricdvfc ovaries. Results are shown 
in Table XI.
Table XI 
RESULTS.
Vol. Progesterone. 17-OH Androst- Oestrone. Bestra-
_________________ Progesterone, enedione._____diol,
L. Ovary 1.5 17.0 29.2 117 4 4
E. Ovary 1.2 15. 13 67 3 3
Table XI . The steroids in the follicular fluid
removed at laparotomy from Patient H are shown. 
Results are expressed as ug./100ml. _____
These results show that this woman responded 
differently from Patients J, K, L and M and in fact 
failed to respond any more even to elevated H.C.G. 
levels.
i
The androstenedione level of the follicular 
fluid was elevated which is the constituent found 
consistently in the ovaries of the untreated Stein- 
Leventhal Syndrome •
Conclusion:
a) Treatment with gonadotrophin was followed "by 
increased excretion of oestriol, pregnanediol, 17- 
oxo and 17-oxogenic steroids in two of the patients, 
h) One patient did not respond during two successive 
months and failed again with an increased level of H.C.G. 
o) Steroids in individual cysts appeared to contain 
the same constituents hut DHA was measured in the 
cyst fluid from one patient. d) The reversal of 
the steroid nattern in the follicular cyst fluid to 
that found in untreated women with the Stein-Leventhal 
Syndrome suggested that the changes brought about by 
gonadotronhin were of a reversible nature.
- 83 -
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DISCUSSION
In the development of a chemical method four 
factors are of imnor-tance (Borth, 1952^ Loraine, 1958)
(i) it is necessary to know how near an analytical 
procedure approaches the true result (aqcuraey)
(ii) the reproducibility of the results (precision)
(iii) the least amount that is distinguishable from zero 
(sensitivity) (iv) and whether the method measures 
what it is claimed to measure (specificity).
Since the amount of oestriol in a given quantity 
of urine cannot be known with certainty, the accuracy 
of the method was investigated by recovery experiments. 
These experiments were performed by adding oestriol to 
acid hydrolysed urine, thus the stage of hydrolysis was 
not examined although it is known that losses occur at 
this point. A further disadvantage is that at low 
levels of adoed oestriol the error in estimating the 
endogeneoos oestriol present may be large by comparison 
with the quantity added, so that the results at very 
low levels of oestriol become meaningless. By adding 
oestriol to acid hydrolysed urine the accuracy of the 
short method was investigated. The mean percentage 
recovery over the range 4.5 - 40.0 jUg./24hr. was between 
76 - 8?%, at the low levels, the mean percentage S.D. 
was createst but comparable with the results published 
by Brown (1955) and Brown, Bulbrook & Greenwood (1957a).
Precision:
The precision of the short method was derived from 
the differences between duplicate estimations over a 
wide range of levels of oestriol. The standard deviation 
of the method of Brown was derived over the range 
recommended by that worker and it was found that there 
was very little difference between the standard deviations 
of the two methods. In fact the standard deviation of 
the short method in the range 4.5 - 9 * •  /24hr. was 
considerably lower than that in the method of Brown.
The standard deviation of the short method, increased as 
the concentration of oestriol increased but it was not 
possible to establish any correlation between the level 
of oestriol and the standard deviation at that level.
Sensitivity:
The lower limit of 5*0^ig./24hr. of oestriol was 
originally chosen by Brown (1955) as the lower limit of
the estimations since "below this the error becomes 
comparatively larve and the values of less than 5*0 yUg/24-hr 
were considered to be of little significant importance.
A later modification of the method by Salokangas &
Bulbrook, (1961) enabled much smalla^uantities of 
oestriol to be estimated with confidence. In the method 
described here a lower limit of 4.5juig/24-hr. was 
arbitarily chosen for normal routine purposes but smaller' 
quantities can be estimated by reducing the volume of 
chloroform used for the extraction of the Kober colour 
and by using micro-cuwfctes"’ for colorimetry.
Specificity:
Conclusive evidence for the specificity of a 
Quantitative chemical estimation is difficult to obtain. 
The best that can be done is to accumulate as much 
evidence as possible to show that the method measures 
what it is supposed to and nothing else. The specificity 
of the original method of Brown, (1955) has been checked 
by many workers (Brown, 1955; Diczfalusy, 1955; Bauld, 
1956; Diczfalusy & Westman, 1956; Brown et al, 1957 a,b; 
Gallagher, Kraychay, Fishman, Brown &. Marrian, 1958;
Brown & Blair, I960; Aldercreutz, Diczfalusy 8-. Engstrom 
I960; Fishman & Brown, 1962). A later modification of 
the method by Salokanvas & Bulbrook (1961) established 
the specificity of the colour extraction procedure.
'The specificity of the short method is established 
on the basis that it includes all of the staves on 
which the specificity of the method of Brown (1955) -as 
based. Also it includ.ed a further step of colour 
extraction into chloroform with the characteristic 
change in the absorption spectrum, of the extracted Kober 
colour of oestriol methyl ether. The only stage of 
the short method which differed from that of Brown (1955) 
was the partition of oestriol between benzene/netroleum 
ether/water. This step was replaced by extraction of 
oestriol from diethyl ether, by dilute alkali and this 
procedure is used on the modification by Brown et al 
(1957 b).
Comparison of tbe two methods suggested that the 
short method was suitable for routine use. It is 
known that some loss of oestriol occurs during acid 
hydrolysis and that this is due to the pivment present 
rather than to the strength of the acid used for 
hydrolysis (Brown & Blair, 1958). The same loss of 
oestriol during hydrolysis probably occurs in the short
method also. However, this method is suitable for 
following the pattern of oestriol excretion during the 
normal menstrual cycle and for the estimation of 
oestriol in the urine of pregnant women. The effects 
of the drugs (Brown et al. 1957 b) which interfere with 
the estimation of oestriol were not investigated.
Since the experimental work on the short method was 
completed another method for the estimation of oestriol 
has been published by Brown & Coyle (1963) , this 
procedure is almost identical to the short method 
described here except that the colour extraction stage 
was omitted. In this method the smallest amount of 
oestriol that was detected was 17.0 ^ Ug./24hr. and at the 
level of 70.0 ps./2Khv. the mean percentage standard 
deviation was Tfc 2S%. These workers compared the method 
with the earlier method of Brown (1955) and found that 
it was suitable , for the estimation of oestriol during 
pregnancy.
The main advantage of the method described in this 
work is that more estimations can be performed during a 
day, it is possible to perform ten estimations compared 
with four estimations by the method of Brown (1955).
The method is now being used to study the response in 
oestriol levels in women with amenorrhoea treated with 
gonadotrophic hormones and to study the excretion of 
oestriol during the pregnancies which followed treatment 
in some of the patients.
-87-
Clinical Trial: Treatment of women with secondary
amenorrhoea usins: human gonadotrophin preparations:
In the present studies several preparations of human 
gonadotrophins have be-ai given in different ways to a 
small number of patients with secondary amenorrhoea in 
experiments designed so that the results could be 
analysed statistically. The enabled a large amount 
of detailed information to be obtained about these 
preparations and methods for their administration from 
a limited amount of material.
The patients had amenorrhoea of long-standing.
They had all been 'ceferred. after thorough gynaecological 
examination and empirical treatment with various 
hormones elsewhere. They had then been under 
observation in the Department of Clinical Endocrinology 
for more than a year during which time they had had 
further treatment. This aimed at establishing whether 
they could be induced to menstruate by suggestion. They 
were given either 0.5®?* stilboestrol daily for 14 days 
each month for three consecutive months or biologically 
inert tablets made by British Drug Houses Ltd., to 
resemble the tablets of stilboestrol. For 12 months 
they received three courses of three months treatment 
each of the control tablets and one of stilboestrol.
The first and last courses were of control tablets but 
the middle two were randomly arranged without the 
order being known to the consultant in charge. None of 
the oatients menstruated spontaneously during this 
time. Shortly before they began treatment with 
gonadotrophins they were re-examined and all were 
found to have atrophied uteri and ovaries with excretion 
of urinary gonadotrophins in. the lower half of the 
normal range, but they had no other evidence of 
organic disease. They were considered to have a bad 
prognosis with regard to spontaneous menstruation and 
fertility but, finally, -each patient received control 
injections of gelatin, instead of F.S.H, during one 
month in the first experiment and again failed to 
respond. These patients have, therefore, been regarded 
as a homogenetus sample of the same population and it is 
likely that a larger series of similar patients would 
respond in a like manner.
The patterns of excretion of oestriol and 
pregnanediol induced by treatment have been compared 
with the mean patterns of excretion in normal women
determined by the same biochemical methods. The normal 
pattern for oestriol described by Brown (1955) showed 
a gradual rise to a peak at mid-cycle followed by an 
abrupt fall. There was a more prolonged secondary 
rise and slower fall during the luteal phase (Figure 
2A and B). It is difficult to assess the variation 
in the excretion of oestriol amongst these normal 
women since Brown only ouoted the maximum, mean and 
minimum figures. Perusal of these charts show, 
however, that there was little rise in the mean response 
during the luteal phase although there was a considerable 
rise in the maximum response. This suggests that only 
a few of his subjects showed much increase in the 
excretion of oestriol at this phase of the cycle. The 
normal pattern for excretion of pregnanediol described 
by Klopper (1957) (Figure 3A, B and C) is simpler than 
that for oestriol and its presence or absence is obvious 
during the luteal phase of the cycle.
Inspection of the results of the individual trials 
in each Experiment show several different patterns of 
excretion. Examples of a single rise of oestriol 
occurring at irid-c7/‘cle can be seen in Figure 4, A3:
9, 36 and 1**-,E12, and of a rise at mid-cycle followed 
by a secondary rise in Figure 8, A5 and 14, B12. These 
are presumed to have been associated with ovulation 
because there was a rise in excretion of pregnanediol 
during the luteal phase of the cycle. Double rises 
in the excretion of oestriol are seen in an exaggerated 
form in Figure 10, D6 and D8. The latter show more 
clearly that the abrupt fall in excretion of oestriol 
immediately after the mid-cycle peak coincides with a 
rise in excretion of pregnanediol. It reflects the 
sudden change in steroid synthesis from oestrogen to 
progesterone and is presumably associated with the 
rupture of a follicle. The large secondary rise in 
oestriol is probably derived from other follicles and 
may indicate multiple ovulation. This is supported, 
by the fact that patient D became pregnant in the 
month during which her figures for steroid, excretion 
followed the pattern shown in Figure 10, D8, and she 
subsequently gave birth to dissimilar twins. It is 
also known that the luteal tissue present after 
ovulation has occurred is capable of secreting oestrogen, 
this is supported by the finding of sustained oestriol 
levels when conception occurred in each of the four 
patients. Oestradiol-1 7B and oestrone have been
detected in extracts of human corpora lutea (Zander, 
Brendle, von Munstermann, Diczfalusy, Martinsen and 
Tillinger, 1959)* A vesry large secondary rise in 
excretion of oestriol is therefore probably undesirable.
An abnormal pattern of excretion of oestriol is 
shown in Figure 9, A7 and 38. Here there is a mid-cycle 
peak without a rise in excretion of pregnanediol and 
it probably represents the development of a follicle 
which failed to nurture. Another type is seen in 
Figure 8, B5. Here there is no mid-cycle peak, of 
oestriol but there is a broad secondary rise which is 
again unassociated with a rise in excretion of 
pregnanediol and presumably also rerresents a failure 
to ovulate. Brown and Matthew (1962) described 
similar patterns in cystic glandular hyperplasia. These 
are all unsatisfactory responses and indicate unsuitable 
stimulation with gonadotrophins. Occasionally the 
peak in excretion of oestriol occurs abnormally early 
as shown in Figure 14-, B13. This might be a delayed 
response to the previous month's treatment.
Only patient C showed an abnormally hi«h output of 
pregnanediol in the control period (Figure 4-,C3). It 
tended to fall to normal on treatment with follicle 
stimulating hormone (Figure 4, 61 and G2).
The magnitude of the responses in some of the
trials in Experiments 2 and 3 tended to obscure the
effects of others in the same experiments. The excretion
of oestriol and pregnanediol by patient D, shown in
Figure 9, D6 and D8, and of pregnanediol by Patient B
in Figure 14-, B12 are examples of such responses. They
were, therefore, omitted from the ahalysis of variance
so that deductions could be made from the remaining
results. Since the figures for the excretion of the
two steroids were analysed separately it was felt that
important information about their relationship to one
another, both in magnitude and timing, may have been
neglected. The responses in each trial were compared
directly to the steroid changes in normal cycles and
(a )scores accorded toy-xncreases in oestriol in the 
ovulatory phase (b) increases in pregnanediol in the 
luteal phase (c) the relative positions of each peak (d) 
for the amount of increase obtained in each peak and (e) 
the length of time that the levels remained elevated. 
Analysis of these scores agreed with the results of the 
statistical analysis and did not add any further 
information.
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Two kinds of experimental error could "be estimated 
from the trials. The- first kind was due to errors 
in collection arid measurement and to short-term day to 
day fluctuations and could, he estimated, from comparisons 
of consecutive samples within each four-day period.
It appears in the Analysis of Variance as the Residual 
Error. It is probable that this error variance 
increased with the magnitude of the response and 
theoretically a transformation of the measurements should 
have been made to equalize the variances. A small 
number of analyses of variance were therefore made on 
the logarithms of the results. The deduction from 
these analyses differed in no way from those made 
previously, but the confidence limits were a little 
wider and asymmetrical.
The second kind of error was due to the 
inconsistency of responses in the same patient to an 
identical treatment. Gemzell et al. (I960) claimed 
that- the effect of E.S.H. on the ovarian size and the 
excretion of oestrogen did not change from one course 
of treatment to another identical one. Without 
replication this error could not be estimated snecifically 
in this series of experiments but it was estimated by 
the analysis of variance and is shown for Exreriments 
1 and 2 as "Residual/Square" and as ''Interaction” in 
Experiment 5. This interaction could be sub-divided 
into six components each attributable to the inter­
dependence of two of the treatment factors. The 
significance of each of these interdependences was used 
to make inferences about the method of treatment rather 
than to measure the experiment error. Since these 
inferences were based on one experimental trial, without 
replication, they will need to be reconsidered in 
further experiments. Tv-e first experiment showed a 
difference in sensitivity between patients to a given 
dose of F.S.H.
Analysis of the figure’s for oestriol for the four 
patients failed to demonstrate any difference in response 
from month to month. The figures for pregnanediol for 
patients A, 3 and D were therefore analysed by use of the 
Youden Square to investigate a possible monthly variation. 
Patient 0 was excluded from this analysis because of her 
abnormally high figures throughout. The analysis 
indicated that the response to treatment during the 
first two months was lower than that in the third and 
fourth months, but that the response in the fourth month
- 9l -
was in fact lower than that In the third month.
This suggested that with the low dosage of F.S.H. used 
there might be a build-up in response which was complete 
by the end of the third month.
The response to the different preparations of 
gonadotrophin was surprising. Each was given in the 
same dosage measured as P.S.H. but they differed widely 
in their content of luteinizing hormone. It was 
anticipated that the preparation with the highest 
concentration of luteinizing hormone and therefore 
greatest total amount of gonadotrophin would be the 
most effective. Moreover it seemed likely that the 
two hormones in this preparation would haye the greatest 
joint action but The results showed that there was 
little difference between preparations, and, if anything, 
the one with the lead: amount of luteinizing hormone was 
the best.
An atteraot was made in the next experiment to 
avoid abnormally high excretion of oestriol in the latter 
half of the cycle since, as suggested earlier, this 
might indicate the development of an excessive number 
of follicles. It was based on some preliminary data 
published by P.8. Brown (1959) which suggested that the 
excretion of P.S.H. is high at the beginning of the 
normal cycle and falls towards tne end. Moreover, Buxton 
and Herrmann (1961) had shown at operation that treatment 
with P.S.H and H.C.G. given together in constant daily- 
dosages had stimulated the production of multiple 
follicles and corpora lutea, but that these were of 
surprisingly different ages. It was thought therefore 
that an initia.l big dose of P.S.H. followed by- 
diminishing daily doses might overcome this complication, 
hut the results failed to confirm this and suggested 
that a constant daily dosage was more effective.
The most abnormal responses were observed when 
H.C.G. was given for the longest duration of time. These 
occurred in the two most sensitive patients in 
Experiment 1A (Figure 8, A5, B5). Since the two least 
sensitive patients failed to show similar responses it 
appears that this effect of H.C.G. is dependant on an 
adeouate dosage of P.S.H. Indeed none of the patients 
showed any response to 24,000 i.u. H.'C.G. when given 
without F.S.H. in the control period.
A rather similar abnormal response occurred in 
Experiment 1 when the most sensitive patient was given
- n -
the preparation of F.S.H. which was most heavily 
contaminated with luteinizing hormone (Figure 4,A4). 
Clearly the interaction "between these hormones 
requires further study.
The clinical responses to the trial have been 
interesting. Uterine bleeding occurred in only 18 
of the 47 months during which follicle stimulating 
hormone was given. These responses are summarised 
in Table XI1. Menstruation was described by the 
patient as normal in 12 and as scanty in six of these.
It is surmising that large responses with a normal 
pattern in the excretion of both oestriol and 
pregnanediol like those shown by Patient A in Figure 9, 
A8 and by Patient E in Figure 14, E12, were not followed 
by menstruation. In contrast bleeding occurred in 
other months when there was little or no increase in 
steroid excretion as shown in Figure 9, B7, B8, B9,
C7, C9 and Figure 14, BIO, Cll, and E13. In some of 
these instances it arrears that the bleeding occurred 
in the month after, rather than in the month of, a good 
rise in steroid excretion (Figure 4, B3 and 14, E13). 
Uterine bleeding therefore appears to be poorly 
related to the steroid response.
Comparison with other published, work:
Gemzell et al (1958) using a crude preparation of 
human pituitary F.8.H. succeeded in inducing ovulation 
and ovarian enlargement in women with secondary 
amenorrhoea and with the Stein-Leventhal Syndrome.
The changes observed, were accompanied by marked increases 
in the levels of urinary oestro.gens and pregnanediol 
’.with changes in endometrium from an atrophic to a 
secretory state in most cases. It was found, that some 
of the patients treated produced oestrogen and 
pregnanediol changes when treated with F.S.H. alone, 
but the greatest changes occurred when F.S.F. ^as 
followed, by H.C.G-. The preparation of F.S.F. used by 
Gemzell and co-workers was contaminated with L.F. so 
this probably explains the effect of the preparation on 
the production of steroid by the ovaries of some of the 
women who were treated.
In this work the effect of F.S.H. alone on 
production of steroids was never studied on its own 
but when a patient with Simmonds’ig disease was treated 
with F.S.H, a steady rise in oestriol excretion occurred
TABLE fcll
Uterine Bleeding During the Three Experiments
Experiment
No.
Patient Month Day of* 
Cycle
Duration 
in Days
Amount of* 
Bleeding
X A 3 2 k 7 Normal
B 3 25 7 Normal
IA A 5 2U k Normal
B 5 25 k Normal
II B 6 2 k 5 Scanty
B 7 10 2 Scanty
B 8 15 1 Scanty
E 9 25 5 Normal
C 7 2 k 3 Scanty
C 8 21 6 Normal
c 9 19 3 Scanty
D 6 2U 6 Normal
D 8 (pregnant)
III A 10 19 6 Normal
B 10 26 5 Normal
B 12 25 6 Normal
C 10 23 5 Normal
c 11 25 2 Scanty
E 13 10 5 Normal
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but in the patientss with secondary amenorrhoea no 
increase had taken place in either oestriol or 
pregnanediol by the fifth day of treatment with P.S.H.
In Experiment '1 large doses of ?,S,H. were given at 
the beginning of some months and the respective doses 
were reduced by constant factors, so that in some 
cases comparatively little E.S.H. was given before 
H.C.G.. nevertheless no changes had occurred in 
steroids up to the fifth day of treatment with F.S.H.
The responses of a women with Simmonds1 and * women 
with the Stein-Leventhal Syndrome will be discussed in 
separate sections.
The ouestion of how long after treatment with 
F.S.H. would H.C.G. be effective in inducing ovarian 
changes was investigated by Johannisson, Gemzell & 
Dicz-falusv (19-1). They administered a large dose of 
F.S.H. in a single injection to 5 amenorrhoeic women 
(2 had primary and 3 had secondary amenorrhoea) and 
found a continuous rise in the oestroven excretion 
which reached a peak value between the sixth and seventh 
days after F.S.H. This they interpreted as being- due 
either to oestrogen production over a long period or to 
the slow disappearance of F.S.H. activity from the 
body so that a continuous stimulation was maintained 
for a week or so. When H.C.G. was administered within 
H8hr. following the injection of F.S.H., the combined 
treatment caused a rapid rise in oestrogen and 
pregnanediol production and since the extra boost to 
the production of steroid maintained the elevated steroid 
levels for about fourteen daystthey interpreted the 
oestrogen production as being due to oestrogen formation 
by the corpus luteum. When the interval betwen treatment 
with F.S.H. and H.C.G. was extended to 96hr. the injection 
of H.C.G. did not bring about any change in steroids 
which indicated that the follicles were no longer 
susceptible to the luteinizing action of H.C.G. These 
observations support the present findings that the 
responses by the ovary are not only dependent on the 
total amount of gonadotrophin administered but are also 
dependent to the relative proportions of L.H. to F.S.H. 
used and the time interval between treatment. This is 
clearly shown in Patient D, Experiment 2, Month 1 when 
an enormous response to wonadotroobin occurred in the 
levels of both oestriol and pregnanediol while slight 
alteration of the total dose and the rate of fall off 
of F.S.H. resulted in no responses, while with an
intermediate total dose in. month 3 the patient showed 
a response similar to month 1. In each of these three 
months the only factors that changed were the total 
dose of F.S.H. and the rates of fall off of F.S.H. 
which suggests that the balance of circulating hormone 
in women is important in the induction of ovulation,
Any defects in this hormone balance would be expected 
to lead to anovulation and the development of follicles 
that fail to rupture.
The outstanding differences between the response^ 
obtained in this work and these of Gemzell and co-workers 
is in the degree to which patients responded. Slightly 
different systems to collect and pool urine specimens 
were adopted but nevertheless some of the patients of 
Gemzell and co-workers freouently produced oestriol 
levels above lmg./24hr. and pregnanediol levels to 
20mg./24hr.jthe only patient who had a response 
comparable with any of Gemzell's patients was Patient D 
in Experiment 2. Prom the work of Gemzell it is not 
possible to ascertain how long the levels of steroids 
remained elevated or if the values published were 
maximum values since only a few specimens of urine 
were collected during each month of treatment. 
Nevertheless there was a high incidence of multiple 
pregnancies in Gemzell's series of patients which 
suggested that the abnormally high responses during 
treatment were the result of multiple ovulation 
(Gemzell 1962). This is clearly undesirable.
Gemzell (I960) has shettfn that no antihormone 
production resulted from repeated treatments with human 
gonadotrophins.and identical steroid responses 
accompanied by menstruation were obtained in a women 
with secondary amenorrhoea who had been treated seven 
times during the course of one year. In the present 
work also the patients retained their responsiveness 
to gonadotrophins after several months of treatment and 
ultimately- all became pregnant. The same treatment 
was not repeated in any two consecutive months in any 
patients due to the statistical design of the 
experiments.
The effects of increased doses of F.S.H. used with
constant high doses of H.C.G (6,000 i.u./day for 5 days)
has been investigated by Rosemberg et al (1962) and their
results suppe^b the findings reported here. They found
increased excretion of steroids with increased doses of
2
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E.S.H. and sometimes a secondary peak in the 
excretion of oestriol occurred.
Gemzell et al (1958) reported some patients 
who failed to respond to the dosages of gonadotrophins 
usually Used, these women were found to he lacking in 
germinative tissue on examination of the ovaries.
This led Gem-zell to adont a standard test dose of 
E.S.H. and H.C.G; -patients were considered unsuitable 
for further treatment if they failed to respond. It 
is interesting to note that of the four patients in 
the first trial Patient D would probably, have been 
rejected under- this scheme, but after increased dosage 
of F.S.H. in Experiment 2 she became presman*.
Other methods of assessing ovarian function have 
included vaginal cytology. Johannisson et al (1961) 
compared this method with, the chemical method for 
oestroeens and pregnanediol but since the correlation 
was not always good it was decided to rely on the 
determination of steroids in this work.
Pregnancies after treatment with gonadotrophins:
It is interesting to note that pregnancies occurred 
in patients A, B and 0 following the type of treatment 
with gonadotrophin that wa.s suggested by the results 
of the nreceedinv experiments. In addition the 
treatment with dexamethasone in patient C was probably 
also effective. The hir-h resting level of pregnenediol 
in this patient was reduced by treatment with dexame tha son® 
which indicated, that it was of adrenal origin. It is 
possible that at the same time as treatment with 
gonadotrophin some adrenal steroid was suppressed which 
had previously inhibited ovulation. Diczfslusv (1Q62) 
showed that certain androgens, and Gemzell (I960) showed 
that progesterone inhibited the effect of exogenous 
gonadotrophin.
BroTm  (1956) has shown that when fertilisation takes 
place the level of oestriol remains elevated after the 
initial peak at ovulation. The four patients in this 
work who became pregnant provided an opportunity to 
study the excretion of hormones from the time of 
ovulation and throughout pregnancy.
Excretion of H.C.G. during pregnancy.
There are as yet few reports on the immunological 
estimation of H.C.G. during pregnancy. Wide (1962) 
has found that the values are usually higher than those
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obtained by bioassay during the last two trimesters of 
pregnancy but unpublished observations from this 
laboratory suggest that the results obtained have been 
more in accord with, bioassav.
Between weeks 9 - 1 0  the level of H.C.G. in 
Patient D reached 500,000 i.u./24hr. It dropped to an 
average of 20,000 i.u./24-hr. for the rest of pregnancy.
Excretion of H.C.G. in patients A and B followed 
tne normal pattern but increased slightly durinsc steroid 
therapy. Smith & .Smith (194-8) suggested that a 
reciprocal relationship exists between the level of 
H.C.G. and oestrogen in urine and blood during pregnancy.
They advanced the hypothesis that H.C.G. is utilised 
by the placenta to promote the synthesis of oestrogen.
Work by Loraine (1058) was unable to surport such a 
hypothesis but the importance of H.C.G. for the 
utilization of citrate by placental homogenates has 
been shown by Treon and Gordon (1958) and H.C.G. has 
been found necessary for the conversion of oestradiol 
to oestriol, 2 methoxy/oestrone and 16—epioestriol by 
perfused placentae (Treon 1959? 1961).
The excretion of H.C.G. in Patient C was very low 
in contrast to the other three patients, the failure 
to produce H.C.G. has been explained by Diczfalu.sy
(1961) as being due to failure of the trophoblast to 
implant into the uterine bed. It was not known what 
effect dexamethascne may have exerted at the early stages 
of pregnancy, so that the dose was decreased in stepwise 
manner. The finding of a low level of H.C.G. in earlyrregrancy 
is claimed by Zondek and Goldberg (1957) to be a better 
indication of any early abortion than is given by the 
measurement of steroids and the present results support 
this view.
The excretion of oestriol during pregnancy.
The excretion of oestriol during the pregnancies of 
Patients A,B and D makes an interesting comparison.
In Patient A the excretion of oestriol was Mthin the 
normal range until week 30 when there was a steady fall 
from 14-.9mg./24-hr. to 6.5mg./24-hr. The excretion 
increased again during treatment with steroids to within 
the normal range.
The excretion of oestriol during the pregnancy of 
Patient B was low and on week 31 it fell to 3»lmg/24-hr.
During treatment with steroids it returned to its former 
level of 5.0mg./24-hr.
In contrast the level of oestriol in Patient D 
was abnormally high soon after treatment with 
gonadotrorhin and by week 16 it had reached 4.3mg./24hr. 
It remained in the upper half of the normal range as 
is usual in twin pregnancies.
The excretion of oestriol in Patient C was within 
the normal range until about the 45th day when it 
gradually fell up to the time of operation.
Excretion of Pregnanediol during Pregnancy.
All of the patients showed a high excretion of 
pregnanediol in the early stages of pregnancy with a 
characteristic fall in excretion when the excretion 
of H.C.G. rose. The excretion of pregnanediol then 
remained within the normal range in Patient A until 
the 29th week when the value fell from 3?*0mg/24hr. to 
15.2rag./24hr. by the 31st week. During treatment with 
steroids it rose together with oestriol and at the end 
of pregnancy had amroached the normal mean. In 
contrast the nregnanediol level in Patient B remained 
at about the lower limit of the normal range until the 
29th week when it fell from 20.0mg./24hr. to 10mg./24hr. 
on week 31 • During treatment with steroids only a 
slight increase occurred in the presrnanediol level.
■The excretion of pregnanediol in Patient C was normal 
until about day 50 after which it gradually decreased up 
to the time of operation. The initial rise in 
pregnanediol in Patient D was grossly abnormal, reaching 
84mg.,/24hr. which is not usually encounters© even at 
full term. The progesterone level in blood was 
10.2^iv./100ml. of plasma at this time, this level was 
between three to five times as high as normal values 
for this stage of pregnancy which suggests that multiple 
ovulation had occurred. The excretion of presnanediol 
however fell gradually and remained about the normal 
mean value until delivery. Menstruation has not 
occurred since in any of the patients that became 
pregnant during treatment with gonadotrophins.
-  9 7 -
The fall in the excretion of steroids during the 
pregnancies of Patients A and B was more than could he 
accounted for hy daily flxictuation and was probably 
the result of failing function on the part of the 
placentae. The level of urinary oestriol is 
considered by most ’workers to reflect the viable state 
of the ; foetus (Breitner, 1954-; Zondek & Goldberg, 1957; 
Zondek & PMffer, 1959; 'Ten Berge 1959? i960, Kellar, 
Matthew, MacKay, Brown & Hoy, 1959; and Furuhjelm, 1962). 
The vrork of Cassmer (1959) has shown that the separation 
of placenta from foetas in vivo led to a parallel drop 
in all oestrogens but in situ nerfusion of the placenta 
restored the oestrogens within one hour.
On the other hand the level of pregnanediol in the 
urine is thought to be more dependent on the presence 
of the placenta rather than the viable state of the 
foetus. The pregnanediol level can remain elevated 
in cases of intra-uterine foetal death (Appleby & 
Norymberski , 1957; Diczfalusy, 1961) and in two cases 
of abdominal pregnancy Allen (1953) showed that after 
removal of a living child with the placenta left in 
situ, the pregnanediol level remained elevated for 
several weeks. Cassmer (1959) showed that after induced 
foetal death the pregnanediol levels remained elevated 
until removal of the placenta.
The fall in both oestriol and pregnanediol levels 
clearly indicated placental failure and steroid, therapy 
was begun using the biologically active progestagen 
17-a hydroxy progesterone caproate (Zarrow, Neher, Lazo- 
Wasem & Salhanick, 1957; Reifenstein, 1957). This 
compound is more active biologically than progesterone 
and has a prolonged action due to slow absorption from 
the injection site. In addition the ester is 
unchanged whereas progesterone itself is partly 
metabolised (Davis &. Wied, 1955; Plotz & Davis, I960).
The source of oestrogen in the treatment of 
Patient A was principally f\o re this ter one with smaller 
nuantities of oestradiol monobenzoate and ethinyl 
oestradiol. The last two steroids were also given to 
Patient B.
The method of Klopper et al (1957) was suitable 
for use during steroid therapy since 17-a hydroxy 
progesterone caproate is not excreted in the urine as 
pregnanediol or pregnanetriol (Bongiovanni, Bberlein & 
Cara, 1957; Brooks, I960 and Plotz & Davis. I960).
The work of Brown & Blair (i960) and. Brener, Dardenne 
& Nocke (1^60) suseests that neither ethinyl oestradiol 
or norethi ste^one contrihute to an increase in urinary 
oestriol as measured by the method of Brown (1955) o? 
can be modified by any chemical stage in the method so 
as to contribute to the "oestriol" fraction. It is 
probable that 1 7 - hydroxy progesterone caproate is 
metabolised to oestrogen by the placenta but a striking 
difference was seen between the oestrio] excretion 
patterns of Patient A and Patient B who was treated 
with much greater Quantities of l?-a hydroxy progesterone 
csrroate.
The fall in the excretion of steroids during the later 
st=ae of pregnancy maw he due to a variety of catises.
It may be due to increased metabolism of steroid precursors 
to other compounds or a change in the biological "half- 
life" of progesterone. The work of Pearlman (3 957) 
suggestes that the turn over r^ te of progesterone was 
the same in both pregnant and non-pregnant women but no 
study has been undertaken in cases of placental failure.
The increased steroid levels during therapy may be due 
to an improved vascular supply to the placenta as well 
as to the fact that beneficial results can be obtained 
in some cases by confining the patient to bed. The 
results in Patient B show the value of frequent 
estimations during pregnancy. The absolute amount of 
oestriol excreted does not give an accurate assessment 
of placental function but the trend in the excretion 
of oestriol is important.
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Discussion to Section III
Treatment of a woman "with. Simmond 1 s Disea.se usins 
human gonadotrophins.
The response to exogenous gonadotrophin by the 
patient with Simmonds' disease differed from that of 
tne other patients stud.ied. She produced very large 
amounts of oestriol but very little pregnanediol while 
the other patients were able to produce both steroids, 
then the dose of H.C.G. was given together with the 
last injections of P.S.H. the level of pregnanediol 
never rose above 3 .Omg./24-hr. although on two 
occasions the oestriol level rose to over ?00p.g./24-hr.
The addition of other hormones did not appear to 
be successful. Menstruation occurred in some months 
but it was thought to be due to "withdrawal bleeding" 
after the fall in oestrogeft secretion. It was found 
that the greatest response in oestriol occurred, when 
H.C.G. was given together with P.S.H. and that 
intermediate responses were obtained when H.C.G. was 
given partly ’with and partly after I’.S.H. In month 
1 the level of oestriol increased after treatment with 
with F.S.H. alone. This has not been found to occur 
in the x^omen with secondary amenorrhoea but occurred 
in the patients with the Stein-Leventhal Syndrome.
It is known that progesterone is a metabolite on 
the biosynthetic pathway leading to the formation of 
oestrogen in the human ovary ( S m i t h  & Ryan 1961,
Ryan & Smith, 1961 a ,b) and it has also been found in 
the follicular fluid from ovaries of normal ’women 
and women with the Stein-Leventhal syndrome (Short ft 
London 1961; Shorty 1962) . It is probable that in 
this patient the pregnanediol excrete* is derived from 
the progesterone formed in the metabolic pathway leading 
to oestrogen formation rather than from progesterone 
formed by luteal tissue resulting from ovulation.
Similar types of cycles have been deseffifeed by Brown ft 
Matthew (1962) in women with cystic glandular hyperplasia. 
In these women the oestriol excretion rose to a high 
as symmetrical peak, at mid—cycle and xwas follox^ed by 
menstruation when the oesurogen level fell, ho cnan^e 
occurred in pregnanediol and. tne cycles were 
considered to be anovulatory.
GemSfell (i960) found that a large increase in 
oestriol excretion occurred "but little pregnanediol 
was excreted when a hypopituitary dwarf was treated 
with HP-F.S.H. Ovarian enlargement and ovulation 
has been reported by Gemgell (1961) after HP-F.S.H. 
followed by H.O.G. in another hypopituitary dwarf 
with primary amenorrhoea and hypogonadism, but again 
the greatest change occurred in the excretion of 
oestribl. The oestriol level rose to over 40C^ jg./ 
24-hr. but the pregnanediol remained at less than 
lmg./24hr.
The differences in the type of responses obtained 
by women with impaired pituitary function suggests that 
longer treatment with H.C.G. is necessary before 
ovulation can be induced and that the relative doses 
of F.S.H. and LH used in this work were incorrect.
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The effect of treatment with gonadotrophin on the 
excretion of steroids “by women with the Stein-Levethal 
Syndrome.
In this study the design of Fetter et al (1961) 
was used, whereby adrenocortical activity was suppressed 
by the administration of dexamethasone and simultaneously 
ovarian activity was stimulated by treatment with 
gonadotrophins. Thus any defects in the production 
of ovarian steroids should be shown up.
In all patients the excretion of oestriol increased 
after treatment with dexamethasone. It has also been 
shown that this is preceeded by an increase in the 
excretion of P.S.H. (Butt, Crooks, Cunningham & Palmer 
1963). The increase in oestriol is also evident from 
the results of Fetter et al (1961). After treatment 
with F.S.H. and P.S.H. followed by H.C.G. the excretion 
of oestriol increased, again. Fetter et al (1961) also 
noted increased excretion of oestriol following H.C.G. 
alone but little change in oestrone and oestradiol.
Thus it was postulated that there was,a defect in the 
metabolism of oestrogens which lead to an exaggerated 
excretion of 16-OH metabolites such as oestriol and 
16-hydroxyoestrone.
The excretion of pregnanediol was suppressed by 
dexamethasone presumably becavise some of it arose from 
the adrenal cortex.
As in the experiments on patients with secondary 
amenorrhoea it is clear that a normal ovulatory pattern 
in the excretion of oestriol and pregnanediol is only 
obtained with certain combinations of P.S.H. and H.C.G. 
When the time interval between injections of P.S.H. was 
reduced to 4- days a very large increase in oestriol 
occurred accompanied by very high levels of pregnanediol. 
When the interval between injections of P.S.H. was 12- 
days a normal pattern was obtained. The dosage was 
also important in the group of women with secondary 
amenorrhoea and some only responded to very high doses 
of P.B.H. In this series, however, only one patient (F) 
failed to respond to a total dose of 4-QOOmg. equivalents 
P.S.H. and some showed enormous increases in oestriol. 
Thus it seems that in general these patients are more 
sensitive to exogengoas gonadotrophin.
The effect of gonadotrophin on th® excretion of 
Dehydroepiandrosterone.
Dexamethasone completely suppressed the excretion 
of D.H.A. in the first 3 patients investigated 
(Patients G, H and I) and futhermore D.H.A. was'not 
detected after simultaneous treatment with gonadotrophin. 
Similar results have been reported hy Fetter et al(1961). 
However in the other patients (J and K) it was found 
that when injections of F.S.H. were given at intervals 
of 4 days the excretion of D.H.A. did increase which 
suggests that some D.H.A. is of ovarian origin since 
there is no evidence that the preparation of P.S.H. 
had stimulated the adrenal cortex and in view of its 
method of preparation would he unlikely to he 
contaminated hy A.C.T.H. Similar results have heen 
reported hy Mahesh & Greenhlatt (1961), and Mahesh., 
Greenhlatt, Aydar & Roy (1962) following treatment with 
f5-methasone and human pituitary P.S.H. D.H.A. was 
also found in the fluid obtained from follicular cysts 
(Mahesh et al 1962; Mahesh & Greenhlatt, 1962).
It is.interesting that in the present studies 
both D.H.A. and oestriol were detected in the urine,
If the blockage in 3p-ol dehydrogenase vras complete 
(Mahesh & Greenhlatt, 1961), no formation of oestriol 
would he expected since the principal metabolic pathway 
from -pregnenolone. —  17 a hydroxy pregnenolone - D.H.A. - 
oestrogen would he blocked at D.H.A. The oestriol 
may therefore he formed from precursors on a different 
metabolic pathway which may he pregnenolone - 
progesterone - ITtAhydroxy progesterone - androstenedione - 
19-hydroxy androstebedione - oestrogen. These two 
metabolic pathways have been established by the work 
of Ryan & Smith (1961 a,b) and Smith & Ryan (1961). 
Furthermore Mahesh & Greenhlatt (1962) showed that 
slices of polycystic ovaries that contained large 
ouantities of D.H.A. formed oestrogen from androstenedione 
as precursor hut failed to form androstenedione when 
incubated with D.H.A.
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(Plie effect of gonadotrophi n on the excretion of 
Fractions II and XXI,
Dexamethasone reduced the levels of both fractions 
II and III and little change Occurred in fraction III 
during simultaneous treatment with gonadotrophin.
The level of fraction III indicates the excretion of 
11-oxygenated corticosteroids and thus demonstrated 
that adrenocortical steroid production remained at a 
fairly constant level during treatment with gonadotrophins 
On the other hand fraction II which reflects the 
excretion of pregnanetriol, increased after treatment 
with gonadotrophins and presumably was of ovarian 
origin. Pregnanetriol has also been found in 
increased quantities after treatment by Mahesh & 
Greenblatt (1961). There is good evidence that 
pregnanetriol may be of ovarian origin from studies 
during the menstrual cycle of normal women (Pickett, 
Kyriakid es, Stern & Sommerville, 1959; Potherby, I960; 
Pickett & Kellie, 1962; Pickett & Sommerville , 1962 and 
Potherby, 1962). The ovarian precursor of 
pregnanetriol is thought to be 17-fit “hydroxy progesterone 
which has been found in human ovarian tissue (Zander,
1958) and in follicular fluid (Short, 1962)* It has 
also been found in the follicular fluid of patients 
studied in this work, when increased quantities were 
found coincident with increased amounts of progesterone 
and elevated levels of urinary pregnanediol. It has 
also been demonstrated that 17a hydroxy progesterone 
and androstenendione can be formed from progesterone 
in both human and bovine ovaries (Salmon, Vande Wiele 
& Lieberman, 1956; Wiest, Zander, Holmstrom, 1959;
Sweat, Berliner, Bryson, Nabors, Haskell & Holmstrom,
I960, Ease, Porchielli & Borfman, 1961; and Axelrod & 
Goldzieher, 1962).
It is well established that the ovary is capable 
of producing steroids excreted as 17-oxosteroids'
(Borell, 1954 and Personen & Timonen & Kikkonen 1959) 
and that increased quantities of 17-oxosteroids and 
17-hydroxy corticosteroids are excreted after 
stimulation of human ovaries by treatment with 
gonadotrophin (Keetal et al, 1957) Gemgell et al, 1958; 
Mahesh & Greenblatt, 1961). The failure to achieve 
complete suppression of the level of 17-oxosteroids by 
a standard dose of .dexame thasone is used by Netter et al 
(.19.61) as a diagnostic test to separate patients with 
menstrual irregularities into those who have elevated 
production of androgen from the ovary and those who 
have non.
In this work it was found that dexamethasone 
failed to suppress the level of 17-oxosteroids in one 
patient (G) but suppressed the levels of 17,-oxosteroids 
to different degrees in patients H and I. Treatment 
with gonadotrophin increased the level of 17-oxosteroids 
in both patients G and H.
In the patients not treated with dexamethasone 
increased levels of 17-oxosteroid#s and 17-oxogenic. 
steroids occurred in four of the five patients after 
treatment with gonadotrophin. To explain similar 
findings Gem^ell et al (1958) suggested that the results 
may be due to (1) contamination of the gonadotrophin 
with A.C.T.H but in the preparations of Gemzell and 
in these preparations contamination by A.C.T.H. can be 
precluded by the technique used to prepare the 
gonadotrophins. (2) It may be possible that the
gonadotrophins may exert a direct action on the adrenal 
cortex - it is not possible to verify this until the 
sequence of amino acids in thd gonadotrophin molecules 
is elucidated and tested for A.C.T.H. activity.
(3) The most likely source of the increased 17-oxogenic 
and 1 7 -oxosteroids is from the increased production of 
ovarian steroids. It has been amply demonstrated that 
the ovary is capable of producing metabolites of 17 a. 
hydroxy progesterone and progesterone. Furthermore in 
this work increased quantities of 17-a hydroxy progesterone 
has been shown to occur in follicular fluid after treatment 
with gonadotrophin. Thus it appears that the ovary is 
the site of production of the increased levels of 
17-oxogenic and 17-oxosteroids.
The effect of treatment with gonadotrophin oii the
excretion of 17-oxogenie and 17-oxosteroids♦
The effect of treatment with gonadotrophin on the
excretion of Androstenol.
Dexamethasone decreased the levels of androstenol 
which indicat ed that the adrenal cortex was the principal 
source of urinary androstenol. The use of A.C.T.H 
further established this. Nevertheless even in theipresence of dexamethasone increased leveirs occurred 
after treatment with gonadotrophins. When the ovaries 
of patients J, K, 1  and M were subjected to increased 
stimulation by reducing the time intervals between 
injections, the levels of androstenol increased. This 
suggests that the ovary too can form androstenol, since 
no change occurred in the excretion of fraction III 
showing that adrenocortical activity remained relatively 
constant. Brookshahk (1962) found that when normal 
men and women were treated with A.C.T.H, increased 
levels of androstenol resulted and in men increased 
levels were also found after treatment with H.C.G.
(1 ,0 0 0 i.u./day for 5 days) which suggests that 
androstenol was of gonadal as well as adrenocortical 
origin. The rise in the excretion of androstenol in 
both sexes after puberty and the significant decrease 
in androstenol in women, over 4-5 years suggests that a 
connection exists between gonadal function and 
androstenol excretion. The exact biosynthetic pathway 
leading to the formation of androstenol is specxilative 
at the moment.
A hypothetical pathway has been proposed by 
Brooksbarik (1962) . This is shown diagramatically.
This was based on the finding of Gower & Haslewood 
(1 9 6 1) that the testis of rats can form androstenol in- • 
vitro from acetate. The conversion of testosterone 
in vitro to the closely related androsta - 4-:16 dien- 
5-one by human liver (Stylianou, Porchielli, Tummillo 
8-. Dorfman, 1961, b) and to the latter and androst - 16- 
en - ol by rat testis has been demonstrated (.Stylianou 
et al, I96l,a). However, the marked Enhancement of 
androstenol excretion by A.C.T.H. indicates that it 
do<=s not arise only from testosterone (via androsta - 
4-}16 - died - 5 - one) but can be formed in vivo from 
adrenal steroids. In view of the importance of D.H.A 
as a product of the adrenal (Vande Wiele & Lieberman, 
I960) a possible origin of androstenol would seem to 
be from D.H.A. via androst- 5 - ene - 3J3, 17 ^ diol
H°
DehycLroepiandrosterone
HO
Andr o s t - 5 -  ene-3(3,1 7(3-diol
A 1 6
ossible metabolic in terrelatio n s between androgens and -steroid s
(TIgar, Miller & Dorfman, 1954)-, androsta- 5, 16 - 
dien 3B - ol and androsta - 4, 16 - dien 3 - one.
These reactions are also shown.
It has 'been demonstrated that testosterone can he 
formed hy human ovaries tissue (Sandor & Lanthier, I960; 
Kase et al, 1961, and Leon, Castro & Dorfman, 1962) and 
testosterone can he converted into oestrogen hy human 
ovarian tissue (Baggett, Bngel, Savard & Dorfman, 1956* 
Wotiz, Davis, Lemon & Gut, 1956» West, Damast, Sarro 
& Pearson, 1956, Ryan 1959, Ryan & Smith 1961a).
The findings in this work indicate that the human ovary 
can also form androstenol. The findings of Ryan, (1959) 
on the aromatization of steroids hy human placental 
homogenates showed that 16-<?L hydroxy testosterone was 
an intermediate in the conversion of 5 androstene
#*\»L3B, 16 oC , 17B triol can be formed from D.H.A. hy 
perfusion through intact rat liver (Ungar et al, 1954). 
This suggests that androstenol may play a key role in 
the production of androgen as has been proposed hy 
Dorfman (1961). 16'ol hydroxytestosterone has been found
hy Stylianou et al (196.1 h) when 4C1^  testosterone was 
incubated with human liver slices, so that this compound, 
16~dvhydroxy testosterone, may he of more importance 
in the metabolism of and^gens and oestrogens than 
androsta— 4 : 16 dien — 3 one as proposed hy 
Brookshank (1962).
- /o£_
The steroids -present in follicular fluid.
The presence of relatively large quantities of 
androstenedione in the follicular fluid of patients 
H snd I \'jas similar to the findings of Short &
London (1961), Short (1962a). Both patients excreted 
little pregnanediol at the time at which the follicular 
fluid was removed and the oestriol level was either low 
or h^d decreased. In keeping with the work of Short 
& London (1961) and Short (1962a) , oestradiol-17 ]8 was 
not detected.
A marked difference was noted "between patients 
H and I and patients J and K. The follicular fluid 
was removed from the latter when the excretion of 
urinary oestriol and pregnanediol was elevated and it 
contained relatively large quantities of progesterone, 
17-0^  hydroxy progesterone and oestradiol-l?]3 with 
decreased levels of androstenedione. A small quantity 
of oestrone and 2o«A hydroxy pregn - 4 - en - 3 - one 
was detected in the follicular fluid from patient K. 
Short (1962b) has found the latter steroid in high 
concentration in luteal tissue of the mare but could 
detect none in the follicular fluid of the same animal. 
Oestrone and oestradiol-17 jp have been detected in 
extracts of corpora lutea by Zander, Brendle, von 
Munstermann, DiEzfalusy, Martinsen & Tillinger (1959). 
The finding of progesterone and 17qLhydroxy progesterone 
in these latter patients demonstrated the effect of 
the gonadotrophic hormones on the constituents found 
in the follicular fluid. Warren & Salhanick (1961) 
claimed that the defective enzyme system in the 
ovaries of women with the Stein-Leventhal Syndrome lay 
in an excessive activity of the enzyme 17*Ahydroxylase 
rather than an enzyme blockage. This work clearly 
shows that the relative amounts of steroids found in 
follicular fluid was dependent upon the predominant 
hormone acting on the ovary immediately before the 
follicular fluid was removed. If L.H. had been the 
active hormone then increased progesterone and 17"<*. 
hydroxy progesterone would be expected to be present 
due to the luteinizing action of L.H.
It is now known that when a mature follicle 
ruptures either by a mechanical means or by the action 
of L.H. that the biosynthetic pathway leading to the 
formation of oestrogen is broken in some way and that
- / o q .
the metabolic pathway is arrested at adt - progesterone 
so accounting for the increased level of pregnanediol 
that occurs after ovulation. A change in endocrine 
cell type occurs at ovulation also (Harrison, 194-6).
It is known that 2 types of endocrine cells exist in 
the normal ovary, these are the theca interna which 
contain all the enzyme systems necessary for the 
conversion of progesterone to oestradiol 1? B and the 
granulosa cells which lack these enzymes and produce 
mainly progesterone (Short, 1962 a, Huang & Pearlman, 
1962).
The changes found in the constituents of the 
follicular fluid pf patients j and K. The cyst fluid 
of Patient L had both D.H.A. and androstenedione 
oresent in the same follicles with small quantities of 
17-cl^  hydroxy progesterone also. The occurrence of 
both androstenedione and D.H.A, toe-ether in the same 
follicular fluid has been reported by Short (1962a). 
Patient N had a small quantity of 17~tA hydroxy 
■progesterone but considerably more androstenedione. 
These findings indicated that the changes that occurred 
after treatment with gonadotrophin were of a transient 
nature and that the steroids found in the cyst fluid 
of untreated women with the Stein-Leventhal Syndrome 
re-appear when treatment has been discontinued. It 
thus apnears that under the continual influence of 
gonadotrophin, the enzyme defect in the biosynthesis 
of oestrogens may be corrected at least temporarily.
It is not possible to decide if the follicles present 
after gonadotrophin treatment had,been already present 
before treatment or whether they are newly formed 
follicles. On regression these follicles had the 
cyst fluid constituents of untreated women.
Several theocies have been advanced to explain the 
occurrence of polycystic ovaries in the Stein-Leventhal 
Syndrome. Originally hypergonadotronhinism was cited 
as the basis of the polycystic ovary (Stein & Leventhal 
1935) hut it was found by McArthur, Ingersoll & 
Worcester (1958) that the excretion of L.H. in urine was 
not always elevated in these patients. Taymsr & 
Barnard (1962) showed that L.H. was increased in about 
50% of a small group of women with the Stein-Leventhal 
Syndrome, butv^ ri lull cystine ovaries-. Considerable
fluctuation occurred in the excretion of L.H. in all 
of the patients studied. The response of some patients
to corticoid therapy has implicated the adrenal 
cortex into consideration (Greenblatt 1953 , 1958,
Jones, Howard & Langford, 1953), and it has he eh 
proposed by Gallagher, Kappas, Heilman, Lipsett,
Pearson & West (1958) that the abnormality may involve 
dysfunction of adrenal gland, pituitary gland and 
ovary. Mahesh & Greenblatt (1961) suggest that since 
the ovaries are so responsive to exogenous gonadotrophin 
that hundreds of follicles receive inadequate stimulation 
by endogenous hormones so producing a myriad of micro 
follicular cysts with general enlargement of the ovary. 
The possibility also exists that the syndrome may be 
related to the sex chromatin pattern since the report 
by Vague, Picard, Vitry* Galinier, Pavier & Miller 
(1956) who found a male sex chromatin pattern in the 
buccal smear of one of the group of four patients with 
the Stein-Leventhal Syndrome.
SUMMAET
In this research work a short rapid method 
for the estimation of oestriol in urine was 
developed,
This method was compared to a longer published 
method and found to be suitable for the estimation 
of small Quantities of oestriol and for following 
the excretion of oestriol during pregnancy.
This method was discussed with reference to 
accuracy, specificity, sensitivity and precision.
The effects of different preparations of human 
urinary and pituitary gonadotrophins on the 
excretion of oestriol and pregnanediol by a group 
of women with secondary amenorrhoea.
Each period of treatment with gonadotrophins 
was designed in a statistical manner and the 
results were analysed by comparison to the changes 
in the excretion of oestriol and pregnanediol during 
the menstrual cycle of normal women.
In Experiment 1. three different preparations 
of F.S.H. were used followed by a constant dose of 
H.C.G. given for four days.
The analysis of the results indicated that the 
best preparation appeared to be 0P2#
In Experiment la. each patient was treated with 
a constant high dose of CP2, and H.C.G. (6,000 i.u/ 
day) was given for four days with the last four 
days of F.S.H. and for the four days after it.
The effect of varying the total and daily dosage of 
E.S.H. was investigated. The dose of F.S.H, 
decreased by factors of 0.7i 0.8, 0.9 in three of 
the f our months and in one month a constant dose 
of F.S.H. was used. H.C.G. (6,000 i.u.) was given 
4 d^ys after treatment with F.S.H.
One patient had an abnormally big response 
during the first month of treatment, no response at 
a lower dose and a big response at an intermediate 
dose level of F.S.H.
-  m  -
9. The analysis of results indicated that the high 
dosaee of F.S.H. appeared to he more effective 
than the low dosages.
10. Th.e use of a constant dose of F.S.H. appeared 
to he more effective than when different daily 
dosages were used.
11. During this experiment one patient became 
pregnant and was replaced in the group hy another 
patient.
In Experiment 3 the total dosage of F.S.H, the
total dosage of H.C.G, and the timing of administration
of the two hormones was investigated.
12. From the analysis of this experiment it appeared
that the most effective way to give H.G.G. was ir a 
dosage of 18,000 i.u. (or higher) in a single 
injection after F.S.H.
13- The analysis also suggested that the higher 
dosages of F.S.H. vie re more effective.
14- . The graphic responses of these three experiments
were compared to the excretion patterns of oestriol 
and pregnanediol during the normal cycle, hy a method 
of awarding scores to different characteristics of 
-the induced cycles hut this did not supply any more 
information than the statistical analysis.
Using the information gained in the experiments 1 - 3  
each patient was treated further with what appeared 
to he the most effective treatment to induce 
ovulation.
18. Three of the patients treated in this manner
became pregnant, two gave birth to normal single 
children, one aborted and the woman who became 
pregnant during Experiment 2 gave birth to dissimilar 
twins.
16. The excretion of oestriol, pregnanediol and H.C.G. 
during the pregnancy of each patient was studied.
17. A comparison was made between the excretion of 
oestriol and pregnanediol by three of these patients 
and the excretion patterns of normal pregnant women.
The effect of P.S.H. and H.C.G. on the excretion 
of oestriol and pregnanediol by a woman with 
Simmonds1 disease was studied.
18. The results of giving H.C.G. in different ways 
relative to F.S;H. showed that the patient could 
produce large quantities of oestriol hut comparatively 
little pregnanediol.
19- The greatest-change in the excretion of both 
oestriol and pregnanediol occurred when H.C.G. was 
given together with the last four days of F.S.H.
20. The effects, of other trophic, hormones, 
dexamethasone^ and thyroxin did not apnear to
supplemert; the action of the gonadotrophins in inducing 
a pattern of steroid excretion which indicated 
ovulation.
21. The scheme of treatment that had been used 
successfully to induce ovulation in women with 
secondary amenorrhoea. was not successful in this 
patient.
- 1 > $ -
In a group of women with the Stein-Leventhal Syndrome 
the hormones controlling the excretion of steroids 
were investigated,
22. Dexamethasone suppressed the excretion of D.H.A 
completely and caused a reduction in the levels of 
androstenol, pregnanediol, fraction IX and III and 
both 17-oxo and 17-oxogenic steroids.
23* After administration of dexamethasone the
excretion of oestriol increased.
24-. In the Presence of dexamethasone, when F.S.H.
alone was given the level of oestriol increased but 
little change occurred in any of the other steroids.
25. After the combined treatment with F.S.H. and. 
H.C.G. the levels of pregnanediol, oestriol, 
androstenol, fraction II and 17-oxosteroids increased 
but the level of D.H.A. remained suppressed.
26. In the absence of dexamethasone and usin^ a 
scheme of treatment which had a four day interval 
between infections of F.S.H. followed two days later 
by H.C.G., the levels of oestriol, pregnanediol,
D.H.A., anctfostenol, fraction II and both 17-oxo ahd 
1 7 -oxogenic steroids increased.
- I/if. -
27. When comparatively little change had occurred 
in the levels of urinary steroids, the cyst fluid 
removed at the same time contained comparatively 
large ouantities of endfostenedione.A
28. When the levels of oestriol and pregnanediol 
were elevated in urine the cyst fluid removed at 
operation contained progesterone, 17-*Ahydroxy 
progesterone and oestradiol-l?ji.
When the cyst fluid was removed from patients 
at longer intervals following treatment with 
gonadotrophins, it was found to contain the same 
steroids that are found in the cyst fluid of 
untreated women.
0^. Androstenedione and D.H.A.. were found in cyst
fluid which was removed from individual cysts of 
one natient..
The findings in this work were discussed and 
compared to the findings of other workers.
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STEROID NOMENCLATURE.
Trivial Name: Chemical N^me:
Androsterone 3 <L-Hydroxy-5 -androstan- 17-one
Ae ti o ch o1analone 3 <k -Hydroxy- 5B-androstan- 17-one
Ardrostenol Androst-16-en-3<£ -ol.
Androstenedione A /j.ZX-Androstene-3, 17-dione
Dehydroepiandrosterone A  ^Androstene-3B-ol-l?-one 
(D.H.A.)
Pregnaned iol 5^3-Pre gnane- 3JL 2G<?L -diol
Progesterone Pregn-4-ene 3, 70-dione
17-Hydroxyprogesterone 1?^ -Hydroxy pregn-4-6ne-3,
Pregnanetriol
20- dione
5J3-Pnegnane-3cA , 17<K , 20& - 
triol
Pregnenetriol A^-Pregnene-3B,17s< , 20 triol r
Pregnenolone /\ ^ -Pregnen-3B-ol-20-one
17-Hydroxy pregnenolone 17 rA Hydroxy /S^-Pregnen-^R-ol
20-one
Oestriol 3,16^, 17B-Trihydroxyoestra 
1,3?5 (10) triene
Oestrone 3-Hydroxyoestra-l,3?5, (10)- trien-17-one
Oestradiol
Testosterone
3,l?B-Dihydroxyoestra-l,3,3 
(10) triene
17p-Hydroxy-androst-4— en-3- 
one
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